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General introduction
Chapter 1 

1General introduction
introduction
This thesis aims to improve our understanding of the mechanisms of action involved in 
pregnancy-induced vasodilation.
Pregnancy is one of the most unique experiences in a woman’s life and affects human 
physiology in many ways. The cardiovascular system is one of the most strongly affected 
because it provides the fetus with oxygen and nutrients needed for growth and development.
The cardiovascular adaptations to the increased metabolic needs of the various organs 
develop early in the first half of pregnancy. The main changes are a generalized reduction in 
systemic vascular resistance and consequently an increase in blood flow. By mid-pregnancy 
in humans vascular resistance has decreased by about 50% and cardiac output has increased 
by 40% 1;2. As a result, blood pressure at mid-pregnancy is about 10% lower than in 
nonpregnant women. The increase in flow varies between organs and is quite pronounced 
in the mesenteric vascular bed, that provides flow to the bowels, and the renal vascular 
bed, that provides flow to the kidneys 1-4. These changes are the physiological response 
to profound vasodilation, the mechanisms of which are not completely understood. 
Pregnancy-induced vasodilation is not limited to humans and occurs to a variable extent in 
all mammals. Most studies on vascular adaptations in pregnancy have been performed in 
rodents that show more or less comparable vascular changes 3;5;6.
Vascular resistance is determined by the smallest arteries and arterioles throughout 
the body and not so much by the large arteries like the aorta. The small vessels have 
three layers, each of which can contribute to vascular tone. These layers are: 1. The 
tunica intima, consisting of endothelium cells (ECs) and a supporting extra-cellular matrix 
(ECM), 2. The tunica media, consisting of smooth muscle cells (SMCs) and ECM, and 
3. The tunica adventitia, consisting of fibroblast, autonomic nerves and ECM. From 
studies in nonpregnant rodents we know that vascular tone results from several pathways 
that affect the EC, SMC or ECM. These pathways are graphically depicted by Figure 1 
in Chapter 2 and include: 1. Flow mediated vasodilation, the vasodilator response to 
a certain flow increase (representing the nitric oxide (NO) dependent vasodilation), 2. 
Reactivity to vasodilator agents (including acetylcholine, bradykinin, adrenomedullin 
and isoproterenol), 3.) Reactivity to vasoconstrictor agents (such as phenylephrine, 
norepinephrine and angiotensin-II), 4. Myogenic reactivity, the vasoconstrictor response 
to a certain pressure increase in the presence of intact SMC (representing SMC reactivity 
to pressure changes), and 5. Compliance, the vasodilator response to a certain pressure 
increase in the absence of intact SMC (representing the elasticity of the ECM). However, 
it is not well-defined how pregnancy affects these pathways.
The factors that are responsible for changing the EC, SMC and ECM-dependent 
pathways during pregnancy are largely unknown. The pregnancy-related hormone relaxin 
is thought to be an important factor. This can be concluded from several observations. In 
nonpregnant rats, reIaxin administration induces systemic vasodilator responses as observed 
in healthy mid-pregnancy, including an increase in cardiac output, heart rate, stroke volume, 
and renal plasma flow, and a decrease in systemic vascular resistance 7-9. In pregnant rats, 
blockade of relaxin (by selective antibodies completely) normalizes pregnancy-induced 
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vasodilator changes to nonpregnant values 10. These observations suggest the involvement 
of relaxin in the gestational vascular adaptations during pregnancy.
For this thesis we questioned which mechanisms are responsible for adaptation of 
the different pathways during pregnancy and during exposure to the hormone relaxin in 
nonpregnant rats.
oVerVieW oF tHe tHesis
literature review
Previous studies have suggested that pregnancy may affect multiple pathways, including 
upregulation of the endothelium-dependent NO pathway 11, reduction of the responsiveness 
to vasoconstrictor stimuli 12, decrease in myogenic reactivity 13, and increase in arteriolar 
compliance 13. However, one may question to what extent these responses are universally 
valid across species, strains, gestational age and vascular beds, given the many differences 
in methodology and results between the various studies. 
In order to study the validity of the responses involved in pregnancy-induced vasodilation 
under various experimental conditions, we took an approach novel to physiological 
research. We performed systematic reviews and meta-analyses on animal data, analogous 
to the systematic reviews that are commonly used in human medicine. We hypothesized 
that the extent of vascular adaptation to pregnancy is similar across species, strains and the 
course of pregnancy in mesenteric and renal vasculature (Chapters 2 and 3). 
effect of pregnancy on vasomotor control
Systemic vascular adaptations in humans and rats are virtually complete at mid-pregnancy, 
yet the mechanisms have not been studied extensively. Most research on the underlying 
pathways has been performed only in late pregnancy and it is by no means certain that 
the pathways involved are identical in mid- and late pregnancy. We hypothesized that 
midgestational vasodilation is mediated by upregulation of endothelium-dependent 
mechanisms and vascular compliance, and downregulation of vasoconstrictor agent 
sensitivity and myogenic reactivity (Chapter 4).
effect of relaxin exposure on vasomotor control in normal, overweight, 
aged and hypertensive rats
Relaxin has been implied as a major factor in normal vascular adaptations to pregnancy. It 
is an insulin-like growth factor hormone produced by the ovaries and the placenta. Relaxin 
induces vasodilator responses comparable to those observed during pregnancy (increased 
cardiac output, heart rate, stroke volume, and renal plasma flow, and decreased systemic 
vascular resistance) 7-9. Blockade of this hormone by antibodies completely reverses 
pregnancy-induced vascular adaptations 10. Impaired vascular adaptations in pregnancy 
are common in overweight, aged and chronic hypertensive subjects. We hypothesized 
that resistance to relaxin in overweight, aged and hypertensive rats may negatively affect 
vascular adaptations to relaxin (Chapters 5, 6 and 7).
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1General introduction
Research almost always leads to new insights and ideas for future studies. This also 
applies to our studies. Therefore, in the final chapter we put our findings into a broader 
perspective (Chapter 8).
In summary, this thesis aims to explore the mechanisms of action of adaptation of 
the different pathways during pregnancy and during exposure to the hormone relaxin in 
nonpregnant rats. To this end, we posed three research questions: 1. To what extent are the 
pregnancy-induced changes in the renal and mesenteric vasculature similar among species, 
strains and gestational periods (Chapter 2 and 3)? 2. To what extent is midgestational 
vasodilation mediated by upregulation of endothelium-dependent mechanisms and 
vascular compliance, and downregulation of vasoconstrictor agent sensitivity and myogenic 
reactivity (Chapter 4)? and 3. To what extent are local vascular responses to relaxin impaired 
in overweight, aged and hypertensive female rats (Chapter 5, 6 and 7)?
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Chapter 2 
adaptive chanGes of mesenteric arteries  
in preGnancy: a meta-analysis 
Joris van Drongelen, 
Carlijn R. Hooijmans, 
Frederik K. Lotgering, 
Paul Smits, 
Marc E.A. Spaanderman
American Journal of Physiology, 
Heart and Circulatory Physiology 2012 Sep;303 (6):H639-57
aBstract
The vascular response to pregnancy has been frequently studied in mesenteric artery models 
by investigating endothelium cell (EC) and smooth muscle cell (SMC)-dependent responses 
to mechanical (flow-mediated vasodilation, myogenic reactivity, and vascular compliance) 
and pharmacological stimuli (G protein-coupled receptor responses: GqEC, GsSMC, GqSMC). 
It is unclear to what extent these pathways contribute to normal pregnancy-induced 
vasodilation across species, strains, and/or gestational age, and at which receptor level 
pregnancy affects the pathways. We performed a meta-analysis on responses to mechanical 
and pharmacological stimuli associated with pregnancy-induced vasodilation of mesenteric 
arteries and included 55 (188 responses) out of 398 studies. Most included studies (84%) 
were performed in Wistar and Sprague Dawley rats (SDR) and compared late gestation 
versus nonpregnant controls (80%). Pregnancy promotes flow-mediated vasodilation in all 
investigated species. Only in SDR, pregnancy additionally stimulates both vasodilator GqEC 
sensitivity (EC50 reduced by -0.76 [-0.92, - 0.60] log[M]) and GsSMC sensitivity (EC50 reduced 
by -0.51 [-0.82, -0.20] log[M]), depresses vasopressor GqSMC sensitivity (EC50 increase in 
SDR by 0.23 [0.16, 0.31] log[M]) and enhances arterial compliance. We conclude that: 1. 
Pregnancy facilitates flow-mediated vasodilation at term, among all investigated species, and 
the contribution of additional vascular responses is species and strain specific, and 2. Late 
pregnancy mediates vasodilation through changes at the receptor level for the substances 
tested. The initial steps of vasodilation in early pregnancy remain to be elucidated.
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introduction
Vascular adaptation to pregnancy is characterized by marked vasodilation. Vasodilation is 
reflected by a reduction in systemic vascular resistance. Systemic vascular resistance drops 
early in gestation, is at its lowest at midgestation, and gradually increases toward term. 
This is true for both humans 1;2 and animals 3. 
The local vascular mechanisms underlying adaptation to pregnancy have been studied 
extensively, mainly in animal experiments. They involve both endothelium cell- (EC) and 
smooth muscle cell- (SMC) dependent changes. The underlying mechanisms are complex 
and probably gestational age-specific and species- or strain-specific. As a result of such 
confounding factors, conclusions from various studies may seem inconsistent. Systematic 
review is a tool to determine qualitative and quantitative responses objectively, while 
taking into account methodological quality, study design and various confounders. It has 
been used to evaluate human research on a variety of topics, as collected in the Cochrane 
database 4. The same technique is applicable to animal experimental work 2. 
Adaptation to pregnancy has been studied in several vascular beds and by a variety 
of stimuli. The mesenteric circulation has been commonly used because this vascular bed 
is quantitatively important, since it receives one-third of cardiac output in pregnancy 2;5, 
and because it is easily accessible for study. The local vascular responses can be arranged 
by the stimuli imposed or the pathways involved. Mechanical stimuli include flow-
mediated vasodilation, myogenic reactivity, and arterial compliance. Electric stimuli 
concern experiments on electric field stimulation (EFS). Pharmacological stimuli consist of 
responses to agents such as acetylcholine, norepinephrine, and phenylephrine. As most 
of these pharmacological stimuli involve G protein-coupled receptors, the response to the 
agents can be arranged according to their receptor pathways. These include the EC (GqEC-) 
pathway and two SMC (GqSMC- and GsSMC-) pathways 
6-12, as shown in Figure 1.
Many authors have generalized the conclusions of their vascular studies from species, and/
or strain, and/or gestational age period, to pregnancy in mammals in general. The aim of our 
study was to evaluate to what extent vascular adaptation to pregnancy is indeed similar across 
species, strains and the course of pregnancy. To study this effect, we applied the methods of 
meta-analysis to experimental data, limiting ourselves for practical reasons to one important 
vascular bed, that of the mesenteric circulation. The questions to be answered were the 
following: 1. To what extent do mechanical stimuli and/or pharmacological receptor pathways 
contribute to normal vasodilation of the mesenteric circulation in pregnancy across species, 
strains, and/or gestational age? and 2. At which receptor level does pregnancy affect the 
different pathways in this circulation across species, strains, and/or gestational age?
Materials and MetHods
literature search 
We searched the PubMed and Embase databases for (all) original studies on adaptive 
responses of mesenteric arteries to a first pregnancy, from 1948 (PubMed) and 1980 
(Embase) until April 2012. No restriction was used for language or species (studies on 
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humans were included). The search strategies focused on pregnancy, mesenteric arteries, 
and vasoconstrictor and/or vasodilator responses, as detailed in Tables 1 and 2.
selection of studies
From the original studies identified by the literature search, we selected studies qualified for 
inclusion in the meta-analysis, through the three-phase selection process shown in Figure 2. 
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Figure 1. The three common types of G protein coupled receptors, the involved agents and the simplified 
endothelium cell (EC) and smooth muscle cell (SMC) pathways. 
1.  The GqEC-pathway: acetylcholine, bradykinin and methacholine enhance EC phospholipase C activity 
and the formation of phosphatidylinositol 3-kinase (PI3K), which enhances inositol 1,4,5-triphospate 
(IP3) and  diaglycerol (DAG) production. This leads to Ca
2+-infux in the EC and Ca2+-release from the 
sarcoplasmic reticulum. This in turn enhances the availability of Ca++/Calmodulin and activates Akt/
phospokinase B (Akt/PKB), leading to endothelial nitric oxide synthase (eNOS) activation and the 
production of nitric oxide (NO), prostacyclin (PGI2) and endothelium-dependent hyperpolarizing factor 
(EDHF). These substances diffuse to the SMC, where they activate protein kinase G (PKG) through 
guanyl cyclase (GC) and protein kinase A (PKA) through adenyl cyclase (AC). These substances induce 
vasodilation by blockade of the Ca2+-channel influx and stimulation of the K+-channel efflux.
2.  The GqSMC-pathway: angiotensin-II, endothelin, norepinephrine, phenylephrine, thromboxane (U46619), 
and vasopressin activate SMC phospolipase C, leading to the formation of inositol 1,4,5-triphospate 
(IP3) and diaglycerol (DAG). This leads to Ca
2+-influx in the SMC and Ca2+-release from the sarcoplasmic 
reticulum, which results in vasoconstriction.
3.  The GsSMC-pathway: adrenomedullin, calcitonin gene-related peptide (CGRP), human chorionic 
gonadotrophin (hCG) and isoproterenol activate SMC adenylate cyclase (AC), which enhances protein kinase 
A (PKA) production. This stimulates K+-influx and inhibits Ca2+-influx, which results in vasodilation.
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In phase 1, all potential studies were screened for inclusion criteria on the basis of 
title and abstract. The screening was performed independently by two investigators (first 
and second author). In case of any doubt, the full publication was evaluated. Differences 
between investigators were resolved by mutual agreement or, in case of remaining 
disagreement, by a third investigator (M. Leenaars, Central Animal Laboratory, SYRCLE). 
Inclusion criteria were: 1. Original data, 2. Healthy subjects, 3. First pregnancy, 4. 
Nulliparous controls, 5. Age-matched subjects, 6. Mesenteric artery vasoconstrictor and/or 
vasodilator responses, and 7. Standard medium used in the experiments. As some studies 
did not literally describe information concerning inclusion criteria 3, 4, and 5, studies were 
included if it was very assumable that they complied. 
In phase 2, articles that passed the initial screening were analyzed in full, by the same 
two investigators for the same inclusion criteria. 
In phase 3, full articles that passed the inclusion criteria were evaluated for the assessability 
of the responses, based on the presence of greater of equal to five measurements for each 
response. From these, we included all responses in the absence of any blockade, in the 
presence of denuded endothelium or blockade of well-known, commonly studied, EC 
vasodilator mechanisms [blockade of nitric oxide (NO) and/or prostacyclin (PGI2)]. 
data extraction
From each article with assessable responses, data were extracted. We recorded primary 
data on species, strain, gestation age (early, mid-, and late gestation, defined by trimester), 
estrous/cycle stage, and type of myograph. From each vascular response we recorded the 
number of subjects, effect-size, and standard deviation or standard error of the mean. In 
case of missing, incomplete, or indeterminate data, an effort was made to complete the 
data by approaching the authors by e-mail. The response rate to these requests was 46%. 
In case of duplicate reporting, we used only the results of the most recent publication. 
From the pharmacological and electrical responses, we extracted the sensitivity 
(EC50 = effective concentration, needed to obtain 50% of maximum effect) and maximum 
effect (Emax = not responding to ≥2 further increases in concentration or intensity). From the 
mechanical responses, we determined only the direction of the effect (favoring vasodilation, 
vasoconstriction, or no effect), because quantitative comparison was not feasible. This was 
caused by the highly variable outcome measures reported in these studies and the use of 
statistics (often ANOVA) that did not allow calculation of overall effect-sizes. 
Quality assessment
The quality of each study was assessed by two independent investigators (first and second 
author), based on randomization, blinding of outcome assessment, age or weight of 
subjects, and number of animals used at study entry and analysis. Subsequently, each 
response was ranked on three points: 1. Clear number of subjects used for analyses, 2. 
Presence of a response graph (based on at least 5 measurements), and 3. Achievement 
of Emax. The overall quality of the responses was expressed as the percentage of responses 
that fulfilled the criteria compared with the total number of responses in each study. 
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Table 1. Literature search-strategy for Pubmed.
Component Description
Pregnancy “pregnancy”[MeSH Terms] OR “pregnancy”[tiab] OR “pregnancies”[tiab] OR 
“gestation”[tiab] OR “pregnant”[tiab] OR “maternal-fetal relations”[tiab]
Mesenteric arteries “mesenteric arteries”[MeSH Terms] OR “Mesentery/blood supply”[Mesh] OR 
“mesenteric”[tiab] OR “mesentery artery”[tiab] OR  “mesentery arteries”[tiab] 
OR “mesenterial artery”[tiab] OR “mesenterial arteries”[tiab] OR “arteria 
mesenterica”[tiab] OR “omental microvessels”[tiab] OR “omental arteries”[tiab] 
OR “omental artery”[tiab]
Vasoconstrictor and 
vasodilator responses
“vasoconstriction”[MeSH Terms] OR “vasoconstriction”[tiab] OR 
“vasoconstrictions”[tiab] OR “vasoconstrictor agents”[MeSH Terms] OR 
“vasoconstrictor agents”[Pharmacological Action] OR “vascular resistance”[MeSH 
Terms] OR “vascular resistance”[tiab] OR “vascular capacitance”[MeSH Terms] 
OR (“vascular”[tiab] AND “capacitance”[tiab]) OR “vasoconstrictor”[tiab] OR 
“vasoconstrictors”[tiab] OR “vasopressor”[tiab] OR “vasoactive agonist”[tiab] OR 
“vasoactive agonists”[tiab] OR “vasopressors”[tiab] OR “vasomotor system”[MeSH 
Terms] OR “vasomotor system”[tiab] OR “peripheral resistance”[tiab] OR “artery 
constriction”[tiab] OR “vessel constriction”[tiab] OR “vasoconstrictive”[tiab] OR 
“vasoconstricting”[tiab] OR “vasoconstricted”[tiab] OR “vasodilation”[MeSH 
Terms] OR “vasodilation”[tiab] OR “vasodilatation”[tiab]  OR “vasodilatating”[tiab] 
OR “vasodilating”[tiab]  OR “vasodilative”[tiab]  OR “vasodilatative”[tiab]  OR 
“artery dilation”[tiab] OR “vessel dilation”[tiab] OR “artery dilatation”[tiab] OR 
“vessel dilatation”[tiab] OR “vasodilator agents”[MeSH Terms] OR “vasodilator 
agents”[Pharmacological Action] OR “vasodilator”[tiab] OR “vasodilators”[tiab] 
OR “vasorelaxation”[tiab] OR “Vascular Endothelium Dependent Relaxation”[tiab] 
OR “Endothelium Dependent Relaxation”[tiab] OR “Vascular Endothelium-
Dependent Relaxation”[tiab] OR “Endothelium-Dependent-Relaxation”[tiab] OR 
“hemodynamics”[MeSH Terms] OR “hemodynamics”[tiab]OR “hemodynamic”[tiab] 
OR “vasodilated”[tiab] OR “vasoactive agent”[tiab] OR “vasoactive drug”[tiab] 
OR “vasoactive drugs”[tiab] OR “dilation”[tiab]  OR “dilatation”[tiab]  OR 
“contraction”[tiab] OR “relaxation”[tiab]
data analysis
Values of EC50 and Emax for pharmacological and electrical stimuli were analyzed and 
displayed in forest plots (Review Manager 5, The Cochrane Collaboration, 2008). 
Responses to pharmacological stimuli were grouped together by the type of stimulus 
and type of G protein-coupled pathway (GqEC, GqSMC, and GsSMC) involved. If they could 
not be attributed to such pathway, they were arranged by type of stimulus (NO donors, 
EFS, MgSO4, and potassium). Subgroup analysis was performed to assess species and 
strain differences and to explore possible causes for heterogeneity. The responses were 
calculated as weighed mean differences (pregnant minus nonpregnant) for EC50 or as 
standardized mean differences (pregnant minus nonpregnant) for Emax, depending on 
whether the variable was uniformly expressed among studies or not. These data were 
presented as means ± 95% confidence interval. P <0.05 was considered statistically 
significant. Responses to mechanical stimuli were analyzed qualitatively and the direction 
of combined responses was determined relative to the number of animals.
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Variation of the combined responses was expressed as heterogeneity, calculated as 
I2, under the assumption of a random effects model (Review Manager 5).  A value of I2 
<60% represents moderate heterogeneity, and I2 >60% is substantial to considerable 
heterogeneity 13.
Publication bias was assessed by the method of Egger et al. (for 10 or more studies) 14 
or by the amount of funnel plot asymmetry (for less than 10 studies). 
The robustness of results from meta-analysis  was assessed by sensitivity-analysis 13. To 
this effect we repeated all analyses in the presence and absence of the excluded studies 
to determine the extent to which decisions made during in- and exclusion based on parity 
or age-matching had any major effect on our results.
References used for analysis included the following: 15-20;23;26;35-79.
Table 2. Literature search-strategy for Embase.
Component Description
Pregnancy exp pregnancy/ OR (pregnancy or pregnant).ti,ab. OR (pregnacies or gestation).
ti,ab. OR (pregnancy or pregnant or pregnacies or gestation).ti,ab.
Mesenteric arteries exp mesenteric artery/ OR mesenteric.ti,ab. OR mesentery artery.ti,ab. OR 
mesentery arteries.ti,ab. OR mesenterial artery.ti,ab. OR mesenterial arteries.
ti,ab. OR arteria mesenterica.ti,ab. OR (mesenterium adj3 circulation).ti,ab. OR 
(mesentery adj3 circulation).ti,ab. OR (mesenterial adj3 circulation).ti,ab. OR 
(mesenterium adj3 blood flow).ti,ab. OR (mesentery adj3 blood flow).ti,ab. OR 
(mesenterial adj3 blood flow).ti,ab. OR mesentery vessel.ti,ab. OR mesentery 
vessels.ti,ab. OR mesentery blood vessel.ti,ab. mesentery blood vessels.ti,ab. OR 
mesenterial vessel.ti,ab. OR mesenterial vessels.ti,ab. OR mesenterial blood vessel.
ti,ab. OR mesenterial blood vessels.ti,ab. OR (omental arteries or omental artery 
or omental microvessels or omental microvessel).ti,ab.
Vasoconstrictor and 
vasodilator responses
exp vasoconstriction/ OR exp vasoconstrictor agent/ OR vasoconstrict*.ti,ab. OR 
exp vascular resistance/ OR blood flow resistance.ti,ab. OR blood vessel resistance.
ti,ab. OR (peripheral adj1 resistance).ti,ab. OR vascular vessel resistance.ti,ab. OR 
artery resistance.ti,ab. OR exp hemodynamics/ OR exp blood vessel capacitance/ OR 
blood vessel capacitance.ti,ab. OR vascular capacitance.ti,ab. OR (hemodynamic or 
hemodynamics).ti,ab. OR (haemodynamic or haemodynamics).ti,ab. OR vasopressor.
ti,ab. OR exp vasoactive agent/ OR (vasoactive agonist OR vasoactive agonists or 
vasoactive agent or vasoactive agents or vasoactive drug or vasoactive drugs).
ti,ab. OR (vessel contriction or vessel contrictions or artery contriction or artery 
constrictions).ti,ab. OR exp vasodilatation/ OR (vasodilatation or vasodilation or 
vasodilator or vasodilatator or vasodilating or vasodilative or vasodilatative).ti,ab. 
OR (vaso dilatation or vaso dilation or vaso dilator or vaso dilatator or vaso dilating 
or vaso dilative or vaso dilatative).ti,ab. OR vaso relaxation.ti,ab. OR vascular 
endothelium dependent relaxation.ti,ab. OR vascular endothelium-dependent 
relaxation.ti,ab. OR endothelium dependent relaxation.ti,ab. OR endothelium-
dependent relaxation.ti,ab. OR (vessel dilatation* or vessel dilation* or vascular 
dilation* or vascular dilatation* or vasorelaxation* or artery dilatation* or artery 
dilation*).ti,ab. OR (dilatation* or dilation* or relaxation* or contraction*).ti,ab.
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results
Our search identified 398 studies on vascular adaptation to pregnancy, involving the mesenteric 
vascular bed. From these, 345 studies were not included for the reasons shown in Figure 2, 
leaving 55 studies that met the criteria for inclusion in the meta-analysis. Human studies did 
not meet the criteria for inclusion. In one case double reporting was suspected 15;16.
The characteristics of the included studies are shown in Table 3. Most studies concerned 
rodents [rats=46 (Spraque-Dawley rats (SDR) and Wistar rats (WR), mice=5 (C57BL/6J), 
and guinea pigs=2 (Hartley)], one study used sheep and one used pigs. Most of the studies 
had methodological shortcomings (Table 4). Only 25% (14/55) reported the number of 
animals used in the study, 53% (29/55) parity; only 4% (2/55) performed randomization, 
and 0% blinded outcome. 
From the 55 included studies with 266 vascular responses, 188 responses fully met the 
criteria for inclusion in the meta-analysis, as shown in Figure 2. Stimuli were pharmacological 
Identified studies (n=398)
Subtracted studies (n=96)
Title and abstract (n=302)
- No healthy first pregnancy versus virgin control (n=258)
- No mesenteric artery vasoconstrictor/vasodilator response (n=19)
- No standard medium (n=5)
- No original data; review (n=20)
Included studies (n=55)
Full article (n=43)
- No healthy first pregnancy versus virgin control (n=12)
- No mesenteric artery vasoconstrictor/vasodilator response (n=26)
- No age-matching (n=5)
Included responses (r=188)
- Pharmacological /
Electrical (r=160)
* EC50 described (r=83)
* Emax described (r=63)
* Graph present (r=130)
- Mechanical (r=28)
* Graph present (r=27)
Responses (r=78)
- Response <5 measurements (r=38)
- Other blockade than NO, PGI2, endothelium (r=40)
Figure 2. Flow chart for selection, inclusion and exclusion of studies and responses on vascular adaptation 
to pregnancy in mesenteric arteries.
n= number of studies; r= number of responses.
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(82%, 154/188), electrical (3%, 6/188), and mechanical (15%, 28/188) and were 
performed in early (2%, 3/188), mid- (12%, 23/188), and late (86%, 161/188) pregnancy 
(one undefined pregnancy stage). For pharmacological and electrical responses, EC50 was 
detectable in 52% (83/160) of cases and Emax in 39% (63/160), and a graph was present in 
81% (130/160). For mechanical responses the effect size was quantified in 7% (2/28) and 
a graph was present in 96% (27/28). Responses were obtained by wire-myography (49%, 
93/188), pressure myography (18%, 33/188), pressure-perfusion myography (9%, 16/188), 
and whole organ perfusion (24%, 46/188).
pharmacological responses
Vascular adaptation to pregnancy, assessed in mesenteric arteries through pharmacological 
stimuli related to the GqEC-coupled pathway, is shown in Figure 3. Responses were available 
for mid- and late gestation, mainly in rats. In midgestation, two studies in SDR showed no 
significant effect of acetylcholine or bradykinin on EC50, Emax, or the overall (acetylcholine 
plus bradykinin) GqEC response. In late gestation, responses differed for SDR and WR. In 
WR, data from four studies showed no significant effect of pregnancy on EC50 or Emax for 
any stimulus. In SDR, the responses from three studies showed considerable heterogeneity 
for EC50 and Emax. This was largely caused by one whole organ perfusion myography 
response (Parent et al. 17), as exclusion of this response markedly reduced heterogeneity. 
The two other wire-myograph studies in SDR showed a reduction in EC50 (by -0.76 [-0.92, 
-0.60] log[M]) in late gestation. In guinea pigs, pregnancy slightly reduced EC50 (by -0.34 
[-0.47, -0.20] log[M]). This suggests in SDR and to a lesser amount in guinea pigs, but not 
WR, that GqEC-mediated vasodilation is activated in late pregnancy.
The effect of pregnancy on the GqEC-pathway in mesenteric arteries under blockade 
is shown in Figure 4. Responses were available for late gestation only, in WR, SDR, mice 
and guinea pigs. In both WR, SDR, and mice, blockade of NO and/or PGI2 abolished any 
GqEC-mediated vasodilation, if present. In guinea pigs, however, the reduction in EC50 in 
pregnancy persisted under blockade of NO and PGI2. Apparently, in WR the GqEC-pathway 
is not activated, in SDR and mice it is activated and NO and PGI2 dependent, and in guinea 
pigs the pathway is activated and independent of NO and PGI2.
Vasoconstriction through pharmacological stimuli related to the GqSMC-coupled 
pathway in mesenteric arteries in pregnancy is shown in Figures 5 and 6. The responses 
to the various agents showed considerable heterogeneity. The overall GqSMC response at 
midgestation showed no effect of pregnancy. Responses for late gestation were available 
in SDR, WR, mice and guinea pigs. The overall GqSMC response suggested downregulation 
of vasoconstriction, but the responses differed markedly between species and strains. In 
WR and guinea pigs, pregnancy did not affect EC50 or Emax for all agents studied, except 
for one response 18 in WR of increased sensitivity to norepinephrine. This response caused 
considerable heterogeneity. Additionally, the data showed funnel plot asymmetry, which 
may suggest publication bias. SDR and mice showed reduced vasoconstrictor sensitivity, 
as demonstrated by the increase in EC50 and no change in Emax for all agents tested. 
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Table 3. Characteristics of included studies, arranged by author and year.
Study Species (strain)
Estrous 
stage control 
group
Gestation
period
Myograph
typea
Number of 
described 
responses
Ballejo et al., 2002 rat (WR) estrous late PPM 10
Chauhan et al., 2007 rat (SDR) di-estrous - WM 1
Chu et al., 1993 rat (WKY) - late WOP 14
Chu et al., 1994 rat (WKY) - late WOP 6
Chu et al., 1998 rat (WKY) - late WOP 2
Cockell et al., 1996 rat (WR) - late PM / PPM 4
Coelho et al., 1997 rat (WR) estrous late WOP 4
Cook et al., 2001 mouse (C57BL/6J) - late PM 4
Cooke et al., 2003 mouse (C57BL/6J) all stages late WM 6
Crandall et al., 1990 rat (SDR) - mid/late WM 5
Dalle Lucca et al., 2000 rat (SDR) estrous mid PPM 4
D’Angelo et al., 1993 rat (SDR) all stages late PM 2
Davidge et al., 1992 rat (SDR) - late WM 10
Euser et al., 2005 rat (SDR) - late PM 1
Gangula et al., 2004 rat (SDR) all stages late WM 1
Gerber et al., 1998 rat (SDR) - late WM 7
Gerber et al., 1999 rat (WR) - late WM 6
Goulopoulou et al., 2012 rat (SDR) all stages late WM 6
Hagedorn et al., 2007 mouse (C57BL/6J) - late WM 2
Hart et al., 1986 rat (SDR) estrous late WM 4
Hermsteiner et al., 1999 rat (SDR) - mid/late PM 8
Hermsteiner et al., 2001 rat (SDR) di-estrous mid/late PM 6
Hines et al., 1992 rat (SDR) - late WOP 2
Kim et al., 1994 guinea pig (Hartley) - late WM 7
Koumentaki et al., 2002 rat (WR) - late WM 5
Lanlua et al., 2002 rat (SDR) all stages late WM 1
Le Marquer-Domagala et al., 1997 rat (-) - late WOP 6
Learmont et al., 1996 rat (WR) - late WM / PM 6
Mackey et al., 1992 rat (SDR) - late PM 1
Mandelbaum et al., 1999 rat (WR) - late WOP 4
Massicotte et al., 1987 rat (SDR/WKY) - late WOP 4
McLaughlin et al., 1986 rat (SDR) all stages all WM 6
Meyer et al., 1993 rat (SDR) - late PM 2
Meyer et al., 1997 rat (SDR) - late PM / PPM 2
Meziani et al., 2005 rat (WR) - late WM 4
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Table 3. Continued.
Study Species (strain)
Estrous 
stage control 
group
Gestation
period
Myograph
typea
Number of 
described 
responses
Miller et al., 2002 rat (SDR) - late WM 2
Neves et al., 2003 rat (SDR) all stages late PM 2
Nuwayhid et al., 1975 sheep (-) - late WOP 1
Ognibene et al., 2012 rat (WR) di-estrous late WOP 4
Parent et al., 1990 rat (SDR) - late WM 3
Parent et al., 1989 rat (SDR) - mid/late WOP 4
Pascoal et al., 1995 rat (SDR) - late WM 4
Powers et al., 2004 mouse (-) - late WM 6
Ralevic et al., 1996 rat (SDR) - late WOP 22
Resende et al., 2004 rat (WR) estrous late WOP 5
Ross et al., 2007 rat (SDR) di-estrous late WM 3
Stice et al., 1987 pig (Yorkshire gilt) all stages early PPM 2
St-Louis et al., 1995 rat (SDR) all stages late WM 5
Van Drongelen et al., 2011 rat (WR) all stages mid PPM/WM 6
Van Eijndhoven et al., 2007 rat (-) - mid WM 6
Van Eijndhoven et al., 2008 rat (WR) - mid WM 4
Van Eijndhoven et al., 2003 rat (WR) - mid WM 2
Veerareddy et al., 2002 mouse (C57BL/6J) - late PM 6
White et al., 1998 guinea pig (Hartley) - late WM 2
a WM = wire myograph, PM = pressure myograph, PPM = pressure-perfusion myograph, WOP = whole 
organ perfusion
Apparently, in WR and guinea pigs the GqSMC-mediated vasoconstrictor sensitivity is not 
affected, whereas in SDR and mice the pathway is reduced in late pregnancy.
The effect of late pregnancy on the GqSMC-pathway in mesenteric arteries under 
blockade is shown in Figure 7. Responses were available for late gestation only in SDR, 
mice, and guinea pigs, but not in WR. In these species, blockade of NO, PGI2, or absence 
of endothelium did not affect EC50 or Emax, except for the responses in SDR in which EC50 
remained elevated 19. This suggests that the downregulation in late pregnancy of the 
vasoconstrictor GqSMC-mediated pathway is dependent on endothelium-related changes 
in mice and guinea pigs, but not convincingly in SDR.
The effect of pregnancy on the SMC relaxing GsSMC-pathway in mesenteric arteries is 
shown in Figure 8. Responses were available for mid- and late gestation mainly in SDR, to 
a limited extent in WR, and not in other species. Human chorion gonadothrophin (hCG) 
responses were qualitatively different from all other GsSMC-coupled responses. In SDR, 
hCG increased EC50 in the presence of endothelium, and reduced EC50 in the absence of 
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Table 4. Quality assessment of the included studies and subsequent responses.
Study
Study quality Response quality
(1) (2) (3) (4) (5) Score (6) (7) (8) Score
Ballejo et al., 2002 - - + + - 2 0.4 0.6 0.2 1.2
Chauhan et al., 2007 - - ? - - 0 1.0 1.0 0.0 2.0
Chu et al., 1993 - - ? + - 1 1.0 0.0 0.0 1.0
Chu et al., 1994 - - ? - - 0 0.0 0.0 0.0 0.0
Chu et al., 1998 - - ? - - 0 1.0 0.0 0.0 1.0
Cockell et al., 1996 - - + + - 2 1.0 1.0 1.0 3.0
Coelho et al., 1997 - - + + - 2 1.0 1.0 0.5 2.5
Cook et al., 2001 - - ? + - 1 0.0 0.8 0.0 0.8
Cooke et al., 2003 - - ? + + 2 0.8 0.8 0.0 1.7
Crandall et al., 1990 - - + - - 1 1.0 0.6 0.0 1.6
Dalle Lucca et al., 2000 - - + + - 2 1.0 1.0 0.3 2.3
D’Angelo et al., 1993 - - + + - 2 1.0 1.0 1.0 3.0
Davidge et al., 1992 - - + + + 3 0.2 0.5 0.5 1.2
Euser et al., 2005 - - + + + 3 1.0 1.0 1.0 3.0
Gangula et al., 2004 - - ? + - 1 1.0 1.0 1.0 3.0
Gerber et al., 1998 - - ? - + 1 0.9 1.0 0.6 2.4
Gerber et al., 1999 - - + + - 2 1.0 0.8 0.5 2.3
Goulopoulou et al., 2012 - - + + - 2 1.0 1.0 0.0 2.0
Hagedorn et al., 2007 - - ? + - 1 1.0 1.0 1.0 3.0
Hart et al., 1986 - - ? + - 1 1.0 0.5 0.0 1.5
Hermsteiner et al., 1999 - - + + - 2 0.9 0.4 0.0 1.3
Hermsteiner et al., 2001 - - + + - 2 1.0 1.0 0.3 2.3
Hines et al., 1992 - - + - - 1 1.0 0.0 0.0 1.0
Kim et al., 1994 - - ? - - 0 1.0 1.0 1.0 3.0
Koumentaki et al., 2002 - - + + - 2 1.0 0.4 0.4 1.8
Lanlua et al., 2002 - - ? + - 1 1.0 0.0 0.0 1.0
Le Marquer-Domagala et al., 1997 - - + + - 2 0.5 0.7 0.2 1.3
Learmont et al., 1996 - - + + - 2 1.0 0.8 0.4 2.2
Mackey et al., 1992 - - + - + 2 1.0 1.0 1.0 3.0
Mandelbaum et al., 1999 - - + + - 2 1.0 1.0 0.0 2.0
Massicotte et al., 1987 - - ? + - 1 1.0 1.0 0.0 2.0
McLaughlin et al., 1986 - - + - - 1 1.0 1.0 0.5 2.5
Meyer et al., 1993 - - + + - 2 1.0 1.0 0.0 2.0
Meyer et al., 1997 - - + - + 2 0.0 0.0 0.0 0.0
Meziani et al., 2005 - - ? + - 1 1.0 0.8 0.0 1.8
Miller et al., 2002 - - ? + - 1 0.5 0.5 0.0 1.0
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it. It seems likely that hCG activates both EC- and SMC-receptors. For this reason hCG-
responses were not included in further analysis of the GsSMC-pathway. In WR, vasodilation 
was upregulated in midgestation, as CGRP was associated with a marked reduction in 
EC50 and an increase in Emax. Late in pregnancy, isoproterenol increased EC50 and did not 
affect Emax, indicating less vasodilation compared with controls. In late pregnant SDR, 
adrenomedullin and CGRP reduced EC50, whereas isoproterenol did not. Overall, in late 
pregnancy, SDR were more sensitive to GsSMC-coupled vasodilation than nonpregnant 
controls, whereas WR were not. 
The effect of pregnancy on non-G protein-coupled responses in mesenteric arteries is 
presented in Figures 9 en 10. Responses were available for SDR in mid- and late gestation, 
and for WR and mice in late gestation. Independent of gestational age, species, or strain, 
pregnancy did not affect EC50 or Emax to any type of NO donor or potassium. This suggests 
Table 4. Continued
Study
Study quality Response quality
(1) (2) (3) (4) (5) Score (6) (7) (8) Score
Mitchell et al., 2007 - - ? + - 1 0.8 0.8 0.8 2.3
Neves et al., 2003 - - + - - 1 0.0 1.0 0.0 1.0
Nuwayhid et al., 1975 - - ? - - 0 0.0 0.0 0.0 0.0
Ognibene et al., 2012 - - + + + 3 0.5 0.0 0.0 0.5
Parent et al., 1990 - - ? + - 1 1.0 1.0 0.7 2.7
Parent et al., 1989 - - ? + - 1 1.0 1.0 0.5 2.5
Pascoal et al., 1995 + - + + - 3 1.0 1.0 0.0 2.0
Powers et al., 2004 - - ? + - 1 0.3 0.3 0.0 0.7
Ralevic et al., 1996 - - + + - 2 0.0 0.1 0.0 0.2
Resende et al., 2004 - - + - - 1 1.0 1.0 0.2 2.2
Ross et al., 2007 - - ? + - 1 1.0 1.0 0.0 2.0
Stice et al., 1987 + - ? + + 3 1.0 0.5 0.0 1.5
St-Louis et al., 1995 - - + + + 3 0.8 0.8 0.8 2.4
Van Drongelen et al., 2011 - - + + + 3 1.0 1.0 1.0 3.0
Van Eijndhoven et al., 2007 - - + + + 3 0.2 0.3 0.0 0.5
Van Eijndhoven et al., 2008 - - ? + + 2 0.0 0.5 0.0 0.5
Van Eijndhoven et al., 2003 - - ? + + 2 1.0 1.0 0.0 2.0
Veerareddy et al., 2002 - - ? + - 1 1.0 1.0 0.0 2.0
White et al., 1998 - - ? - + 1 1.0 1.0 1.0 3.0
(1) randomization, (2) blinding of outcome assessor, (3) virgin/nulliparous at entry study, (4) age or 
weight of animals described, (5) number of used animals clear from methods, (6) fraction of responses 
with clear number of animals used for statistical analyses (as a percentage of the number of described 
responses), (7) fraction of responses with dose-response curve containing ≥5 measurements, (8) fraction 
of responses with accomplished Emax.
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EC50 Emax
Substance / study MD [95% CI] I2 MD [95% CI] SMD [95% CI] I2 SMD [95% CI]
MID-GESTATION
(without blockade)
- Acetylcholine
Dalle Lucca SDR -0.40 [-0.92, 0.12] -0.21 [-1.25, 0.83]
Subtotal SDR -0.40 [-0.92, 0.12] n.a. -0.21 [-1.25, 0.83] n.a.
- Bradykinin
Parent SDR* -0.13 [-0.34, 0.08] -0.09 [-0.88, 0.69]
Subtotal SDR -0.13 [-0.34, 0.08] n.a. -0.09 [-0.88, 0.69] n.a.
Overall SDR -0.17 [-0.36, 0.03] 0% -0.13 [-0.76, 0.49] 0%
LATE-GESTATION
(without blockade)
- Acetylcholine
Gerber WR 0.04 [-0.24, 0.32] 1.23 [0.23, 2.23]
Koumentaki WR -0.13 [-0.31, 0.05] 0.24 [-0.62, 1.10]
Learmont WR -0.21 [-0.53, 0.11] 0.33 [-0.44, 1.11]
Gerber SDR -0.72 [-0.94, -0.50] 1.20 [0.51, 1.89]
Pascoal SDR -0.80 [-1.02, -0.58] 0.02 [-0.86, 0.89]
Kim GP -0.27 [-0.49, -0.05] Not estimable
Kim GP -0.17 [-0.61, -0.27] Not estimable
Kim GP -0.41 [-0.59, -0.23] Not estimable
Subtotal WR -0.10 [-0.24, 0.03] 0% 0.54 [-0.03, 1.11] 21%
Subtotal SDR -0.76 [-0.92, -0.60] 0% 0.64 [-0.52, 1.80] 77%
Subtotal GP -0.34 [-0.47, -0.20] 0% Not estimable
Subtotal all -0.35 [-0.55, -0.14] 83% 0.61 [0.11, 1.11] 45%
- Bradykinin
Resende WR* 0.00 [-0.22, 0.22] 0.00 [-1.13, 1.13]
Parent SDR* 0.26 [0.07, 0.45] -0.51 [-1.40, 0.39]
Subtotal all 0.14 [-0.12, 0.39] 67% -0.31 [-0.97, 0.35] 0%
- Methacholine
Cooke mice -0.80 [-0.93, -0.67] Not estimable
Powers mice Not estimable 0.97 [-0.21, 2.15]
Subtotal mice -0.80 [-0.93, -0.67] n.a. 0.97 [-0.21, 2.15] n.a.
Overall WR -0.07 [-0.19, 0.04] 0% 0.44 [-0.03, 0.92] 7%
Overall SDR -0.42 [-1.12, -0.28] 97% 0.27 [-0.78, 1.32] 80%
Overall SDR# -0.76 [-0.92, -0.60] 0% 0.64 [-0.52, 1.80] 77%
Overall mice -0.80 [-0.93, -0.67] n.a. 0.97 [-0.21, 2.15] n.a.
Overall GP -0.34 [-0.47, -0.20] 0% Not estimable
Overall all -0.30 [-0.53, -0.06] 93% 0.43 [-0.02, 0.89] 52%
Favors more
vasodilation
Favors less
vasodilation
Favors less
vasodilation 
Favors more
vasodilation
-1 -0.5 0 0.5 1-1 - . -1 -0.5 0 0.5 1-4 -2 42
Figure 3. Effect of mid and late pregnancy on mesenteric artery responses to stimuli involved in vasodilation 
through the GqEC-coupled pathway.
The effect of pregnancy on EC50 (the dose of stimulus inducing 50% response) is depicted as mean difference 
(MD) and its 95% confidence interval (95% CI). Emax (maximum response) is presented as standardized 
mean difference (SMD) and its 95% CI. Studies and totals based on Sprague Dawley rats (SDR), Wistar rats 
(WR), mice and guinea pigs (GP). * Whole Organ Perfusion Myograph. # Whole Organ Perfusion Myograph 
excluded. I2 represents the amount of heterogeneity. n.a. = not applicable.
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EC50 Emax
Substance / study MD [95% CI] I2 MD [95% CI] SMD [95% CI] I2 SMD [95% CI]
LATE-GESTATION
(NO-blockade)
- Acetylcholine
Pascoal SDR -0.07 [-0.47, 0.33] -0.40 [-1.28, 0.49]
Kim GP -0.43 [-0.80, 0.06] Not estimable
Subtotal all -0.26 [-0.61, 0.09] 40% -0.40 [-1.28, 0.49] n.a.
- Methacholine
Cook mice Not estimable -3.30 [-5.40, -1.21]
Cooke mice Not estimable -0.28 [-1.25, 0.69]
Subtotal mice Not estimable n.a. -1.64 [-4.59, 1.31] 85%
Overall mice Not estimable n.a. -1.64 [-4.59, 1.31] 85%
Overall all -0.26 [-0.61, 0.09] 40% -0.98 [-2.28, 0.32] 72%
(PGI2-blockade)
- Acetylcholine
Gerber WR 0.27 [-0.24, 0.78] 0.40 [-0.51, 1.31]
Mitchell SDR Not estimable 0.92 [-0.45, 2.29]
KimGP -0.39 [-0.63, -0.15] Not estimable
Subtotal all -0.10 [-0.74, 0.54] 81% 0.56 [-0.20, 1.32] 0%
- Methacholine
Cooke mice Not estimable -1.01 [-2.06, 0.03]
Subtotal mice Not estimable n.a. -1.01 [-2.06, 0.03] n.a.
Overall all -0.10 [-0.74, 0.54] 81% 0.06 [-1.05, 1.16] 67%
(NO- and PGI2-blockade)
- Acetylcholine
Koumentaki WR 0.14 [-0.43, 0.71] 0.28 [-0.92, 1.47]
Mitchell SDR Not estimable 0.03 [-1.36, 1.41]
Subtotal all 0.14 [-0.43, 0.71] n.a. 0.17 [-0.73, 1.08] 0%
- Methacholine
Cooke mice Not estimable -0.48 [-1.46, 0.51]
Subtotal mice Not estimable -0.48 [-1.46, 0.51] n.a.
Overall all 0.14 [-0.43, 0.71] n.a. -0.13 [-0.79, 0.54] 0%
Favors more
vasodilation
Favors less
vasodilation
Favors less
vasodilation 
Favors more
vasodilation
-1 -0.5 0 0.5 1-1 - . -1 -0.5 0 0.5 1-4 -2 42
that pregnancy does not affect SMC-sensitivity to EC-dependent stimuli. Single responses 
showed that vasoconstrictor response to electrical field stimulation (EFS) in late pregnant 
WR reduced Emax 
19;20; in SDR MgSO4 reduced EC50. This suggests that late pregnancy may 
affect vascular tone also through non-G protein-coupled responses. 
Figure 4. Effect of late pregnancy on mesenteric artery responses to stimuli involved in vasodilation through 
the GqEC-coupled pathway after blockade of the nitric oxide- (NO), prostacyclin- (PGI2) pathway or both.
The effect of pregnancy on EC50 (the dose of stimulus inducing 50% response) is depicted as mean difference 
(MD) and its 95% confidence interval (95% CI). Emax (maximum response) is presented as standardized mean 
difference (SMD) and its 95% CI. Studies and totals based on Sprague Dawley rats (SDR), Wistar rats (WR), 
mice and guinea pigs (GP). I2 represents the amount of heterogeneity. n.a. = not applicable.
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EC50 Emax
Substance / study MD [95% CI] I2 MD [95% CI] SMD [95% CI] I2 SMD [95% CI]
MID-GESTATION
(without blockade)
- Angiotensin-II
Hermsteiner SDR -0.23 [-0.44, -0.02] -0.34 [-1.29, 0.61]
Subtotal SDR -0.23 [-0.44, -0.02] n.a. -0.34 [-1.29, 0.61] n.a.
- Endothelin
Hermsteiner SDR -0.41 [-0.75, -0.07] 0.43 [-0.77, 1.64]
Subtotal SDR -0.41 [-0.75, -0.07] n.a. 0.43 [-0.77, 1.64] n.a.
- Norepinephrine
Crandall SDR 0.02 [-0.07, 0.11] -2.08 [-3.69, -0.47]
Subtotal SDR 0.02 [-0.07, 0.11] n.a. -2.08 [-3.69, -0.47] n.a.
- Phenylephrine
Van Drongelen WR 0.04 [-0.04, 0.12] 0.31 [-0.60, 1.22]
Hermsteiner SDR -0.08 [-0.19, 0.03] -1.32 [-2.17, -0.47]
Subtotal all -0.01 [-0.13, 0.10] 67% -0.51 [-2.11, -1.08] 85%
Overall SDR -0.12 [-0.25, 0.02] 67% -0.77 [-1.72, 0.18] 66%
Overall all -0.07 [-0.17, 0.04] 69% -0.53 [-1.37, 0.32] 69%
(NO-blockade)
- Phenylephrine
Van Drongelen WR -0.02 [-0.11, 0.07] n.a. -0.50 [-1.41, 0.42] n.a.
Subtotal WR -0.02 [-0.11, 0.07] n.a. -0.50 [-1.41, 0.42] n.a.
Favors more
vasoconstriction
Favors less
vasoconstriction
Favors less
vasoconstriction
Favors more
vasoconstriction
-0.34 [-1.29, 0.61]
0.43 [-0.77, 1.64]
-2.08 [-3.69, -0.47]
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Figure 5. Effect of mid pregnancy on mesenteric artery responses to stimuli involved in vasoconstriction 
through the GqSMC-coupled pathway in presence and absence of nitric oxide (NO) blockade.
The effect of pregnancy on EC50 (the dose of stimulus inducing 50% response) is depicted as mean difference 
(MD) and its 95% confidence interval (95% CI). Emax (maximum response) is presented as standardized mean 
difference (SMD) and its 95% CI. Studies and totals based on Sprague Dawley rats (SDR) and Wistar rats 
(WR). I2 represents the amount of heterogeneity. n.a. = not applicable.
The effect of pregnancy on vascular responses to mechanical stimuli was assessed 
qualitatively, as shown in Figure 11. Responses on early-gestation were available only 
in SDR, responses on midgestation in both WR and SDR, whereas qualitative different 
responses on late gestation were available in WR, SDR, and mice. In mid- and late 
pregnant WR, only flow-mediated vasodilation was upregulated. In SDR, compliance 
Figure 6. Effect of late pregnancy on mesenteric artery responses to stimuli involved in vasoconstriction 
through the GqSMC-coupled pathway.
The effect of pregnancy on EC50 (the dose of stimulus inducing 50% response)  is depicted as mean difference 
(MD) and its 95% confidence interval (95% CI). Emax (maximum response) is presented as standardized mean 
difference (SMD) and its 95% CI. Studies and totals based on Sprague Dawley rats (SDR), Wistar rats (WR), 
mice and guinea pigs (GP). * Whole Organ Perfusion Myograph. I2 represents the amount of heterogeneity. 
n.a. = not applicable. ◄
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EC50 Emax
Substance / study MD [95% CI] I2 MD [95% CI] SMD [95% CI] I2 SMD [95% CI]
LATE-GESTATION
(without blockade)
- Angiotensin-II
Hermsteiner SDR 0.19 [0.05, 0.33] 0.67 [-0.17, 1.51]
Subtotal SDR 0.19 [0.05, 0.33] n.a. 0.67 [-0.17, 1.51] n.a.
- Endothelin
Hermsteiner SDR 0.17 [-0.04, 0.38] 0.00 [-1.19, 1.19]
Subtotal SDR 0.17 [-0.04, 0.38] n.a. 0.00 [-1.19, 1.19] n.a.
- Norepinephrine
Gerber WR -0.23 [-0.43, -0.03] -0.08 [-0.98, 0.82]
Learmont WR 0.17 [0.06, 0.28] -0.38 [-1.15, 0.40]
Massicotte WR* 0.17 [-0.04, 0.38] -0.72 [-1.68, 0.24]
Crandall SDR 0.22 [0.09, 0.35] 2.58 [1.09, 4.07]
Massicotte SDR* 0.39 [0.13, 0.65] -0.60 [-1.55, 0.35]
Parent SDR 0.24 [-0.01, 0.49] 0.39 [-0.27, 1.05]
Subtotal WR 0.04 [-0.21, 0.29] 84% -0.35 [-0.85, 0.15] 0%
Subtotal SDR 0.25 [0.15, 0.35] 0% 0.63 [-0.84, 2.11] 85%
Subtotal all 0.15 [0.01, 0.30] 74% 0.07 [-0.62, 0.76] 71%
- Phenylephrine
Koumentaki WR 0.01 [-0.11, 0.13] -0.23 [-1.05, 0.59]
Meziani WR 0.01 [-0.17, 0.19] Not estimable
D’Angelo SDR 0.48 [0.24, 0.72] -0.79 [-2.05, 0.46]
Davidge SDR 0.18 [0.09, 0.27] -0.50 [-1.65, 0.66]
Hermsteiner SDR 0.25 [0.14, 0.36] Not estimable
Parent SDR 0.37 [0.13, 0.61] 0.27 [-0.38, 0.93]
Pascoal SDR 0.06 [-0.15, 0.27] -0.13 [-1.19, 0.93]
Cook mice 0.25 [0.05, 0.45] Not estimable
Hagendorn mice 0.27 [0.16, 0.38] Not estimable
White GP 0.11 [-0.04, 0.26] -0.13 [-1.06, 0.80]
Subtotal WR 0.01 [-0.09, 0.11] 0% -0.23 [-1.05, 0.59] n.a.
Subtotal SDR 0.25 [0.14, 0.35] 58% -0.08 [-0.54, 0.39] 0%
Subtotal mice 0.27 [0.17, 0.36] 0% Not estimable -
Subtotal all 0.19 [0.11, 0.27] 66% -0.12 [-0.49, 0.26] 0%
- U46619
Goulopoulou SDR -0.45 [-0.92, 0.02] -0.38 [-1.21, 0.44]
Kim GP 0.07 [-0.13, 0.27] Not estimable
Kim GP 0.18 [-0.41, 0.77] Not estimable
Kim GP 0.17 [-0.06, 0.40] Not estimable
Kim GP -0.03 [-0.26, 0.26] Not estimable
Subtotal GP 0.07 [-0.05, 0.20] 0% Not estimable -
Subtotal all 0.03 [-0.13, 0.18] 35% -0.38 [-1.21, 0.44] n.a.
- Vasopressin
Massicotte WR* 0.11 [-0.17, 0.39] -0.33 [-1.26, 0.60]
Massicotte SDR* 0.41 [0.18, 0.64] 0.37 [-0.57, 1.30]
Subtotal all 0.27 [-0.02, 0.56] 62% 0.02 [-0.66, 0.70] 6%
Overall WR 0.04 [-0.08, 0.16] 65% -0.32 [-0.71, 0.07] 0%
Overall SDR 0.23 [0.16, 0.31] 51% 0.12 [-0.30, 0.53] 52%
Overall mice 0.27 [0.17, 0.36] 0% Not estimable -
Overall GP 0.09 [-0.01, 0.18] 0% Not estimable -
Overall all 0.16 [0.11, 0.22] 61% -0.04 [-0.31, 0.24] 36%
Favors more
vasoconstriction
Favors less
vasoconstriction
Favors less
vasoconstriction
Favors more
vasoconstriction
-1 -0.5 0 0.5 1-1 - . -1 -0.5 0 0.5 1-4 -2 42
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EC50 Emax
Substance / study MD [95% CI] I2 MD [95% CI] SMD [95% CI] I2 SMD [95% CI]
LATE-GESTATION
(NO-blockade)
- Norepinephrine
St-Louis SDR 0.26 [-0.20, 0.72] -0.26 [-1.01, 0.48]
Subtotal SDR 0.26 [-0.20, 0.72] n.a. -0.26 [-1.01, 0.48] n.a.
- Phenylephrine
Davidge SDR 0.19 [0.06, 0.32] Not estimable
Pascoal SDR 0.09 [-0.13, 0.31] -0.13 [-1.19, 0.93]
Cook mice 0.00 [-0.14, 0.14] Not estimable
White GP -0.02 [-0.17, 0.13] 0.27 [-0.66, 1.21]
Subtotal SDR 0.16 [0.05, 0.28] 0% -0.13 [-1.19, 0.93] n.a.
Subtotal all 0.07 [-0.04, 0.17] 46% 0.10 [-0.61, 0.80] 0%
- U46619
Kim GP 0.27 [-0.05, 0.59] -0.31 [-1.25, 0.63]
Subtotal GP 0.27 [-0.05, 0.59] n.a. -0.31 [-1.25, 0.63] n.a..
- Vasopressin
St-Louis SDR 0.18 [-0.03, 0.39] 0.51 [-0.25, 1.26]
Subtotal SDR 0.18 [-0.03, 0.39] n.a. 0.51 [-0.25, 1.26] n.a.
Overall SDR 0.17 [0.07, 0.27] 0% 0.06 [-0.43, 0.56] 9%
Overall GP 0.09 [-0.19, 0.37] 61% -0.02 [-0.68, 0.64] 0%
Overall all 0.10 [0.01, 0.19] 28% 0.04 [-0.35, 0.42] 0%
(PGI2-blockade)
- Phenylephrine
Davidge SDR 0.12 [0.02, 0.22] Not estimable
Subtotal SDR 0.12 [0.02, 0.22] n.a. Not estimable
- U46619
Kim GP 0.26 [-0.06, 0.58] -0.50 [-1.53, 0.54]
Subtotal GP 0.26 [-0.06, 0.58] n.a. -0.50 [-1.53, 0.54] n.a.
Overall all 0.13 [0.04, 0.23] 0% -0.50 [-1.53, 0.54] n.a.
(without endothelium)
- Phenylephrine
Davidge SDR 0.18 [0.04, 0.32] Not estimable
Subtotal SDR 0.18 [0.04, 0.32] n.a. Not estimable
- U46619
Kim GP 0.19 [-0.56, 0.94] 0.47 [-0.58, 1.52]
Subtotal GP 0.19 [-0.56, 0.94] n.a. 0.47 [-0.58, 1.52] n.a.
Overall all 0.18 [0.04, 0.32] 0% 0.47 [-0.58, 1.52] n.a.
Favors more
vasoconstriction
Favors less
vasoconstriction
Favors less
vasoconstriction
Favors more
vasoconstriction
0.13 [0.04, 0.23]
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Figure 7. Effect of late pregnancy on mesenteric artery responses to stimuli involved in vasoconstriction 
through the GqSMC-coupled pathway after blockade of the nitric oxide- (NO), prostacyclin- (PGI2) pathway 
or endothelium denudation.
The effect of pregnancy on EC50 (the dose of stimulus inducing 50% response) is depicted as mean difference 
(MD) and its 95% confidence interval (95% CI). Emax (maximum response) is presented as standardized mean 
difference (SMD) and its 95% CI. Studies and totals based on Sprague Dawley rats (SDR), Wistar rats (WR), 
mice and guinea pigs (GP). I2 represents the amount of heterogeneity. n.a. = not applicable.
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EC50 Emax
Substance / study MD [95% CI] I2 MD [95% CI] SMD [95% CI] I2 SMD [95% CI]
MID-GESTATION
(without blockade)
- CGRP
Van Eindhoven WR -2.58 [-4.41, -0.75] 2.08 [0.95, 3.21]
Subtotal WR -2.58 [-4.41, -0.75] n.a. 2.08 [0.95, 3.21] n.a.
- (hCG)
Hermsteiner SDR# 1.05 [0.84, 1.26] Not estimable
Subtotal SDR 1.05 [0.84, 1.26] n.a. Not estimable
Overall -2.58 [-4.41, -0.75] n.a. 2.08 [0.95, 3.21] n.a.
LATE-GESTATION
(without blockade)
- Adrenomedullin
Chauhan SDR -0.61 [-1.01, -0.21] 1.33 [0.18, 2.47]
Ross SDR -0.36 [-0.69, -0.03] 1.00 [0.20, 1.80]
Subtotal SDR -0.46 [-0.72, -0.21] 0% 1.11 [0.45, 1.77] 0%
- CGRP
Gangula SDR -1.12 [-1.70, -0.54] Not estimable
Subtotal SDR -1.12 [-1.70, -0.54] n.a. Not estimable
- (hCG)
HermsteinerSDR# 0.68 [0.48, 0.88] Not estimable
Subtotal SDR 0.68 [0.48, 0.88] n.a. Not estimable
- Isoproterenol
Ballejo WR 0.25 [0.12, 0.38] -0.20 [-0.86, 0.46]
Parent SDR -0.24 [-0.50, 0.02] 0.36 [-0.58, 1.29]
Subtotal all 0.02 [-0.46, 0.50] 91% -0.02 [-0.55, 0.52] 0%
Overall SDR -0.51 [-0.82, -0.20] 65% 0.86 [0.33, 1.40] 0%
Overall all -0.37 [-0.80, 0.06] 91% 0.44 [0.02, 0.85] 62%
(without endothelium)
- (hCG)
Hermsteiner SDR# -0.44 [-0.70, -0.18] Not estimable
Subtotal SDR -0.44 [-0.70, -0.18] n.a. Not estimable
Favors more
vasodilation
Favors less
vasodilation
Favors less
vasodilation
Favors more
vasodilation
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Figure 8. Effect of mid and late pregnancy on mesenteric artery responses to stimuli involved in vasodilation 
through the GsSMC-coupled pathway in presence and absence of endothelium.
The effect of pregnancy on EC50 (the dose of stimulus inducing 50% response)  is depicted as mean difference 
(MD) and its 95% confidence interval (95% CI). Emax (maximum response) is presented as standardized mean 
difference (SMD) and its 95% CI. Studies and totals based on Sprague Dawley rats (SDR) and Wistar rats 
(WR). I2 represents the amount of heterogeneity. n.a. = not applicable. # excluded study-response because 
of both EC and SMC involvement.
was upregulated in early and midgestation without change in myogenic reactivity. In late 
pregnant SDR, flow-mediated vasodilation and compliance were upregulated, and two 
out of three studies showed a reduction in myogenic reactivity. One study showed similar 
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EC50 Emax
Substance / study MD [95% CI] I2 MD [95% CI] SMD [95% CI] I2 SMD [95% CI]
MID-GESTATION
(without blockade)
- Nitroprusside
Parent SDR* 0.09 [-0.34, 0.52] -0.08  [-0.61, 0.77]
Subtotal SDR 0.09 [-0.34, 0.52] n.a. -0.08  [-0.61, 0.77] n.a.
LATE-GESTATION
(without blockade)
- Nitroprusside
Gerber WR 0.10 [-0.37, 0.57] -0.15 [-1.05, 0.76]
Learmont WR -0.24 [-0.82, 0.34] Not estimable
Parent SDR* -0.06 [-0.37, 0.49] 0.00 [-0.82, 0.82]
Cooke mice 0.00 [-0.10, 0.10] Not estimable
Subtotal WR -0.03 [-0.40, 0.33] 0% -0.15 [-1.05, 0.76] n.a.
Subtotal all 0.00 [-0.09, 0.09] 0% -0.07 [-0.67, 0.54] 0%
- SpermineNONOate
Koumentaki WR 0.03 [-0.25, 0.31] -0.37 [-1.30, 0.56]
Gerber SDR -0.04 [-0.62, 0.54] 0.76 [-0.27, 1.78]
Subtotal all 0.02 [-0.23, 0.27] 0% 0.17 [-0.93, 1.28] 61%
Overall WR 0.01 [-0.22, 0.23] 0% -0.25 [-0.90, 0.39] 0%
Overall SDR 0.04 [-0.30, 0.39] 0% 0.31 [-0.42, 1.04] 22%
Overall all 0.00 [-0.08, 0.09] 0% 0.02 [-0.43, 0.48] 0%
Favors more
vasodilation
Favors less
vasodilation
Favors less
vasodilation
Favors more
vasodilation
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Figure 9. Effect of mid and late pregnancy on mesenteric artery responses to nitric oxide (NO).
The effect of pregnancy on EC50 (the dose of stimulus inducing 50% response)  is depicted as mean difference 
(MD) and its 95% confidence interval (95% CI). Emax (maximum response) is presented as standardized mean 
difference (SMD) and its 95% CI. Studies and totals based on Sprague Dawley rats (SDR), Wistar rats (WR) and 
mice. * Whole Organ Perfusion Myograph. I2 represents the amount of heterogeneity. n.a. = not applicable.
Table 5. Summary of qualitative changes in mesenteric artery adaptation to pregnancy.
Early-gestation Midgestation Late-gestation
WR SDR WR SDR WR SDR
Vasodilator
- GqEC . . . =
2 =4 ↑3
- Flow-mediated vasodilation . . ↑1 . ↑1 ↑1
- Vascular compliance . ↑1 =1 ↑1 =1 ↑2
- GsSMC . . ↑
1 . ↓1 ↑4
Vasoconstrictor
- GqSMC . . =
1 =4 =6 ↓12
- Myogenic reactivity . =1 =1 =1 =2 ?3
Pregnancy-induced vascular function: increase (↑), decrease (↓), no change (=), inconsistent effects (?), 
no effects reported (.), Superscripted values are number of responses on which effect is based. EC, 
endothelial cell; SMC, smooth muscle cell
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EC50 Emax
Substance / study MD [95% CI] I2 MD [95% CI] SMD [95% CI] I2 SMD [95% CI]
LATE-GESTATION
(without blockade)
- EFS
Coelho WR* Not estimable -1.47 [-2.76, -0.19]
Subtotal WR Not estimable - -1.47 [-2.76, -0.19] n.a.
Favors more
vasoconstriction
Favors less
vasoconstriction
Favors less
vasoconstriction
Favors more
vasoconstriction
LATE-GESTATION
(without blockade)
- MgSO4
Euser SDR -0.20 [-0.34, -0.06] -0.56 [-1.73, 0.60]
Subtotal SDR -0.20 [-0.34, -0.06] n.a. -0.56 [-1.73, 0.60] n.a.
- Potassium
Koumentaki WR -0.07 [-0.10, -0.04] -0.61 [-1.49, 0.27]
D’Angelo SDR 0.03 [-0.02, 0.08] 0.61 [-0.62, 1.84]
Meyer SDR 0.10 [-0.00, 0.20] Not estimable
Subtotal SDR 0.05 [-0.01, 0.11] 29% 0.61 [-0.62, 1.84] n.a.
Subtotal all 0.01 [-0.09, 0.11] 89% -0.08 [-1.26, 1.11] 60%
Favors more
vasodilation
Favors less
vasodilation
Favors less
vasoconstriction
Favors more
vasconstriction
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Figure 10. Effect of late pregnancy on mesenteric artery responses to electrical field stimulation (EFS), 
MgSO4 and potassium.
The effect of pregnancy on EC50 (the dose of stimulus inducing 50% response) is depicted as mean difference 
(MD) and its 95% confidence interval (95% CI). Emax (maximum response) is presented as standardized mean 
difference (SMD) and its 95% CI. Studies and totals based on Sprague Dawley rats (SDR) and Wistar rats (WR). 
* Whole Organ Perfusion Myograph. I2 represents the amount of heterogeneity. n.a. = not applicable.
results in mice. Single studies on NO blockade showed that flow-mediated vasodilation 
was inconsistently NO dependent in WR, and not NO dependent in SDR. In mice, the 
reduced myogenic reactivity was dependent on NO and independent of PGI2. The data 
suggest that pregnancy upregulates flow-mediated vasodilation in both WR and SDR. 
SDR, but not WR, employ reduced myogenic reactivity and increased compliance. 
robustness of estimates
Sensitivity-analysis was used to assess the robustness of our findings. It showed that the 
results were not affected by extending the inclusion for studies that did not match the 
criteria “nulliparity” (n=11) or “age-matching” (n=18) (data not shown). 
Overall effect-size estimates, across species and strains, showed considerable 
heterogeneity (I2 >60%). For most responses, this could be reduced to an appropriate 
effect-size (I2 <60%) only by stratification for stimulus, and/or species, and/or strain. 
Stratification by strain was applicable only to rats (SDR vs. WR).
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Substance / study Flow-mediated vasodilation Myogenic reactivity Compliance
EARLY-GESTATION
(without blockade)
McLaughlin SDR (n=31) (n=31)
MID-GESTATION
(without blockade)
Van Drongelen WR (n=17) (n=17) (n=20)
McLaughlin SDR (n=31) (n=31)
(NO-blockade)
Van Drongelen WR (n=14)
LATE-GESTATION
(without blockade)
Cockell WR (n=20) (n=32) (n=32)
Learmont WR (n=11)
Mackey SDR (n=11)
McLaughlin SDR (n=34) (n=34)
Meyer (a) SDR (n=10)
Ralevic SDR* (n=11)
St-Louis SDR (n=40)
Veeradaddy mice (n=34) (n=31)
Overall WR
Overall SDR ?
Overall all ?
(NO-blockade)
Cockell WR (n=20)
Van Drongelen WR (n=13)
Ralevic SDR* (n=13)
Veeradaddy mice (n=16)
Overall WR ?
Overall all ?
(PGI2-blockade)
Ralevic SDR* (n=10)
Veeradaddy mice (n=?)
(NO- andPGI2- blockade)
Veeradaddy mice (n=16)
(without endothelium)
Veeradaddy mice (n=6)
Favors less
vasodilation
Favors more
vasodilation
Favors less
vasoconstriction
Favors more
vasoconstriction
Favors less
vasodilation
Favors more
vasodilation
Figure 11. Effect of early, mid and late pregnancy on mesenteric artery responses to flow-mediated 
vasodilation, myogenic response and vascular compliance.
The effect of pregnancy on the response to stimuli, depicted as the difference in direction. ? = unknown 
or non-conclusive data. Studies and totals based on Sprague Dawley rats (SDR), Wistar rats (WR) and mice. 
* Whole Organ Perfusion Myograph. n = number of subjects.
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discussion 
Pregnancy has a profound vasodilator effect, yet the mechanisms underlying the altered 
vessel function in various vascular beds are complex and only partially understood 1;3;20-22. 
Pathways involved in pregnancy-induced vasodilation in mesenteric arteries differ between 
species and even strains (Table 5). Our meta-analysis showed that the considerable heterogeneity 
for several overall responses could be reduced to acceptable levels by stratification for species 
and strain. This was most obvious for the differences between SDR and WR. Pregnancy 
increases flow-mediated vasodilation in both SDR and WR. However, whereas WR do not use 
any other mechanism for vasodilation, SDR additionally increase arterial compliance, activate 
GqEC and GsSMC receptor-coupled vasodilation pathways, and reduce GqSMC-coupled receptor-
mediated vasoconstriction. The differences between the two strains may reflect their vascular 
health, as SDR, but not WR, are known to develop severe vascular dysfunction, including 
chronic progressive nephropathy, peri-/vasculitis, and chronic cardiomyopathy, later in life 
(internal study by K. Weber, The Researcher, no 28, March 2009, Harlan). Teleologically, one 
might argue that SDR must employ the additional mechanisms to cope with the vasodilatory 
demands of pregnancy, whereas flow-mediated vasodilation suffices in WR. If that is the case, 
WR would be the better model to investigate healthy pregnancy vasodilation, whereas the 
SDR is the more appropriate model to examine vascular maladaptation.
Vasodilation and the involved mechanisms are gestational age dependent. Data on 
mechanisms are absent for early pregnancy and limited for midgestation. In mesenteric 
arteries in midgestation WR, flow-mediated vasodilation is upregulated, whereas data on 
the other responses are lacking. In SDR, GqEC- and GqSMC-coupled pathways and myogenic 
reactivity are virtually unaffected, while GsSMC-coupled vasoconstriction is reduced and 
arterial compliance is increased. In late gestation WR flow-mediated vasodilation remains 
increased, while the other responses are not affected. In SDR, GqEC- and GsSMC-coupled 
vasodilation, flow-mediated vasodilation, and vascular compliance are increased, whereas 
the GqSMC-coupled vasoconstrictor pathway is downregulated. This suggests that, dependent 
on the strain, additional vascular responses are elicited with advancing gestation.
Pregnancy enhances relaxation by adaptation of the EC (endothelium-dependent 
pathways) and the SMC itself (endothelium-independent pathways), depending on 
species/strain. Endothelium-dependent vasodilator responses are studied through flow 
and GqEC-related stimuli, which share a common down-stream pathway 
12;23. Our meta-
analysis showed that endothelium-mediated vasodilation in pregnancy depends on 
increased production of NO and PGI2 by the EC, as proposed by Carbillon et al. 
24, whereas 
SMC sensitivity to these substances remains unaltered. The effect of pregnancy on SMC 
itself is studied by deactivation of the EC. Under NO, PGI2 blockade, or endothelium 
denudation, pregnancy reduces the vasoconstrictor GqSMC-coupled pathway and activates 
the vasodilator GsSMC-coupled pathway, whereas myogenic reactivity is not consistently 
affected. These data suggest that pregnancy affects the endothelium-dependent pathways 
and, dependent on the species/strain, also the endothelium-independent pathways.
It is unknown how pregnancy influences the endothelium-dependent and -independent 
responses. For several vasoactive substances, the prereceptor level is unaffected 24. 
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Our meta-analysis shows that pregnancy stimulates the GqEC pathway and blunts the 
GqSMC pathway, whereas they share similar downstream pathways. This suggests that, 
for the substances tested, adaptation takes place at the receptor level and not at the 
pre- or postreceptor level. However, this does not exclude the possibility that other 
substances known to be related to pregnancy-induced vasodilation, for example relaxin 
or progesterone 25;26, might be involved at the prereceptor by acting as a facilitator or 
inhibitor for the reported pathways.
Our meta-analysis aimed to provide insight in the complexity and heterogeneity across 
species and strains concerning vascular responses involved in pregnancy-related vasodilation. 
Several methodological aspects deserve consideration. First, many studies (87%), including six 
in humans 27-32, did not meet the selection criteria shown in Figure 2. As a result, the meta-
analysis is based on responses in rodents [rats (WR and SDR), mice (C57BL/6J), and guinea 
pigs (Hartley)] only. In addition, several of the results showed considerable heterogeneity that 
resulted mainly from differences in species and strains. Therefore, the findings should not be 
extrapolated beyond the limitations of these species/strains. Second, we combined responses 
to an overall G protein-coupled pathway response, as stimuli that share a common receptor-
complex induce comparable effects. However, combining results across stimuli, species and 
strains, may distort reality, especially when responses are qualitatively different. Therefore, the 
overall effects should be interpreted with caution. Third, publication bias may have affected 
overall results across species/ strains. Most notably, SDR may have been overrepresented in the 
meta-analysis. It was the most commonly used animal, possibly due to profound activation of 
multiple pathways, but not necessarily the best representative of normal pregnancy in general. 
SDR is a strain known to have vascular dysfunction and SDR are prone to vascular disease later 
in life. Our meta-analysis shows that SDR employ additional mechanisms to realize the same 
degree of vascular adaptation to pregnancy, as compared with WR. Therefore, conclusions 
based on SDR should not be interpreted as representative of healthy pregnancy in general. 
Fourth, differences in the degree of precontraction between experiments may have affected 
flow-mediated vasodilation, Gq
EC-mediated vasodilation, and myogenic reactivity. This effect 
is likely to be small, because the degree of precontraction apparently has little effect on EC50 
33. 
Fifth, most animal experimental studies included in the analysis did not meet the stringent 
criteria for methodological quality used in systematic reviews of human trials, as details on 
randomization, blinding, withdrawals, and dropouts were often lacking. This may have affected 
our results in an unpredictable manner. We recommend that stringent methodological criteria 
are implemented in animal-experimental studies, through standardized procedures and report 
guidelines as previously advocated 34. Sixth, the overall effects should be interpreted with 
some caution, as the number of studies per subgroup is limited and overall estimates suffer 
from heterogeneity, this despite efforts to reduce heterogeneity by using a random effects 
model, performing subgroup analysis and sensitivity analysis.
In conclusion, our meta-analysis shows that in the mesenteric arterial bed, pregnancy 
increases flow-mediated vasodilation across the rat strains tested, whereas activation of 
additional pathways is species, strain, and gestational age specific. Therefore, results on 
vascular adaptation to pregnancy should not be generalized lightly beyond the limits of 
the study. Second, late pregnancy mediates vasodilation through changes at the receptor 
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level, for the substances tested. It remains a challenge to decipher the initial steps of 
vasodilation in early pregnancy.
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functional vascular chanGes  
of the kidney durinG preGnancy in animals:  
a systematic review and meta-analysis
Chapter 3 
aBstract
Renal vascular responses to pregnancy have frequently been studied, by investigating 
renal vascular resistance (RVR), renal flow, glomerular filtration rate (GFR), and renal artery 
responses to stimuli. Nonetheless, several questions remain: 1. Which vasodilator pathways 
are activated and to what extent do they affect RVR, renal flow and GFR across species, 
strains and gestational ages, 2. Are these changes dependent on renal artery adaptation, 
3. At which cellular level does pregnancy affect the involved pathways? In an attempt to 
answer the questions raised, we performed a systematic review and meta-analysis.
We included 37 studies (116 responses). At midgestation, RVR and GFR change to a 
similar degree across species and strains, accompanied by variable change in renal flow. 
At least in rats, changes depend on NO activation. At late gestation, changes in RVR, renal 
flow and GFR vary between species and strains. In rats, these changes are effectuated 
by sympathetic stimulation. Overall, renal artery responsiveness to stimuli is unaffected 
by pregnancy, except for Sprague Dawley rats in which pregnancy enhances renal artery 
vascular compliance and reduces renal artery myogenic reactivity.
Our meta-analysis shows that: 1. Pregnancy changes RVR, renal flow and GFR 
dependent on NO activation and sympathetic deactivation, but adjustments are 
different among species, strains and gestational ages; 2. These changes do not depend 
on adaptation of renal artery responsiveness; 3. It remains unknown at which cellular 
level pregnancy affects the pathways. Our meta-analysis suggests that renal changes 
during pregnancy in animals are qualitatively similar, even in comparison to humans, but 
quantitatively different.
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introduction
Profound vasodilation takes place in early pregnancy, and results in a major reduction in 
systemic vascular resistance. Vasodilation seems to be maximal at midgestation and slowly 
decreases towards term pregnancy in both humans 1 and animals 2. Several local vascular 
responses, affecting the endothelium cell (EC), smooth muscle cell (SMC) and extracellular 
matrix, are thought to be responsible for gestational vasodilation by: 1. Up regulation of 
the endothelium-dependent nitric oxide (NO) pathway 3, 2. Reduction of the responsiveness 
to vasoconstrictor stimuli 4, 3. Reduction in myogenic reactivity 5, and 4. Increase in arterial 
compliance 5. It remains to be determined to what extent each factor contributes to gestational 
vasodilation at the various stages of pregnancy among different species and strains.
Many studies on the mechanisms of vasodilation in pregnancy have focused on 
the kidney and its renal arteries. The kidney is a prominent vascular region and major 
contributor to systemic vascular resistance in the non-pregnant and pregnant  condition 6;7. 
Vessel tone has been studied by investigating several local vascular responses. These 
responses can be divided by the stimulus involved: 1. Mechanical stimuli (flow-mediated 
vasodilation, myogenic reactivity, arterial compliance), and 2. Pharmacological stimuli, 
which can be subdivided by: a. The agent used (including acetylcholine, norepinephrine, 
phenylephrine, etc.) or b. The mediating receptor complex involved 8. Most studies 
have concentrated on agents that affect the G-protein coupled receptors. These can 
be divided into three common G-protein coupled receptor pathways: the vasodilator 
GqEC-pathway which mediates NO dependent vasodilation, the vasoconstrictor GqSMC-
pathway which induces a calcium rise in the SMC, and the vasodilator GsSMC-pathway 
which induces potassium influx in the SMC 8-15.
Various species, strains and gestational age periods have been investigated and 
often the results have been extrapolated to pregnancy-induced renal adaptation in 
general and to responsible mechanisms in humans. One may question the validity of 
such extrapolations. A previous meta-analysis showed that in mesenteric arteries vascular 
adaptation to pregnancy is strongly dependent on species, strains and gestational ages 8. 
This may also be the case for renal arteries. 
To investigate which mechanisms are responsible for renal vascular changes in 
pregnancy and whether they are dependent on species, strains and gestational age periods, 
we performed a systematic review and meta-analysis on the functional vascular changes of 
the kidney during pregnancy. Questions to be answered included: 1. Which specific renal 
vasodilator pathways are activated in pregnancy and to what extent do they affect RVR, 
renal flow and GFR across species, strains and gestational ages? 2. Are the pregnancy-
induced changes in RVR, renal flow and GFR dependent on renal artery adaptation and 
which specific vasodilator pathways affect the renal artery during pregnancy? and 3. At 
which cellular level does pregnancy affect the involved pathways?
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Materials and MetHods
retrieving the literature
In an attempt to identify all original studies on renal vasoactive responses in animals and 
humans during first pregnancy, we searched the Pubmed (from 1948) and Embase (from 
1980) databases until April 2012. We used a three phase search strategy. Tables 1 and 2 
depict the search-strategy for Pubmed and Embase, respectively. No language restriction 
was used in the primary literature search; later in the process non-English studies were 
excluded. We also searched the reference lists of included studies to identify additional 
studies. The search strategy was developed in cooperation with an information specialist 
from the Medical Library of the Radboud University Nijmegen.
Table 1. Literature search-strategy for Pubmed.
Component Description
Pregnancy “pregnancy”[MeSH Terms] OR “pregnancy”[tiab] OR “pregnancies”[tiab] OR 
“gestation”[tiab] OR “pregnant”[tiab] OR “maternal-fetal relations”[tiab]
Renal circulation “renal artery” [MeSH] OR “renal artery” [tiab] OR “renal arteries” [tiab] OR 
“kidney artery” [tiab] OR “kidney arteries” [tiab] OR “renal blood vessel” [tiab] 
OR “renal blood vessels” [tiab] OR “kidney blood vessel” [tiab] OR “kidney blood 
vessels” [tiab] OR “renal vessel” [tiab] OR “renal vessels” [tiab] OR “kidney 
vessel” [tiab] OR “kidney vessels” [tiab] OR “arteria renalis” [tiab] OR “arteria 
renis” [tiab] OR “kidney/blood supply” [MeSH] OR “renal circulation” [MeSH] 
OR “renal circulation” [tiab] OR “kidney circulation” [tiab] OR “renal blood 
circulation” [tiab] OR “kidney blood circulation” [tiab] OR “renal blood supply” 
[tiab] OR “kidney blood supply” [tiab]
Vasoconstrictor and 
vasodilator responses
“vasoconstriction”[MeSH Terms] OR “vasoconstriction”[tiab] OR 
“vasoconstrictions”[tiab]  OR “vasoconstrictor agents”[MeSH Terms] OR 
“vasoconstrictor agents”[Pharmacological Action] OR “vascular resistance”[MeSH 
Terms] OR “vascular resistance”[tiab] OR “vascular capacitance”[MeSH Terms] 
OR (“vascular”[tiab] AND “capacitance”[tiab]) OR “vasoconstrictor”[tiab] OR 
“vasoconstrictors”[tiab] OR “vasopressor”[tiab] OR “vasoactive agonist”[tiab] 
OR “vasoactive agonists”[tiab] OR “vasopressors”[tiab] OR “vasomotor 
system”[MeSH Terms] OR “vasomotor system”[tiab] OR “peripheral 
resistance”[tiab] OR “artery constriction”[tiab] OR “vessel constriction”[tiab] OR 
“vasoconstrictive”[tiab] OR “vasoconstricting”[tiab] OR “vasoconstricted”[tiab] 
OR “vasodilation”[MeSH Terms] OR “vasodilation”[tiab] OR “vasodilatation”[tiab]  
OR “vasodilatating”[tiab] OR “vasodilating”[tiab]  OR “vasodilative”[tiab]  OR 
“vasodilatative”[tiab]  OR “artery dilation”[tiab] OR “vessel dilation”[tiab] 
OR “artery dilatation”[tiab] OR “vessel dilatation”[tiab] OR “vasodilator 
agents”[MeSH Terms] OR “vasodilator agents”[Pharmacological Action] OR 
“vasodilator”[tiab] OR “vasodilators”[tiab] OR “vasorelaxation”[tiab] OR 
“Vascular Endothelium Dependent Relaxation”[tiab] OR “Endothelium Dependent 
Relaxation”[tiab] OR “Vascular Endothelium-Dependent Relaxation”[tiab] OR 
“Endothelium-Dependent-Relaxation”[tiab] OR “hemodynamics”[MeSH Terms] 
OR “hemodynamics”[tiab]OR “hemodynamic”[tiab] OR “vasodilated”[tiab] 
OR “vasoactive agent”[tiab] OR “vasoactive drug”[tiab] OR “vasoactive 
drugs”[tiab] OR “dilation”[tiab]  OR “dilatation”[tiab]  OR “contraction”[tiab] OR 
“relaxation”[tiab]
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selection of studies and data extraction
The selection and data extraction process was divided into three phases (Figure 2). In the first 
phase, a. one investigator (first author) selected studies on the basis of title and abstract, 
and b. two investigators (first and second author) independently screened all remaining 
abstracts for inclusion criteria. Differences were resolved by mutual agreement. Studies were 
selected if they met the following criteria: 1. Renal vasoconstrictor/vasodilator responses, 
2. First pregnancy versus nulliparous non-pregnant control, 3. Original data, 4.) Healthy 
animals or humans, 5. Age- or weight-matched subjects, and 6. For ex vivo experiments: 
experiments performed in standard medium (defined as a generally accepted medium for 
the type of experiments). In the second phase of selection, non-English papers were excluded 
from further analysis and full articles were analyzed by two investigators (first and second 
author) independently using the same inclusion criteria as described above. Differences 
were resolved by mutual agreement. In the third phase, the first author extracted baseline 
Table 2. Literature search-strategy for Embase.
Component Description
Pregnancy exp pregnancy/ OR (pregnancy or pregnant).ti,ab. OR (pregnacies or gestation).
ti,ab. OR (pregnancy or pregnant or pregnacies or gestation).ti,ab.
Renal circulation exp renal artery/ OR renal artery.ti,ab. OR renal arteries.ti,ab. OR arteria renalis.
ti,ab. OR exp kidney artery/ OR kidney artery.ti,ab. OR kidney arteries.ti,ab. OR 
arteria renis.ti,ab. OR kidney blood vessel/ OR renal blood vessel.ti,ab. OR renal 
blood vessels.ti,ab. OR kidney blood vessel.ti,ab. OR kidney blood vessels.ti,ab. 
OR intrarenal vessel.ti,ab. OR intrarenal vessels.ti,ab. OR renal vessel.ti,ab. OR 
renal vessels.ti,ab. OR kidney vessel.ti,ab. OR kidney vessels.ti,ab. OR exp kidney 
blood flow/ OR kidney blood flow.ti,ab. OR intrarenal blood flow.ti,ab. OR kidney 
bloodflow.ti,ab. OR renal blood flow.ti,ab. OR kidney blood supply.ti,ab. OR renal 
blood supply.ti,ab. OR exp kidney circulation/ OR kidney circulation.ti,ab. OR 
intrarenal circulation.ti,ab. OR kidney blood circulation.ti,ab. OR renal circulation.
ti,ab. OR renal blood circulation.ti,ab.
Vasoconstrictor and 
vasodilator responses
exp vasoconstriction/ OR exp vasoconstrictor agent/ OR vasoconstrict*.ti,ab. OR 
exp vascular resistance/ OR blood flow resistance.ti,ab. OR blood vessel resistance.
ti,ab. OR (peripheral adj1 resistance).ti,ab. OR vascular vessel resistance.ti,ab. OR 
artery resistance.ti,ab. OR exp hemodynamics/ OR exp blood vessel capacitance/ OR 
blood vessel capacitance.ti,ab. OR vascular capacitance.ti,ab. OR (hemodynamic or 
hemodynamics).ti,ab. OR (haemodynamic or haemodynamics).ti,ab. OR vasopressor.
ti,ab. OR exp vasoactive agent/ OR (vasoactive agonist OR vasoactive agonists or 
vasoactive agent or vasoactive agents or vasoactive drug or vasoactive drugs).
ti,ab. OR (vessel contriction or vessel contrictions or artery contriction or artery 
constrictions).ti,ab. OR exp vasodilatation/ OR (vasodilatation or vasodilation or 
vasodilator or vasodilatator or vasodilating or vasodilative or vasodilatative).ti,ab. 
OR (vaso dilatation or vaso dilation or vaso dilator or vaso dilatator or vaso dilating 
or vaso dilative or vaso dilatative).ti,ab. OR vaso relaxation.ti,ab. OR vascular 
endothelium dependent relaxation.ti,ab. OR vascular endothelium-dependent 
relaxation.ti,ab. OR endothelium dependent relaxation.ti,ab. OR endothelium-
dependent relaxation.ti,ab. OR (vessel dilatation* or vessel dilation* or vascular 
dilation* or vascular dilatation* or vasorelaxation* or artery dilatation* or artery 
dilation*).ti,ab. OR (dilatation* or dilation* or relaxation* or contraction*).ti,ab.
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measurements and responses to specific blockade from in vivo and whole organ perfusion 
experiments that related to renal function changes and the involved pathways. In addition, 
all vasodilator and vasoconstrictor responses were extracted both in the absence and 
presence of blockade of NO, prostaglandin (PGI2), renin-angiotensin-aldosterone (RAAS), 
endothelin, vasopressin or the sympathetic system, or combinations of blockade, with and 
without denuded endothelium. Responses had to contain ≥ 5 measurements to be included 
in further analysis, as analysis of sensitivity to stimuli is not accurate with fewer data points.
From each article, study data were extracted and recorded for species, strain, and gestational 
age (early, mid- and late pregnancy, defined as first, second and third trimester, respectively), 
estrous/cycle stage, and experimental setup (in vivo /whole organ perfusion, myograph type 
used). We extracted all reported vascular responses and recorded for each of them the number 
of subjects, effect size, and standard deviation or standard error of the mean. For in vivo and 
whole organ perfusion experiments we detected baseline renal vascular resistance (RVR), renal 
flow (combined renal plasma, blood and perfusion flow), glomerular filtration rate (GFR), 
autoregulatory threshold (lower pressure limit for stable renal flow), and the response to specific 
blockades. For pharmacological responses, we extracted EC50 (concentration inducing 50% 
of the maximum effect) and Emax (maximum response to stimulus) to indicate sensitivity and 
maximum reactivity, respectively. For the mechanical responses, we determined the direction 
of the effect (favoring vasodilation, vasoconstriction, or no effect) and used it for descriptive 
analysis. Parametric comparison of these responses was not possible, as analyses (mostly ANOVA 
statistics) did not allow calculating overall effect sizes and effect measures were reported in 
variable ways (for myogenic reactivity and arterial compliance (absolute values, percentages of 
diameter changes, myogenic tone in relation to passive tone)). In case of missing, incomplete or 
indeterminate data, we approached the authors by email (response rate 33%).
Quality assessment
The methodological quality of the articles was assessed independently by two reviewers (first 
and second author). Data were scored on presence or absence of randomization of allocation 
to groups, blinding of outcome assessment, clearness on nulliparity at entry of study, age or 
weight of subjects described, and number of animals accounted for at the start and the end 
of the study. The quality of the responses reported was ranked for the clarity of the number 
of animals used for analyses, presence of a response graph containing ≥5 measurements, 
and achievement of Emax (defined as the presence of at least two measurements without any 
further increasing effect). The response quality was expressed as percentage of the number of 
responses that complied with these items divided by the total number of responses described 
in the study. It should be noted that the quality assessment determines the quality of the 
methodology required for comparison of responses to the predefined items and that it should 
not be interpreted as judgment of the value of the experiment per se.
Quantitative data synthesis and statistical analysis
Extracted data in RVR, renal flow and GFR at baseline, changes induced by specific 
blockades, and EC50 and Emax for pharmacological stimuli were analyzed for each 
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gestational age period, stratified by species and strain, and displayed in forest plots, 
using Review Manager 5 (The Nordic Cochrane Centre, The Cochrane Collaboration, 
2008). Pharmacological stimuli were analyzed by the type of G-protein-coupled pathway 
(GqEC, GqSMC and GsSMC) involved or by type of stimulus (NO-donors and potassium), 
when applicable. Combined effect sizes were calculated as weighed mean difference 
(MD) for RVR, renal flow, GFR and EC50, and as standardized mean difference (SMD) 
for Emax. Both MD and SMD represent the effect sizes in comparison to control values 
within the same study. In the forest plots data were presented as mean effect sizes with 
95% confidence intervals (CI), as provided by Review Manager 5. Combined effect sizes 
were calculated by using the random effects model (Review Manager 5). P-values <0.05 
were considered to represent statistical significance. In the random effects model some 
heterogeneity beyond sampling errors is allowed to account for anticipated heterogeneity. 
Heterogeneity was presented as I2; I2 <60% represents moderate heterogeneity, I2 >60% 
represents considerable to substantial heterogeneity 16. Publication bias was assessed by 
linear regression analysis as proposed by Egger et al. (for ≥10 studies) 17 or subjective 
assessment of funnel plot asymmetry (for ≤10 studies).
For mechanical stimuli, we used the direction of the measured effects for qualitative 
analysis, and determined the overall weighed direction for each mechanical response, 
based on the total number of animals used.
We performed sensitivity analysis to assess the robustness of our findings, as is 
recommended for systematic reviews 16. This type of analysis shows the influence of 
the used inclusion and exclusion criteria on the results. In the analysis we repeated all 
analyses in the presence of the studies that were excluded on the basis of the criterion first 
pregnancy versus nulliparous non-pregnant control.
References used for analysis included the following: 18-54
results
Our systematic literature search identified 1008 studies concerning the effects of pregnancy 
on vascular changes of the kidney (Figure 1). Based on title and abstract 917 studies were 
excluded, leaving 91 papers for full article evaluation. Thirty-seven studies did not meet the 
inclusion criteria. Seventeen studies were excluded based on their non-English language. 
Finally, 37 studies with 116 vascular responses met the inclusion criteria for meta-analysis. 
The study characteristics are presented in Table 3. Most studies (n=28) used rats (Long 
Evans rats (LER), Sprague Dawley rats (SDR), various strains of Wistar rats (Wistar Kyoto 
(WKY), Munich Wistar (MWR) and Wistar Hannover (WHR)); other species were used 
less frequently (sheep=6, rabbits=2 and guinea pigs (GP)=1). Most studies contained in 
vivo experiments (n=25), while whole organ (perfusion), perfusion myograph and wire 
myograph experiments were less common (n=5, 3 and 4 respectively). Methodological 
limitations were present in a substantial portion of the included studies (Table 4): 43% 
(16/37) did not present the number of animals used, 32% (12/37) did not present parity, 
97% (36/37) did not report having performed randomization, and 0% reported blinding 
of the outcome assessment.
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Table 3. Characteristics of included studies, arranged by author and year.
Study Species (strain)
Estrous 
stage 
control 
group
Gestation 
period
Experiment 
setup
Number of 
described 
baseline 
measurements
Number of 
described 
responses
Annibale et al., 1989 sheep - late WM n.a. 4
Baylis et al., 1986 rat (MWR) - late IV 4 10
Baylis et al., 1988 rat (MWR) - mid IV 3 0
Baylis et al., 1993 rat (SDR and MWR) - mid/late IV 4 4
Baylis et al., 1995 rat (SDR)# - mid/late IV 2 2
Bobadilla et al., 2001 rat (WR) - ? WOP 1 4
Bobadilla et al., 2003 rat (WR) - mid/late WOP 2 16
Bobadilla et al., 2005 rat (WR) - late WOP 1 2
Cha et al., 1993 sheep - late IV 1 0
Cha et al., 1993 sheep - late IV 1 0
Chu et al., 1997 rat (WKY) - late WOP 0 0
Conrad et al., 1989 rat (LE) - late IV 1 1
Conrad et al., 1999 rat (LE) - mid IV 1 2
Danielson et al., 1995 rat (LE) - mid IV 1 3
Danielson et al., 1996 rat (LE) - mid IV 1 2
Fan et al., 1996 sheep - late IV 1 0
Ferris et al., 1983 rabbit - late IV 2 0
Gandley et al., 1997 rat (SDR) - late PM n.a. 4
Gandley et al., 2001 rat (LE) - mid PM n.a. 9
Greenberg et al., 1999 sheep - late IV 1 0
Griggs et al., 1993 rat (SDR) - late PM n.a. 6
Hines et al., 1992 rat (SDR) - mid/late IV 2 4
Hines et al., 2000 rat (SDR) - late IV 1 1
Kim et al., 1994 guinea pig - Late WM n.a. 12
Knight et al., 2007 rat (SDR) - late IV 0 0
Masilamani et al., 1994 rat (SDR) - mid/late IV 1 0
McElvy et al., 2001 sheep - late IV 1 0
Novak et al., 1997 rat (SDR) - mid IV 1 0
Omer et al., 1999 rat (SDR) - late IV 1 1
Patel et al., 1993 rat (SDR) - late IV 2 0
Reckelhoff et al., 1992 rat (WR) - mid IV 2 2
Sen et al., 1997 rat (?) - mid/late IV 2 0
Sicinska et al., 1971 rat (SDR) - late IV 1 0
Van Drongelen et al., 2011 rat (WR) - mid WOP 1 1
Van Eijndhoven et al., 2003 rat (WR) - mid WM n.a. 1
Van Eijndhoven et al., 2007 rat (?) - mid WM n.a. 2
Woods et al., 1987 rabbit - late IV 1 1
WM = wire myograph, PM = pressure myograph, PPM = pressure-perfusion myograph, WOP = whole organ 
perfusion, IV = in vivo. n.a.= not applicable. # data received by email.
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Identified studies (n=1008)
Subtracted studies (n=91)
Exclusion based on title and abstract (n=917)
- No healthy subjects (n=78)
- No first pregnancy versus nulliparous non-pregnant control (n=303)
- No maternal responses (n=286)
- No renal vasoconstrictor/vasodilator response (n=39)
- Review/editorial/case report (n=211)
Included studies (n=37, r=116)
Exclusion based on full article (n=54)
- No healthy subjects (n=1)
- No first pregnancy versus nulliparous non-pregnant control (n=9)
- No renal artery vasoconstrictor/vasodilator response (n=15)
- No age-matching (n=1)
- Combination of the above (n= 11)
- Language other than English (n=17)
In vivo and whole organ 
perfusion experiments (r=78) Renal artery experiments (r=38)
(r=11)• Complete data available
(r=20)Included responses to specific blockade
(r=27)• Complete data available
(r=42)Included baseline measurements
(r=3)
(r=3)
(r=23)
(r=0)
(r=2)
(r=21)
(r=26)
(r=22)
(r=22)
(r=7)
(r=21)
- Pharmacological
EC50 described
Emax described
Graph present
(r=6)• Graph present
(r=6)- Mechanical
(r=28)Included responses
(r=1)
(r=50)
(r=13)
(r=52)
(r=0)
(r=10)
(r=0)
- Presence of blockade other than NO, 
PGI2, endothelium, RAAS, endothelin, 
vasopressin or sympathetic
- <5 measurements
- not pharmacological/mechanical
(r=10)Excluded responses
(r=36)
(r=36)
- not measuring RVR, renal flow or GFR
Excluded responses
Figure 1. Flow chart for selection, inclusion and exclusion of studies and responses on renal vascular 
adaptation to pregnancy. n= number of studies; r= number of responses (gray filling for in vivo and whole 
organ perfusion experiments, dotted filling for renal artery responses).
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Table 4. Quality assessment of the included studies and subsequent responses.
Study
Study quality Response quality
(1) (2) (3) (4) (5) Score (6) (7) (8) Score
Annibale et al., 1989 - - ? - + 1 1.0 1.0 1.0 3.0
Baylis et al., 1986 - - + + + 3 1.0 0.0 0.0 1.0
Baylis et al., 1988 - - + + - 2 1.0 0.0 0.0 1.0
Baylis et al., 1993 - - + - + 2 1.0# 0.0 0.0 1.0#
Baylis et al., 1995 - - + + - 2 1.0 0.0 0.0 1.0
Bobadilla et al., 2001 - - + + - 2 1.0 1.0 0.0 2.0
Bobadilla et al., 2003 - - + + + 3 1.0 1.0 0.0 2.0
Bobadilla et al., 2005 - - + + - 2 1.0 1.0 0.5 2.5
Cha et al., 1993a - - ? + + 2 0.0 0.0 0.0 0.0
Cha et al., 1993b - - ? - + 1 0.0 1.0 1.0 2.0
Chu et al., 1997 - - ? + - 1 1.0 0.0 0.0 1.0
Conrad et al., 1989 n.a. - + + + 3 1.0 0.0 0.0 1.0
Conrad et al., 1999 - - + + - 2 0.0 0.0 0.0 0.0
Danielson et al., 1995 - - + + + 3 0.0 0.0 0.0 0.0
Danielson et al., 1996 + - + + - 3 1.0 0.0 0.0 1.0
Fan et al., 1996 - - ? - + 1 1.0 0.0 0.0 1.0
Ferris et al., 1983 - - ? - + 1 1.0 0.0 0.0 1.0
Gandley et al., 1997 - - + + - 2 1.0 1.0 0.75 2.75
Gandley et al., 2001 - - + - - 1 0.9 0.2 0.2 1.3
Greenberg et al., 1999 - - ? + + 2 0.0 0.0 0.0 0.0
Griggs et al., 1993 - - + + - 2 1.0 0.16 0.33 1.49
Hines et al., 1992 - - + - - 1 1.0 0.0 0.0 1.0
Hines et al., 2000 - - + - + 2 0.33 0.66 0.0 1.0
Kim et al., 1994 - - ? - - 0 1.0 1.0 1.0 3.0
Knight et al., 2007 - - + + + 3 1.0 0.0 0.0 1.0
Masilamani et al., 1994 - - + + + 3 1.0 0.0 0.0 1.0
Masilamani et al., 1994 - - + + + 3 1.0 0.0 0.0 1.0
McElvy et al., 2001 - - ? + + 2 1.0 1.0 0.0 2.0
Novak et al., 1997 - - ? - - 0 0.0 0.0 0.0 0.0
Omer et al., 1999 - - + + - 2 0.0 0.0 0.0 0.0
Patel et al., 1993 - - + - + 2 1.0 0.0 0.0 1.0
Reckelhoff et al., 1992 - - + + - 2 1.0 1.0 1.0 3.0
Sen et al., 1997 - - ? - - 0 1.0 0.0 0.0 1.0
Sicinska et al., 1971 - - ? + + 2 0.0 0.0 0.0 0.0
Van Drongelen et al., 2011 - - + + + 3 1.0 0.0 1.0 2.0
Van Eijndhoven et al., 2003 - - + + + 3 0.0 0.0 0.0 0.0
Van Eijndhoven et al., 2007 - - + + + 3 0.5 0.0 0.0 0.5
Woods et al., 1987 - - + - + 2 1.0 1.0 1.0 3.0
(1) randomization, (2) blinding of outcome assessor, (3) virgin/nulliparous at entry study, (4) age or 
weight of animals described, (5) number of used animals clear from methods, (6) fraction of responses 
with clear number of animals used for statistical analyses (as a percentage of the number of described 
responses), (7) fraction of responses with dose-response curve containing ≥5 measurements, (8) fraction 
of responses with accomplished Emax. n.a.= not applicable. 
# data received by email.
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The 116 subtracted vascular responses could be divided into two categories: 1. In 
vivo and whole organ perfusion studies measuring changes in RVR, renal flow and/or 
GFR, and 2. Renal artery experiments measuring changes in vascular tone. Experiments 
were performed mainly in mid- (34%, 40/116) and late (63%, 73/116) gestation; for four 
responses the gestation period was not defined. Early gestation was not investigated by 
any of the included studies. 
We identified 78 in vivo and whole organ perfusion experiments. Two types of 
experiments could be distinguished based on their objective to determine the effects of 
pregnancy on: 1) RVR, renal flow and GFR, or 2) the response of the kidney to vaso-active 
substances. For the first type of experiments we extracted 42 baseline measurements 
and 20 responses to specific blockades. Thirty-six responses were excluded as they did 
not measure RVR, renal flow or GFR. After exclusion of incomplete data, 27 baseline 
measurements and 11 responses to specific blockades were suitable for meta-analysis. 
For the second type of experiments we identified 23 pharmacological and 3 mechanical 
responses. For pharmacological stimuli, EC50 was reported in 0% of the responses, Emax was 
described in 9% and a graph was present in 91%. For mechanical stimuli, all responses 
were presented graphically without quantified effects.
From the 38 renal artery responses, 28 met the criteria for inclusion. They consisted of 
22 pharmacological stimuli (EC50, Emax and a graph present in 100%, 32% and 95% of the 
cases, respectively) and six mechanical stimuli, all with a graph without quantified effects.
In vivo and whole organ perfusion experiments 
The influence of mid-pregnancy on kidney function is presented in Figure 2. In mid-
pregnancy, overall (across species and strains) RVR decreases by 27%, varying from 18% 
in SDR to 31% in MWR. Renal flow is enhanced to a variable degree, ranging from 13% 
in WHR to 31% in LER. GFR increases by 17% in SDR to 29% in LER. In LER, blockade of 
the NO system completely normalizes the pregnancy-induced change in RVR and GFR, 
while pregnancy-induced increase in renal flow is reduced from 31% to 15%. In WR, NO 
blockade normalizes renal flow completely. Sympathetic or vasopressin blockade has only 
been studied in SDR and does not affect the mid-pregnancy-induced changes in RVR, renal 
flow and GFR. It appears that mid-pregnancy changes in RVR, renal flow and GFR are 
dependent on up regulation of the NO system and not on sympathetic tone or vasopressin.
The magnitude of pregnancy-induced renal changes in rats decreases from mid-
pregnancy towards term. Figures 3 and 4 show renal function in late gestation compared 
to non-pregnant controls. Late pregnancy affects RVR, renal flow and GFR differently 
among species and strains. In LER and MWR, pregnancy does not affect any of the renal 
parameters. Blockade of the renin-angiotensin-aldosteron system (RAAS) did not show 
any effect in LER, but in MWR reduced RVR by 26% and increased renal flow by 26% 
without changing in GFR. In SDR, pregnancy decreases RVR by 19% and increases both 
renal flow and GFR, by 17% and 21% respectively. NO blockade in this strain returns 
renal flow to non-pregnant values with a persistently increased GFR. Under sympathetic 
blockade RVR, renal flow and GFR return to non-pregnant values in these rats, while 
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3renal vascular chanGes durinG preGnancy
vasopressin blockade has no effect on any of the parameters. In rabbits, late pregnancy 
does not significantly affect RVR, while renal flow and GFR are increased by 29% and 39% 
compared to non-pregnant values. These changes are not affected by RAAS-blockade. 
For late pregnant sheep, no data are available on RVR, but renal flow is 21% higher 
than in non-pregnant sheep without a significant difference in GFR. In short, there is no 
consistent pattern of renal changes in late pregnancy across species and strains.
In both mid- and late pregnancy, the overall RVR, renal flow and GFR shows moderate 
to considerable heterogeneity. This cannot be attributed completely to species or strain 
specific effects, as stratification by species and/or strain does not reduce heterogeneity 
to a minimum in all groups. Heterogeneity depends mainly on single responses with 
very small confidence intervals and responses with an estimated effect opposite to other 
studies. We could not identify any methodological issue that might explain these effects.
The influence of pregnancy on the autoregulatory threshold was analyzed qualitatively 
only, as quantitative effect measures of the lower pressure boundary for stable renal flow 
were not reported in the two relevant studies, which used WR and rabbits 21;54. From these 
studies it appears that pregnancy does not affect the renal autoregulatory threshold in 
either mid- or late pregnancy. 
renal artery experiments
The renal artery changes in response to vasodilator GqEC-coupled pharmacological 
stimuli in pregnancy are presented in Figure 5. Our search only detected responses during 
late gestation, and mainly in guinea pigs. In this species, pregnancy does not affect GqEC-
coupled EC50 to acetylcholine and EC50 is unaffected by NO and PGI2 blockade.
The effects of mid- and late pregnancy on the vasoconstrictor GqSMC-coupled pathway in 
several species are shown in Figure 6; no data are available on early gestation. In both mid- and 
late gestation, the GqSMC-coupled EC50 and Emax of phenylephrine and U46619 (thromboxane 
agonist) are unaffected by pregnancy for all species investigated. In guinea pigs under NO and 
PGI2 blockade, pregnancy does not affect the response to U46619. In SDR in the absence of 
endothelium pregnancy increases EC50 in response to phenylephrine, which suggests that the 
pregnancy effect on the SMC is overruled by the endothelium. Apparently, pregnancy does 
not seem to affect the renal artery responsiveness to GqSMC-coupled vasoconstrictor stimuli.
The effect of pregnancy on the renal artery responses to NO and potassium are 
depicted in Figure 7. For NO, only single studies in rats and sheep were available. In mid- 
and late gestation rats and late pregnant sheep pregnancy does not modify the response 
to NO or potassium. This suggests that in general pregnancy does not affect the properties 
of the renal SMC to NO and potassium.
The effect of pregnancy on the renal artery responses to mechanical stimuli was 
assessed qualitatively only, as shown in Figure 8. We did not find studies that investigated 
flow-mediated vasodilation of the renal artery during pregnancy, and only two studies 
that looked at myogenic reactivity and vascular compliance in late gestation. In SDR, 
late pregnancy reduces myogenic reactivity in an endothelium-dependent manner and 
enhances vascular compliance. In sheep, late pregnancy does not affect either myogenic 
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EC50 Emax
Substance / study MD [95% CI] I2 MD [95% CI] SMD [95% CI] I2 SMD [95% CI]
LATE GESTATION
(without blockade)
- Acetylcholine
Kim GP, 2 -0.00 [-0.27, 0.27] Not estimable
Kim GP, 2 -0.03 [-0.23, 0.17] Not estimable
Kim GP, 2 -0.09 [-0.42, 0.24] Not estimable
Subtotal GP -0.03 [-0.18, 0.11] 0% Not estimable
- Methacholine
Griggs SDR, 2 -0.28 [-0.56, 0.00] -0.19 [-1.33, 0.94]
Overall SDR -0.28 [-0.56, 0.00] n.a. -0.19 [-1.33, 0.94] n.a.
Overall GP -0.03 [-0.18, 0.11] 0% -
Overall -0.08 [-0.21, 0.04] 0% -0.19 [-1.33, 0.94] n.a.
(NO-blockade)
-Acetylcholine
Kim GP, 2 -0.17 [-0.46, 0.12] Not estimable
Overall GP -0.17 [-0.46, 0.12] n.a. Not estimable
(PGI2-blockade)
-Acetylcholine
Kim GP, 2 -0.19 [-0.45, 0.07] Not estimable
Overall GP -0.19 [-0.45, 0.07] n.a. Not estimable
Favors more
vasodilation
Favors less
vasodilation
Favors less
vasodilation 
Favors more
vasodilation
-1 -0.5 0 0.5 1-1 - . -1 -0.5 0 0.5 1-4 -2 42
Figure 5. Effect of pregnancy at late gestation on renal artery responses to stimuli involved in vasodilation 
through the GqEC-coupled pathway in the presence and absence of blockade. 
The effect of pregnancy on EC50 (the dose of stimulus inducing 50% response) is depicted as mean difference 
(MD) and its 95% confidence interval (95% CI). Emax (maximum response) is presented as standardized 
mean difference (SMD) and its 95% CI. Studies and totals based on Sprague Dawley rats (SDR) and guinea 
pigs (GP). 1, 2, 3 represents first, second and third part of late gestation. I2 represents the amount of 
heterogeneity. n.a. = not applicable.
reactivity or vascular compliance. Apparently, pregnancy-induced changes in myogenic 
reactivity and compliance depend on the species investigated.
publication bias and sensitivity-analysis 
Publication bias was assessed by subjective determination of funnel plot asymmetry, as 
all analyses consisted of less than 10 studies. We did not detect evidence suggestive for 
publication bias.
Sensitivity-analysis was performed to assess the influence of inclusion criteria on the 
results. We extended the inclusion for studies that did not match the criterium “nulliparity” 
(n=3). The results were not affected by addition of these studies (data not shown). We did not 
extend the analysis for age-matching, because we had not excluded any study for that reason.
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EC50 Emax
Substance / study MD [95% CI] I2 MD [95% CI] SMD [95% CI] I2 SMD [95% CI]
MID GESTATION
(without blockade)
-Phenylephrine
Gandley LER, 3 -0.03 [-0.23, 0.17] Not estimable
Overall LER -0.03 [-0.23, 0.17] n.a. Not estimable
LATE GESTATION
(without blockade)
- Phenylephrine
Griggs SDR, 2 -0.03 [-0.18, 0.12] 0.16 [-1.11, 1.43]
Griggs SDR, 2 0.06 [-1.87, 1.99] 0.55 [-0.43, 1.52]
Annibale Sheep, 2 0.00 [-0.29, 0.29] -0.58 [-1.81, 0.64]
Subtotal SDR -0.03 [-0.18, 0.12] 0% 0.40 [-0.37, 1.18] 0%
Subtotal sheep 0.00 [-0.29, 0.29] n.a. -0.58 [-1.81, 0.64] n.a.
Subtotal all -0.02 [-0.16, 0.11] 0% 0.12 [-0.53, 0.78] 0%
- U46619
Kim GP, 2 -0.19 [-0.53, 0.15] Not estimable
Kim GP, 2 -0.00 [-0.15, 0.15] Not estimable
Kim GP, 2 0.28 [-0.50, 1.06] Not estimable
Kim GP, 2 -0.08 [-0.28, 0.12] Not estimable
Subtotal GP -0.04 [-0.15, 0.07] 0% Not estimable
Overall SDR -0.03 [-0.18, 0.12] 0% 0.40 [-0.37, 1.18] 0%
Overall GP -0.04 [-0.15, 0.07] 0% Not estimable
Overall sheep 0.00 [-0.29, 0.29] n.a. -0.58 [-1.81, 0.64] n.a.
Overall all -0.03 [-0.12, 0.05] 0% 0.12 [-0.53, 0.78] 0%
(NO-blockade)
- U46619
Kim GP, 2 -0.08 [-0.21, 0.04] Not estimable
Overall GP -0.08 [-0.21, 0.04] 0% Not estimable
(PGI2-blockade)
- U46619
Kim GP, 2 -0.03 [-0.32, 0.26] Not estimable
Overall GP -0.03 [-0.32, 0.26] n.a. Not estimable
(without endothelium)
- Phenylephrine
Griggs SDR 0.32 [0.11, 0.53] -0.59 [-1.71, 0.53]
- U46619
Kim GP, 2 0.24 [-0.62, 1.10] Not estimable
Overall all 0.32 [0.11, 0.52] 0% -0.59 [-1.71, 0.53] n.a.
Favors more
vasoconstriction
Favors less
vasoconstriction
Favors less
vasoconstriction
Favors more
vasoconstriction
0.12 [-0.53, 0.78]
-1 -0.5 0 0.5 1-1 - . -1 -0.5 0 0.5 1-4 -2 42
Figure 6. Effect of pregnancy at mid and late gestation on renal artery responses to stimuli involved in 
vasoconstriction through the GqSMC- coupled pathway in presence and absence of blockade. 
The effect of pregnancy on EC50 (the dose of stimulus inducing 50% response) is depicted as mean difference 
(MD) and its 95% confidence interval (95% CI). Emax (maximum response) is presented as standardized mean 
difference (SMD) and its 95% CI. Studies and totals based on Long Evans rats (LER), Sprague Dawley rats 
(SDR), sheep and guinea pigs (GP). 1, 2, 3 represents first, second and third part of mid and late gestation. 
I2 represents the amount of heterogeneity. n.a. = not applicable.
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EC50 Emax
Substance / study MD [95% CI] I2 MD [95% CI] SMD [95% CI] I2 SMD [95% CI]
MID-GESTATION
(without blockade)
-Nitroprusside
Gandley LER, 3 -0.26 [-0.74, 0.22] Not estimable
Overall LER -0.26 [-0.74, 0.22] n.a. Not estimable
LATE-GESTATION
(without blockade)
-Nitroprusside
Griggs SDR, 2 -0.22 [-0.50, 0.06] -0.59 [-1.75, 0.58]
Overall SDR 0.04 [-0.30, 0.39] n.a. -0.59 [-1.75, 0.58] n.a.
LATE-GESTATION
(without blockade)
-Potassium
Annibale sheep, 2 -0.08 [-0.21, 0.05] -0.79 [-2.01, 0.42]
Overall sheep -0.08 [-0.21, 0.05] n.a. -0.79 [-2.01, 0.42] n.a.
Favors more
vasodilation
Favors less
vasodilation
Favors less
vasodilation
Favors more
vasodilation
-1 -0.5 0 0.5 1-1 - . -1 -0.5 0 0.5 1-4 -2 42
Figure 7. Effect of mid and late pregnancy on renal artery responses to nitric oxide (NO) and potassium. 
The effect of pregnancy on EC50 (the dose of stimulus inducing 50% response) is depicted as mean difference 
(MD) and its 95% confidence interval (95% CI). Emax (maximum response) is presented as standardized mean 
difference (SMD) and its 95% CI. Studies and totals based on Long Evans rats (LER), Sprague Dawley rats 
(SDR) and sheep. 1, 2, 3 represents first, second and third part of mid and late gestation. I2 represents the 
amount of heterogeneity. n.a. = not applicable.
Substance / study Myogenic reactivity Compliance
LATE GESTATION
(without blockade)
Annibale sheep, 2 (n=12) (n=12)
Gandley SDR, 2 (n=29) (n=29)
Overall all ? ?
(without endothelium)
Gandley SDR, 2 (n=12)
Favors less
vasoconstriction
Favors more
vasoconstriction
Favors less
vasodilation
Favors more
vasodilation
Figure 8. Effect of pregnancy at late gestation on renal artery responses to myogenic response and vascular 
compliance. 
The effect of pregnancy on the response to stimuli, depicted as the difference in direction. ? = unknown or 
non-conclusive data. Studies and totals based on Sprague Dawley rats (SDR) and sheep. 1, 2, 3 represents 
first, second and third part of late gestation. n = number of subjects.
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discussion
Our meta-analysis confirms the commonly held view that pregnancy reduces RVR and 
enhances renal flow and GFR in animals, as it does in humans 1. Our study has shown that 
the degree of change depends on the functional parameter, species, strain and gestational 
age investigated. Our meta-analysis did not detect changes in renal artery responsiveness. 
More importantly, the underlying mechanisms for the change in RVR, renal flow and GFR 
is not the same between species, strains and gestational age. Therefore each research 
question needs careful choice of the animal model and gestational age period of interest.
Across rat strains at mid-gestation, pregnancy decreases RVR and enhances renal flow 
and GFR, as shown in Figure 2. The effect of pregnancy on RVR and GFR is quite consistent, 
whereas there is considerable variation in renal flow. This may suggest differences in renal 
blood pressure between strains. We observed that the common changes in RVR, renal flow 
and GFR are caused by NO upregulation rather than by change in renal autoregulatory 
threshold to pressure, or sympathetic or vasopressin-regulation.
At late gestation, the pregnancy effects on RVR, renal flow and GFR are dependent on 
the species and strain investigated (Figure 3). In some species or strains, renal parameters 
are not different from non-pregnant values (LER and MWR), while in others late pregnancy 
affects RVR, renal flow and GFR (SDR, rabbits and sheep). The renal autoregulatory 
threshold to pressure changes was not affected in any species investigated. The NO, 
RAAS, sympathetic and vasopressin pathways are differently affected across species and 
strains. In SDR, NO activation affects renal flow, but not GFR. This implies a difference in 
response to NO activation between the afferent and efferent glomerular vasculature.
The pregnancy-induced reduction in RVR and the associated increase in renal flow and 
GFR across the species studied are dependent on gestational age, as shown in Figures 2 
and 3. Our analysis includes data on both mid- and late gestation in LER, MWR and SDR 
(Figure 9). In LER and MWR, all measured renal changes are maximal in mid-gestation and 
return towards non-pregnant levels in late gestation, whereas in SDR there is no difference 
between mid- and late pregnancy response. Responses in LER and MWR qualitatively 
correspond well with human pregnancy, in which renal flow increases in the first and 
second trimesters and decreases markedly towards term 1. Quantitatively, in human 
pregnancy the renal flow increase (around 60%) is more pronounced than in the rat strains 
included in our meta-analysis (LER 31%, MWR 45% and SDR 14%). One may speculate on 
the underlying mechanism for this difference. Possibly the more mature human fetus poses 
a greater demand on the maternal vascular system, than the more immature rat fetus at 
comparable gestational age period. Our data suggest that renal changes during pregnancy 
in humans and rats are qualitatively similar but quantitatively different.
It is questionable if SDR is the right model for renal changes in healthy human 
pregnancy. In contrast to humans in which RVR, renal flow and GFR return towards non-
pregnant values near term, the changes in SDR are maximal in mid-pregnancy and remain 
at maximum level throughout late pregnancy. As shown in Figure 9, this pattern is different 
from that in the other rat strains investigated (LER, MWR), that matches better with the 
human pattern. The persistent changes in SDR may reflect their relatively compromised 
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vascular health. This strain is known to develop severe vascular dysfunction later in life, 
including chronic progressive nephropathy, peri-/vasculitis, and chronic cardiomyopathy 55. 
SDR could be the better model for renal vascular maladaptation, whereas LER and MWR 
seem the more appropriate models for normal pregnancy-induced renal vasodilation.
Our meta-analysis detected considerable heterogeneity (I2 >60%) for overall renal 
flow and moderate heterogeneity (I2 <60%) for overall GFR and RVR. This can only 
partially be attributed to differences between species and strains, as stratification reduced 
heterogeneity substantially only for some subgroups. Additionally, methodological 
differences in determining renal flow (flow probe or para-aminohippurate clearance) may 
have contributed to the heterogeneity. The substantial degree of heterogeneity implies 
that data should not be quantitatively extrapolated to other species or strains.
Renal artery function is not affected by pregnancy, except for SDR. Pregnancy 
does not change the renal artery responsiveness to pharmacological stimuli (GqEC- and 
GqSMC-mediated stimuli, NO and potassium). One study in SDR showed an endothelium-
dependent decrease in renal artery myogenic reactivity and increased vascular compliance 
in late pregnancy. Apparently SDR activate additional mechanisms to realize the same 
degree of vascular adaptation to pregnancy, as compared to other strains. This may 
represent a more generalized pattern, as it has been reported that SDR activate additional 
vascular adaptive pathways also in mesenteric arteries responses in pregnancy 8.
One may question what mechanisms are responsible for the changes in RVR, renal flow 
and GFR in pregnancy, given the lack of a role for renal artery adaptation. Our meta-analysis 
does not provide the answer. Several mechanisms can be considered. Reduced RVR and 
enhanced renal flow and GFR in pregnancy most likely result from regulation by the small 
resistance vessels of the kidney, rather than the renal artery 56. The juxtaglomerular apparatus, 
which regulates afferent and efferent glomerular artery tone, may also be involved through 
resetting of the tubuloglomerular feedback system 57. It seems likely that pregnancy-specific 
hormones, including relaxin or progesterone, play a role in these processes 58;59.
MWR
SDR
LER
Mid LateEarly
50%
-50%
-25%
25%
0%
RVR
Renal flow
GFR
Figure 9. Summary of renal vascular resistance (RVR), renal flow and glomerular filtration rate (GFR) during 
pregnancy in Long Evens rats (LER), Munich Wistar rats (MWR) and Sprague Dawley rats (SDR).
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Several methodological aspects of our meta-analysis deserve discussion. First, the 
quality of all included studies was scored as poor, in terms of the reported number of 
animals, parity, randomization, and blinding the outcome assessment. This is a common 
finding in animal experiments 8, which are primarily concerned with generation and testing 
of hypotheses rather than with rigorous employment of randomized-controlled-trial 
methodology. Nonetheless, the quality of animal experimental work, and therefore the 
reliability of its findings, could benefit from application of strict methodological criteria, 
standardized procedures and reporting guidelines 60. Second, our literature search was not 
designed to identify all studies that reported on pregnancy-induced changes in RVR, renal 
flow and GFR. Because we were primarily interested in the underlying mechanisms, we 
restricted our search to studies investigating responses to vaso-active stimuli. Many studies 
in different animals have investigated RVR, RPF and GFR without using vaso-active stimuli. 
These studies were not included in our meta-analysis. Our data on pregnancy-induced 
changes imply species, strain and gestational age differences in RVR, RPF and GFR, without 
having the intention to be complete on this. Third, despite extensive searches, some of our 
observations are still based on a limited number of animals and strains of animals. Obviously, 
these results have to be interpreted with some restraint. Fourth, publication bias may have 
affected the results. Negative results tend to be underreported, which may therefore lead 
to overestimated effect sizes. Our funnel-plot analysis did not detect any such effect. Fifth, 
one may question whether it is legitimate to group together responses to pharmacological 
stimuli across species and strains. We observed considerable heterogeneity (I2 >60%), 
which implies that one should not regard the responses as uniform across species and 
strains. Sixth, one may question the validity of combining the responses to different stimuli 
according to their assumed common G-protein coupled pathway. If heterogeneity would 
have been low, it would have been reasonable to group together the various stimuli to 
their common pathways, as observed in a former study of our group 61. The moderate 
heterogeneity, observed for most responses in the present study, might imply that the 
assumption is not valid. However, it does not necessarily disprove the validity, because 
heterogeneity may be affected by many methodological aspects of the experiments. Given 
the moderate heterogeneity, one should mainly focus on the qualitative similarities. 
In conclusion, our meta-analysis shows that pregnancy reduces RVR and increases 
renal flow and GFR through NO activation and sympathetic deactivation and not through 
a change in renal artery responsiveness. The cellular level at which pregnancy affects the 
respective pathways remains unknown. Quantitatively, renal vascular changes in pregnancy 
vary between species, strains and gestational age. Our meta-analysis suggests that renal 
changes during pregnancy are qualitatively similar in animals and even in comparison to 
humans, but quantitatively different.
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aBstract
At term pregnancy-induced vasodilation is the resultant of endothelium-dependent 
vasodilation, decreased myogenic reactivity, increased compliance and reduced sensitivity 
to vasoconstrictor agents. We hypothesized that these vascular changes are already 
present at midgestation. In 20 mid-pregnant and 20 nonpregnant Wistar Hannover rats, 
we measured vascular responses of isolated mesenteric arteries and kidney. In the pregnant 
rats compared with the nonpregnant rats, mesenteric flow-mediated vasodilation and 
renal perfusion flow increased 1.52 fold (from 47±5 to 31±4 µl/min) and 1.13 fold (from 
12.8±0.1 to 14.4±0.1 ml/min), respectively. Nitric oxide inhibition reduced mesenteric 
flow-mediated vasodilation to a similar extent in the pregnant and nonpregnant rats; it 
completely blocked the pregnancy-induced increase in renal perfusion flow. Pregnancy did 
not change mesenteric artery sensitivity to phenylephrine, myogenic reactivity, nor vascular 
compliance. At midgestation, alterations in rat mesenteric vascular tone depend primarily 
on flow-mediated endothelium-dependent changes and not on changes in α-adrenergic 
vasoconstrictor sensitivity, myogenic reactivity or vascular compliance.
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introduction
Vasodilation in both human 1 and rat 2 pregnancy is already maximal at midgestation. Under 
physiological conditions in nonpregnant subjects, the renal and mesenteric vascular beds 
receive approximately 25% and 30%, respectively, of total cardiac output 3;4. During pregnancy, 
renal plasma flow (RPF) increases by 40% and mesenteric perfusion increases by 65% 1;5. Based 
on a large body of at term data, vascular adaptation to pregnancy is thought to be the resultant 
of stimulation of the endothelium dependent NO pathway 6, reduced responsiveness to 
vasoconstrictive stimuli 7, decreased myogenic reactivity 8, and increased vascular compliance 8, 
all of which are responses that are likely to interfere with each other. In contrast, data on 
midgestational isolated vessel function are limited. It has been suggested that some of these 
responses may not be affected at mid-term 9;10, despite the fully vasodilated state.
Relaxin, a member of the insulin-like growth factor superfamily, is thought to mediate 
the vasodilation of pregnancy 11;12. In nonpregnant rats, relaxin simulates the local and 
systemic vascular adaptations that are present at midgestation 13;14. Relaxin neutralizing 
antibodies reverse the renal compensatory vascular changes in mid-pregnancy 15. These 
observations suggest a pivotal role of relaxin in gestational vascular adaptation.
We hypothesized that midgestational vasodilation in rats is mediated by the upregulation 
of endothelium-dependent vasodilation and alteration of vasoconstrictor agent sensitivity, 
myogenic reactivity, and vascular compliance that is observed at term. To this end, we 
investigated vascular function in rats in both isolated mesenteric arteries and kidney, because 
these vascular beds strongly determine peripheral resistance during pregnancy.
Materials and MetHods
animals
The experimental protocol was approved by the Animal Experiments Committee of the 
Radboud University Nijmegen Medical Centre, the Netherlands, and was performed in 
accordance to the European guidelines on animal experiments. Forty female virgin Wistar 
Hannover rats (Harlan Netherlands, Horst, the Netherlands) were studied in 2 groups 
at an age of 8-10 weeks, followed by 1-week acclimatization. Group 1 (mid-pregnant 
rats, 10; nonpregnant rats, 10) was used for studies in the Mulvany Halpern myograph 
and group 2 (mid-pregnant rats, 10, and nonpregnant rats, 10) was used for perfusion-
pressure myograph experiments. We used the isolated perfused rat kidney model for 
experiments on both groups (n=40). We housed all rats by 2 in filter-top cages on a 
12/12 hour light/dark cycle and provided them with standard diet (ssniff R/M-H; Ssniff 
Spezialdieten GmbH, Soest, Germany) and water ad libitum. Pregnancy was accomplished 
by mating with an experienced male of similar age. The presence of a semen plug at 
the bottom of the cage was considered successful mating and day 1 of pregnancy. 
Mid-pregnant (midgestation, day 11 of the pregnancy) and nonpregnant animals were 
anesthetized with an intraperitoneal injection of 6 mg/100 g pentobarbital (Apharmo, 
Arnhem, the Netherlands). Furosemide (1 mg/100 g, Sigma-Aldrich Chemie, Zwijndrecht, 
the Netherlands) was injected intraperitoneally to achieve maximal urethral distention for 
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optimal catheter placement. We weighed all animals before surgery. During surgery, blood 
was withdrawn and plasma was stored at -80 °C to measure relaxin concentration with 
a homologous radioimmunoassay. The assay was performed according to the method of 
Sherwood and Crnekovic 16. In our hands, the analytic sensitivity of the assay was 0.51 
ng/ml. Dilution experiments showed good parallelism in the range of 25-100 µl.
pressure-perfusion myograph
Flow-mediated vasodilation, myogenic reactivity to pressure and compliance were analyzed 
in a pressure-perfusion myograph (Pressure Myograph System-Model P100; J. P. Trading, 
Aarhus, Denmark). The responses were determined in phosphate-buffered saline solution 
(119 mM NaCl, 4.69 mM KCl, 25 mM NaHCO3, 1.17 mM MgSO4, 1.18 mM KH2PO4, 5.5 mM 
glucose and 10 mM HEPES), to which were added 2 mM ethylene glycol tetraacetic acid and 
0.01 mM Na-Nitroprusside (for calcium-free phosphate-buffered saline solution) to measure 
compliance or 2.5 mM CaCl2, 0.027 mM Na2 ethylene diamine tetraacetic acid (for calcium 
phosphate-buffered saline solution) to assess flow-mediated vasodilation and myogenic 
reactivity. The buffers were oxygenated with 95% O2 and 5% CO2 at a temperature of 37 
°C. Second-order mesenteric arteries (150-400 µm) were mounted on 2 opposing glass 
cannulas (125 µm). Vascular inner diameter was measured through video recording (Vessel 
View; J. P. Trading, Aarhus, Denmark). Arteries were equilibrated at an intraluminal pressure 
of 60 mmHg for 20 minutes. Subsequently, preconstriction was achieved by the addition of 
the thromboxane A2 agonist, U46619 (9,11-Dideoxy-11α, 9α-epoxymethanoprostaglandin 
F2α; Sigma-Aldrich Chemie, Zwijndrecht, the Netherlands; bath concentration of 10
-7-10-6 
mol/L), thereby reducing the vessel diameter by 30-40% of their basal diameter.
I. Flow-mediated vasodilation
Flow-mediated vasodilation was defined as the vasodilator response to a certain flow 
increase. After reaching a stable contraction, the flow in the vessel was increased by 
16.7 µl/min steps (2-minute interval) from 0 up to 100 µl/min (comparable with a 
shear-stress range of 0-10 dyne/cm2), in the absence or presence of 100 µM of the NO 
antagonist L-NAME (L-Nitro-Arginine Methyl Ester, Sigma-Aldrich Chemie, Zwijndrecht, 
the Netherlands). Meanwhile the intraluminal pressure was maintained at 60 mmHg. 
Vessels were excluded from the study if they attained <20% preconstriction, <10% 
vasodilation over the completed flow-range, or instable pressure because of fluid leakage. 
Flow-mediated vasodilation was expressed as a percentage of the preconstriction status.
II. Mygenic reactivity and vascular compliance
Myogenic reactivity was defined as the vasoconstrictive response to a certain pressure 
increase in the presence of calcium. Compliance was defined as the vasodilator response to 
a certain pressure increase in the absence calcium, to avoid smooth muscle cell contraction. 
To withdraw interference of previous assessments, a new mesenteric vessel was isolated 
and prepared as described earlier. Intraluminal pressure was increased every two minutes 
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by 10 mmHg steps, from 20 mmHg up to 110 mmHg, to successively determine myogenic 
reactivity and compliance (expressed in micrometer µm).
Wire myograph (response tot phenylephrine)
We studied the vasoconstrictor response to phenylephrine (Sigma-Aldrich Chemie, 
Zwijndrecht, the Netherlands) with a Mulvany Halpern myograph (Dual Wire Myograph-
Model 400A, J. P. Trading, Aarhus, Denmark). The bath was filled with physiologic salt 
solution (119 mM NaCl, 4.69 mM KCl, 2.5 mM CaCl2, 25 mM NaHCO3, 1.17 mM MgSO4, 
1.18 mM KH2PO4, 5.5 mM glucose and 0.027 mM ethylene diamine tetraacetic acid) and 
oxygenated with 95% O2 and 5% CO2 at a temperature of 37 ºC. Four second-order 
mesenteric arteries (150-400 µm) were mounted in 2 wire myographs, which were stabilized 
as previously described 17, and set at a tension equivalent to that generated at 90% of 
the inner circumference at 100 mm Hg. The response to 124 mM KCl was measured to 
allow normalization of the phenylephrine response. The response to phenylephrine was 
determined in 8 steps over a range from 10-7 to 10-5 mol/L, in the absence or presence of 100 
µM L-NAME. The data for the 2 arteries in each myograph were averaged when available.
isolated perfused rat Kidney model (iprK)
The intrinsic adaptation of the kidney was assessed in the isolated perfused rat kidney 
model. Within the time frame of our protocol, this model was known to represent stable 
renal function 18. Briefly, the right renal artery was cannulated through the left renal artery 
and aorta. The right ureter was cannulated for urine collection. Perfusion was started 
in situ, and the kidney was removed and placed in a perfused bath at a temperature of 
37.5 °C. The kidney was perfused at a constant pressure of 90 mmHg with oxygenated 
cell-free Krebs-Ringer-Henseheit (containing 113 mM NaCl, 4.8 mM KCl, 25 mM NaHCO3, 
1.4 mM KH2PO4, 2.2 mM CaCl2, 1.4 mM MgCl2, and 5 mM Glucose) and 1.7 mM Pluronic 
F-108 (oxygen carrier and oncotic agent; BASF). Renal perfusion flow (RPFF) was recorded 
real-time with the use of a computer system (Midac testorganizer, W95 [version 3.0]; 
Radboud University Nijmegen Medical Centre, the Netherlands).
Stabilization of the RPFF was accomplished during a 40-minute period. From 40-60 
minutes the basal RPFF (RPFFbaseline) was determined. At 60 minutes L-NAME was added to 
the perfusate (achieving a concentration of 100 µM) to investigate the contribution of NO 
to the relaxin (or placebo) evoked vasodilator response up to 160 minutes (RPFF160). RPFF 
was normalized for body weight (milliliters per minute per 100 grams of body weight).
The data were expressed as means ± standard error of the mean (SE); n indicates 
the number of animals. Flow-mediated vasodilation, response to phenylephrine, and 
RPFF were analyzed by nonlinear regression curve fitting (GraphPad Prism 4.0; Institute 
for Scientific Information, San Diego, California, USA). Subsequent curve fit estimates 
were: 1) maximal vascular diameter after flow change (Diammax), 2) flow rate inducing 
50% dilation; flow-sensitivity (Flow50%), 3) maximum response to phenylephrine (Rmax), 
4) phenylephrine concentration that induced a 50% response (C50%), 5) RPFFbaseline, and 
6) RPFFbaseline minus RPFF160 (RPFFdelta). Overall myogenic reactivity (MRoverall; corrected for 
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percentage preconstriction) and overall vascular compliance (VCoverall) were analyzed by 
using analysis of variance for repeated measures (Greenhouse-Geisser correction; version 
16.0.2; SPSS, Chicago, Illinois, USA). Selective straight-line curve fitting was performed 
over the range of 60 to 110 mmHg, for both myogenic reactivity (MR>60) and compliance 
(VC>60), to estimate the hill slope. Baseline characteristics were analyzed with the Student’s 
t-test. A p-value of <0.05 was considered to represent statistical significance.
results
The study population contained 20 pregnant and 20 nonpregnant female virgin Wistar 
Hannover rats with a mean age of 94±2 days. Consistent in all experimental settings, 
pregnant rats were approximately 7% heavier at mid-pregnancy than nonpregnant rats 
(246±3 g versus 229±4 g, p<0.01). At midgestation, plasma relaxin levels were higher than in 
nonpregnant animals (2.4±0.3 ng/ml versus 1.1±0.1 ng/ml, p<0.01). Baseline characteristics 
of isolated mesenteric arteries (basal diameter, percentage preconstriction to U46619, and 
vasoconstrictor response to 124 mM KCl) were comparable in both groups (Table 1).
Table 1. Baseline vascular characteristics of mesenteric arteries in nonpregnant and pregnant rats.
Nonpregnant (n) Pregnant (n)
Flow-mediated vasodilation
L-NAME absence
- Basal diameter (µm) 274±10 (8) 268±7 (9)
- Preconstriction (%) 41±2 (8) 36±1 (9)
L-NAME presence
- Basal diameter (µm) 274 ±11 (7) 265±9 (7)
- Preconstriction (%) 35 ±1 (7) 32±2 (7)
Myogenic reactivity
- Basal diameter (µm) 275 ±8 (10) 270±7 (7)
- Preconstriction (%) 41 ±3 (10) 45±3 (7)
Vascular compliance 
- Basal diameter (µm) 275 ±8 (10) 273±7 (10)
Response to phenylephrine
L-NAME absence
- Basal diameter (µm) 262 ±16 (8) 252±10 (10)
- KCl contraction (mN) 13.9 ±0.6 (8) 13.2±1.0 (10)
L-NAME presence
- Basal diameter (µm) 258 ±10 (9) 263±10 (10)
- KCl contraction (mN) 13.1 ±0.7 (9) 12.4±0.7 (10)
Values presented as means ± SE, n = number of animals.
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Flow-mediated vasodilation
Figure 1 represents the flow-mediated vasodilator response and corresponding curve-fit 
estimates in mesenteric arteries. At midgestation, pregnancy increased sensitivity to flow 
(decreased Flow50%) 1.52 fold (from 47±5 to 31±4 µl/min, p<0.05) without altering maximal 
reactivity (Diammax 29±2 and 24±2 % in pregnant and nonpregnant rats, respectively). NO 
blockade reduced maximal reactivity (Diammax) in both pregnant and nonpregnant rats by 
21±1 and 20±4 %, respectively, although a difference in flow sensitivity persisted (Flow50% 
24±4 and 57±10 µl/min in pregnant and nonpregnant rats, respectively, p<0.05). This 
indicates that the upregulation of flow-mediated vasodilation at midgestation does not 
depend on stimulation of the NO pathway.
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Figure 1. Flow-mediated vasodilator response in mesenteric arteries in mid-pregnant (P) and nonpregnant 
(NP) rats in absence (nP=9 and nNP=8) and presence of L-NAME (nP=7 and nNP=7).
Responses were performed in pressure-perfusion myograph experiments (in absence of L-NAME). 
Vasodilation is displayed as a percentage of preconstriction to U46619 in non-linear regression curves at the 
left part of the figure. The derivative Flow50% (the amount of flow inducing a 50% response) is presented in 
a bar-graph on the right side. § within weight group difference p<0.05.
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Myogenic reactivity and vascular compliance
Figure 2 shows myogenic reactivity and vascular compliance. Pregnancy did neither affect 
myogenic reactivity: MRoverall (p=0.19) and MR>60 (-2±2 versus -2±2 µm/10 mmHg), nor 
vascular compliance: VCoverall (p=0.56) and VC>60 (3±2 versus 3±2 µm/10 mmHg).
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Table 2. Phenylephrine response curve-fit estimates of the wire myograph experiments in nonpregnant and 
pregnant rats in absence and presence of 100 µM L-NAME, estimating the concentration of phenylephrine 
inducing a 50% response (C50%) and the maximum response (Rmax) as a percentage of the maximum 
response to 124 mM KCl.
Nonpregnant (n) Pregnant (n)
* C50% (µM) - without L-NAME 1.74±0.12 (9) 1.91±0.13 (10)
- with L-NAME 1.26±0.11 (9) 1.20±0.08 (10)
* Rmax (%) - without L-NAME 114±4 (9) 118±4 (10)
  - with L-NAME 128±6 (9) 120±4 (10)
Values presented as means ± SE, n = number of animals.
Figure 2. Myogenic reactivity (circles; nP=7 and nNP=10) and compliance (squares; nP=10 and nNP=10) in 
mesenteric arteries in mid-pregnant (P) and nonpregnant (NP) rats.
The response to pressure evaluated in pressure-perfusion myograph experiments. Differences tested by 
repeated measurement analyses (correction for percentage preconstriction for myogenic reactivity).
response to phenylephrine
Table 2 depicts the curve-fit estimates of the response to phenylephrine. Both sensitivity 
(C50%) and maximum response (Rmax) to phenylephrine were comparable among pregnant 
and nonpregnant rats. L-NAME increased sensitivity (reduced C50%) to a similar degree in 
both pregnant and nonpregnant rats.
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Isolated Perfused Rat Kidney model (IPRK)
Figure 3 details the RPFF response curves of pregnant and nonpregnant rats. Pregnancy 
increased RPFFbaseline 1.13 fold (from 12.8±0.1 to 14.4±0.1 ml/min, p<0.05) and RPFFdelta 
(NO dependent vasodilation) 1.23 fold (from 6.5±0.2 to 8.0±0.2 ml/min, p<0.05).
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Figure 3. Renal perfusion flow (RPFF) in response to 100 µM L-NAME (at 60 minutes) in mid-pregnant 
(P; nP =16) and nonpregnant (NP; nNP =13) rats.
The responses were analyzed in IPRK experiments.
DISCUSSION
The present study investigated the extent to which each of the independent local 
responses in isolated mesenteric arteries and kidney in rats contributed to mid-pregnancy 
vasodilation. We showed that midgestation is characterized by enhanced flow-mediated 
(endothelium-dependent) vasodilation and not by a concomitant increase in vascular 
compliance, reduced α-adrenergic vasoconstrictor agent sensitivity or myogenic reactivity. 
As such, our observations at mid-term differ from those observed at term.
In contrast to vascular adaptation in rats at term, mid-term local vascular adaptation 
seems to rely on endothelium-dependent changes only. Our study does not allow direct 
comparison of vascular responses at mid-term and term. We did not include a group of rats 
at term, because this has already been investigated in extent. However, our findings are in line 
with those of others, who reported that early pregnancy increased (endothelium-dependent) 
responsiveness to acetylcholine 19 and flow 20. Apparently, in contrast to observations in rats 
at term 21, at mid-term the increased responsiveness to flow of mesenteric arteries does not 
depend on NO upregulation. We speculate that prostaglandins and endothelium-derived 
hyperpolarizing factor also contribute to midgestational vasodilation. As observed by others 
at mid-term, we did not detect pregnancy-induced changes in sensitivity to phenylephrine 9. 
Possible because of strain differences, and in contrast to others, we did not find changes in 
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vascular compliance 8. Although we did not investigate other vasoconstrictor agents, our data 
imply that midgestational vasodilation directly relates to endothelium-dependent vascular 
adjustment and not to changes in smooth muscle cell or extra-cellular matrix function.
In vivo data report that RPF increases approximately 1.4 fold in both humans and 
rodents at mid-term 1;22. After isolation, RPFF increases only 1.13 fold. The difference may 
be the consequence of depletion of humoral and autonomic control in ex vivo, compared 
with in vivo experiments. However, one may address the effects of impaired oxygen-
delivery, which is associated with whole organ perfusion, on renal function. Because we 
optimized oxygen-delivery by using the oxygen-carrier Pluronic, it seems unlikely that 
hypoxia-induced changes are responsible for our findings. Our data on RPFF in the isolated 
rat kidney seem to be in line with in vivo observations 23 and in isolated renal arteries 24 
at mid-term, in that the gestational rise in RPFF is completely NO dependent. As far as 
we know, there are no comparable studies that have used the isolated rat kidney model. 
Our findings show that, in an isolated setting, the intrinsic NO dependent modifications 
account for only 13% of midgestational renal adaptation. The decrease of mid-term renal 
vasodilatation, as observed in vivo, can be accounted for in the in vitro setting itself and 
subsequent depletion of humoral and autonomic factors.
Our data supply insight in different types of vascular responses that are involved in 
midgestational local vascular function. Nevertheless, some potential limitations must be 
addressed. First, we have not randomized rats that did and did not conceive, which may 
have led to selection bias. Because the Wistar Hannover rat is known to be a uniform 
outbred line with high reproductive qualities 25, we think that it is unlikely that this may 
have affected our results. Second, we did not schedule experiments of nonpregnant rats 
at a particular estrous stage. Although not visible in our results, this could have led to 
heterogeneity and increased variability of the nonpregnant group.
Changes in endothelium, smooth muscle cell, and extra-cellular matrix function 
mediate gestational vasodilation. Endothelium-dependent adaptation involves upregulation 
of 3 parallel mechanisms, that concern the stimulation of NO 6, endothelium-derived 
hyperpolarizing factor 26 and prostaglandin 27;28 pathways. Possibly depending on the type of 
vascular bed, one pathway predominates while the others fulfill a supportive role. This may 
explain the persistence of increased flow-mediated vasodilation under NO blockade, as we 
observed. Smooth muscle cell adaptation in pregnancy depends mainly on these endothelium-
changes 29, although matrix metalloproteases enhance extra-cellular matrix elasticity 30. There 
is evidence to suggest that relaxin is an important factor involved in gestational upregulation 
of endothelium dependent vasodilation and matrix metalloproteases 11;31. Because we 
detected only a small increase in relaxin levels at midgestation, we speculate that low levels 
of relaxin mainly enhance endothelium-dependent vasodilation. As pregnancy proceeds 
to term, both flow-mediated changes and higher levels of relaxin may promote vessel-
remodeling and reduce smooth-muscle cell reactivity.
In summary, these in vitro experiments suggest that, in rats, vasodilation in mesenteric 
arteries at midgestation is mediated mainly by an increase in flow-mediated (endothelium-
dependent) changes and not by adjustment of α-adrenergic vasoconstrictor sensitivity, 
myogenic reactivity or vascular compliance.
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impaired vascular responses to relaxin 
in diet-induced overweiGht female rats
Chapter 5 
aBstract
Relaxin mediates renal and mesenteric vascular adaptations to pregnancy by increasing 
endothelium-dependent vasodilation and compliance, and decreasing myogenic 
reactivity. Diet-induced overweight and obesity are associated with impaired endothelium 
dysfunction and vascular remodeling leading to a reduction in arterial diameter. In this 
study, we tested the hypothesis that local vascular responses to relaxin are impaired in 
diet-induced overweight female rats on a high-fat cafeteria-style diet for 9 weeks. Rats 
were chronically infused with either relaxin or placebo for 5 days, and vascular responses 
were measured in isolated mesenteric arteries and the perfused kidney. Diet-induced 
overweight significantly increased sensitivity to phenylephrine (by 17%) and vessel wall 
thickness, and reduced renal perfusion flow (RPFF; by 16%), but did not affect flow-
mediated vasodilation, myogenic reactivity, and vascular compliance. In the normal 
weight rats, relaxin treatment significantly enhanced flow-mediated vasodilation (2.67 
fold), decreased myogenic reactivity, and reduced sensitivity to phenylephrine (by 28%), 
but had no effect on compliance or RPFF. NO blockade by L-NAME diminished most 
relaxin-mediated effects. In diet-induced overweight rats, the vasodilator effects of relaxin 
were markedly reduced for flow-mediated vasodilation, sensitivity to phenylephrine 
and myogenic response, compared with the normal diet rats, mostly persistent under 
L-NAME. Our data demonstrate that some of the vasodilator responses to in vivo relaxin 
administration are impaired in isolated mesenteric arteries and the perfused kidney in 
diet-induced overweight female rats. This does not result from a decrease in Rxfp1 (relaxin 
family peptide receptor) expression but is likely to result from downstream disruption to 
endothelium-dependent mechanisms in diet-induced overweight animals.
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introduction
Relaxin, a member of the insulin-like growth factor superfamily, is an important vasodilatory 
hormone of pregnancy 1-4. Mostly based on renal vascular studies, four mechanisms 
are thought to be involved in relaxin-mediated vasodilation: upregulated endothelium 
dependent NO pathway 5;6, blunted responsiveness to vasoconstrictive stimuli 7, decreased 
myogenic reactivity 8, and increased compliance 9. Chronic administration of relaxin to 
nonpregnant female rats induces vascular adaptations comparable to those observed 
in pregnancy 5;10, through mechanisms involving matrix metalloproteases, endothelin B 
receptors and vascular endothelial growth factor 11, whereas relaxin neutralizing antibodies 
completely abolish the vascular vasodilator effects in rat pregnancy 12. These observations 
suggest a pivotal role of relaxin in gestational vascular adaptation.
A high-fat diet, inducing mild overweight in rats, predisposes one to endothelium 
dysfunction 13 and reflects the human dietary etiology of overweight 14, which clinically 
translates into an increased risk for gestational hypertensive disease 15. It has been proposed 
that attenuated adaptation of the above mentioned mechanisms may precede gestational 
hypertensive disorders 16;17. However, it is unknown whether diet-induced overweight 
affects normal pregnancy-like relaxin-induced vascular changes. The mesenteric and renal 
vascular beds predominately contribute to peripheral resistance. In nonpregnant healthy 
conditions, they receive about 25% and 30% of total cardiac output 18;19, whereas during 
pregnancy renal plasma flow (RPF) and mesenteric vascular perfusion increases by 40% 
and 65% 20;21. We hypothesized that diet-induced overweight induces relaxin-resistance, 
defined as the inability to produce comparable vascular responses to relaxin exposure as 
observed in healthy controls. To this end, we performed an experimental ex vivo study on 
relaxin-induced vascular responses in isolated mesenteric arteries and kidney in normal 
weight and diet-induced overweight female rats.
Materials and MetHods
animals
The experimental protocol was approved by the Animal Experiments Committee of the 
Radboud University Nijmegen Medical Centre, the Netherlands, and was performed in 
accordance with the European guidelines on animal experiments. Virgin female Wistar 
Hannover rats (Harlan Netherlands, Horst, the Netherlands) received either a regular diet 
(ssniff R/M-H, n=20, used in a previous cohort 22) or a high-fat cafeteria-style diet (ssniff 
EF R/M acc. D12451 (II), 45%kJ as fat, n=20) ad libitum from an age of 21 days onwards. 
A comparable high-fat diet has previously been shown to result in non significant mild 
overweight, normal lipid profile, and insulin resistance 23;24. Rats were housed in filter-top 
cages on a 12/12 hour light/dark cycle. At an age of 73-85 days, rats were randomly 
assigned (independent from estrous stage) to chronic infusion for 5 days with either 
placebo or recombinant human H2 relaxin (both containing 5 mM sodium acetate, pH 
5.0; Corthera., San Mateo, California, USA). This readily available human relaxin induces 
vascular responses in nonpregnant rats comparable to those attributed to endogenous 
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relaxin in pregnant rats 5;12. On day 0, an osmotic minipump (Alzet, model 2001, DURECT, 
Cupertino, California, USA) was implanted subcutaneously under isofluorane anesthesia. 
The osmotic minipump infused human relaxin at a dose of 4 µg/h for 5 days. This dose 
of relaxin results in plasma relaxin concentrations equivalent to mid-pregnant rats: 
30 ng/ml 5;25. On day 5, the rats were anesthetized with an intraperitoneal injection of 6 
mg/100 g pentobarbital (Apharmo, Arnhem, the Netherlands). Furosemide (1 mg/100g, 
Sigma-Aldrich Chemie, Zwijndrecht, the Netherlands) was also injected intraperitoneally to 
achieve maximal urethral distention for optimal catheter placement. Blood was withdrawn 
from the vena cava to measure plasma human H2 relaxin concentration levels (Human 
Relaxin-2 Quantikine ELISA kit DRL200, R&D Systems, Minneapolis, USA). Continuation 
of chronic relaxin exposure was maintained during all experiments by exposing both 
mesenteric arteries and isolated kidney to perfusate and tissue bath solutions containing 
30 ng/ml of the trial-medication supplied (relaxin or a comparable amount of placebo; 
incubation time 30 minutes).
pressure-perfusion myograph
The flow-mediated vasodilation, the myogenic reactivity to pressure and compliance were 
analyzed in a pressure-perfusion myograph (Pressure Myograph System-Model P100, 
J. P. Trading, Aarhus, Denmark). The responses were determined in basic phosphate 
buffered saline (PBS: 119 mM NaCl, 4.69 mM KCl, 25 mM NaHCO3, 1.17 mM MgSO4, 
1.18 mM KH2PO4, 5.5 mM glucose and 10 mM HEPES), with additional 2 mM EGTA 
and 0.01 mM Na-Nitroprusside (for calcium-free-PBS) to measure compliance and 2.5 
mM CaCl2, 0.027 mM Na2EDTA (for calcium-PBS) to assess flow-mediated vasodilation 
and myogenic reactivity. The buffers were oxygenated with 95% O2 and 5% CO2 at a 
temperature of 37 ºC. Second-order mesenteric arteries (150-400 µm) were mounted on 
two opposing glass cannulae (125 µm). Vascular inner diameter was measured through 
video recording (Vessel View, J. P. Trading, Aarhus, Denmark). Arteries were equilibrated at 
an intraluminal pressure of 60 mmHg during 20 minutes. Subsequently, thromboxane A2 
agonist, U46619 (9,11-dideoxy-11α, 9α-epoxymethanoprostaglandin F2α, Sigma-Aldrich 
Chemie, Zwijndrecht, the Netherlands) was added (bath concentration of 10-7-10-6 M) to 
preconstrict vessels to 30-40% of their basal diameter.
I. Flow-mediated vasodilation
Flow-mediated vasodilation is defined as the vasodilator response to a certain flow 
increase. After reaching a stable contraction, the flow in the vessel was increased every 2 
minutes in 16.7 µl/min steps from 0 up to 100 µl/min (comparable to shear-stress range 
of 0-10 dyne/cm2), in the absence and presence of 100 µM of the NO antagonist L-NAME 
(L-Nitro-Arginine Methyl Ester, Sigma-Aldrich Chemie, Zwijndrecht, the Netherlands), 
while maintaining a mean intraluminal pressure of 60 mmHg. Vessels attaining less than 
20% preconstriction, less than 10% vasodilation over the completed flow range or with 
instable pressure due to fluid leakage were excluded from the study. Flow-mediated 
vasodilation was expressed as a percentage of the preconstriction status.
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II. Myogenic reactivity and vascular compliance
Myogenic reactivity is defined as the vasoconstrictive response to a certain pressure increase 
in the presence of calcium. Compliance is defined as the vasodilator response to a certain 
pressure increase in the absence of calcium, to avoid smooth muscle cell contraction. A new 
mesenteric vessel was isolated and prepared as described above. Intraluminal pressure was 
increased every 2 minutes in 10 mmHg steps from 20 mmHg to 110 mmHg to determine 
successive myogenic reactivity and compliance. For the latter, outer and inner vessel 
diameters and wall thickness were measured, and stress-strain relationship was obtained.
Wire myograph (response to phenylephrine)
We studied the vasoconstrictor response to phenylephrine (Sigma-Aldrich Chemie, 
Zwijndrecht, the Netherlands) with a Mulvany Halpern myograph (Dual Wire Myograph-
Model 400A, J. P. Trading, Aarhus, Denmark). The bath was filled with physiological 
salt solution (PSS: 119 mM NaCl, 4.69 mM KCl, 2.5 mM CaCl2, 25 mM NaHCO3, 1.17 
mM MgSO4, 1.18 mM KH2PO4, 5.5 mM glucose and 0.027 mM EDTA) and oxygenated 
with 95% O2 and 5% CO2 at a temperature of 37 ºC. Four second-order mesenteric 
arteries (150-400 µM) were mounted in two wire myographs, stabilized as previously 
described 26, and set at a tension equivalent generated at 90% of the inner circumference 
of 100 mmHg. The response to 124 mM KCl was measured (used for normalization of the 
phenylephrine response). The response to phenylephrine was determined in eight steps 
over a range from 10-7 M to 10-5 M, in the absence or presence of 100 µM L-NAME. The 
data of the two arteries in each myograph were averaged when available.
isolated perfused rat Kidney Model
Vascular adaptation of the isolated kidney to relaxin was assessed in the isolated perfused rat 
kidney (IPRK) model. Within the time frame of our protocol, this model shows stable renal 
perfusion flow (RPFF) and provides an indication of renal function 27, but may not reflect 
effective renal plasma flow responses in vivo. Briefly, the right renal artery was cannulated 
via the left renal artery and aorta. The right ureter was cannulated for urine collection. 
Perfusion was started in situ and the kidney was removed and placed in a perfused bath at 
a temperature of 37 °C. The kidney was perfused at a constant pressure of 90 mmHg with 
oxygenated cell-free Krebs-Ringer-Henselheit (containing 113 mM NaCl, 4.8 mM KCl, 25 
mM NaHCO3, 1.4 mM KH2PO4, 2.2 mM CaCl2, 1.4 mM MgCl2, and 5 mM Glucose) and 1.7 
mM Pluronic F-108 (oxygen carrier and oncotic agent, BASF, Arnhem, the Netherlands). RPFF 
was recorded in real-time with the use of a computer system (Midac testorganizer, W95 
[version 3.0], Radboud University Nijmegen Medical Centre, the Netherlands).
Stabilization of the RPFF was accomplished during a 40 minute period. From 40 
to 60 minutes the basal renal plasma flow (RPFFbaseline) was determined. At 60 minutes 
L-NAME was added at a final concentration of 100 µM to the perfusate to investigate 
the contribution of NO to the relaxin (or placebo) evoked vasodilator response up to 160 
minutes (RPFF160). RPFF was normalized for body weight (ml/min/100g body weight).
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Rxfp1 gene expression
Rxfp1 gene expression was analyzed by Quantitative Polymerase Chain Reaction (qPCR), 
as described previously 28. Total RNA was extracted from frozen mesenteric arteries with 
Trizol (GIBCO) according to the manufacturer’s instructions. Forward/reverse primers and 
6-carboxy fluorescein (FAM)-labeled TaqMan probes were specific for the full-length rat 
Rxfp1 from Biosearch Technologies (Novato, California, USA). Rxfp1 gene expression 
was compared with expression of the ribosomal 18S reference gene and presented as 
normalized ΔCT, transformed by 2
n where n = (-ΔCT) 
28. 
statistical analysis
The data are expressed as means ± standard error of the mean (SE). Flow-mediated 
vasodilation, stress-strain relationship, response to phenylephrine and RPFF were 
analyzed by nonlinear regression curve fitting (GraphPad Prism 4.0, Institute for Scientific 
Information, San Diego, California, USA). Subsequent curve fit estimates were: Diammax 
[maximal vascular diameter after flow change], Flow50% (flow rate inducing 50% dilation, 
flow-sensitivity), K1 and K2 (exponential constants for stress-strain relationship), Rmax 
(maximum response to phenylephrine) and C50% (phenylephrine concentration inducing 
a 50% response), RPFFbaseline (basal RPFF), and RPFFdelta (RPFFbaseline minus RPFF160). Overall 
myogenic reactivity (MRoverall; corrected for percentage preconstriction) and overall vascular 
compliance (VCoverall) were analyzed by using ANOVA for repeated measures (Greenhouse-
Geisser correction; SPSS 16.0.2, SPSS., Chicago, Illinois, USA). Selective straight line 
curve fitting was performed for both myogenic reactivity (MR>60) and compliance (VC>60), 
estimating the slope over the range of 60 to 110 mmHg. Baseline characteristics were 
analyzed with Student’s t-test. In all analyses, we compared relaxin versus placebo in 
normal weight rats, relaxin versus placebo in diet-induced overweight rats, and normal 
weight versus diet-induced overweight placebo-treated rats. A p-value of <0.05 was 
considered to be statistically significant.
results
The study population contained 20 normal weight female rats on the normal diet and 
20 diet-induced female rats on the high-fat diet with average ages of 82±1 and 84±1 
days respectively. One rat on the high-fat diet failed to thrive for unknown reasons and 
was excluded from the study. Overall, the high-fat diet induced mild overweight, as rats 
on the high-fat diet were 13% heavier than those on the normal diet (234±4 g versus 
208±2 g, p<0.001). Plasma concentrations of human H2 relaxin in the relaxin-treated 
female rats were comparable in both weight groups (74±16 ng/ml in normal weight 
rats versus 61±5 ng/ml in diet-induced overweight rats, p=0.44), and were significantly 
elevated compared with placebo-treated female rats (less than 15.6 pg/ml). Plasma relaxin 
concentrations were comparable after correction for weight (36±8 ng/ml/100 g in normal 
weight rats versus 27±3 ng/ml/100 g in diet-induced overweight rats, p=0.30) and did not 
differ significantly between the two groups.
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Basal diameter of the mesenteric vessels and percentage precontraction to U46619 did 
not differ significantly between normal weight and diet-induced overweight female rats or 
between those chronically infused with relaxin and placebo (Table 1). For the most part, 
this was also seen in the presence and absence of L-NAME in the different experimental 
settings. However, under L-NAME, the response to 124 mM KCl was significantly increased 
in the relaxin-treated diet-induced overweight group, compared with placebo-treated 
diet-induced overweight female rats (15.1±0.7 versus 12.1±0.6 mN, respectively).
Flow-mediated vasodilation
Flow-mediated vasodilation in the mesenteric arteries of placebo-treated female rats 
did not differ significantly between normal weight and diet-induced overweight animals 
either in the absence (p=0.32) or presence (p=0.08) of L-NAME (Table 2). Similarly, 
although the maximum response to flow (Diammax) was slightly higher in the diet-induced 
Table 1. Baseline vascular characteristics of mesenteric arteries in normal weight and diet-induced 
overweight female rats, pre-treated with relaxin (4 µg/h for 5 days) or placebo.
Normal weight Diet-induced overweight
Placebo (n) Relaxin (n) Placebo (n) Relaxin (n)
Flow-mediated vasodilation
L-NAME absence
- Basal diameter (µm) 296±16 (6) 314±15 (7) 295±4 (6) 306±11 (7)
- Precontraction (%) 42±4 (6) 37±2 (7) 43±5 (6) 37±3 (7)
L-NAME presence
- Basal diameter (µm) 311±16 (5) 330±18 (4) 293±2 (6) 306±8 (8)
- Precontraction (%) 38±2 (5) 36±5 (4) 38±3 (6) 39±5 (8)
Myogenic reactivity
- Basal diameter (µm) 304±11 (8) 319±11 (10) 294±13 (9) 302±10 (9)
- Precontraction (%) 41±3 (8) 45±3 (10) 38±2 (9) 39±2 (9)
Vascular compliance 
- Basal diameter (µm) 309±8 (8) 318±12 (9) 281±14 (9) 301±10 (9)
Response to phenylephrine
L-NAME absence
- Basal diameter (µm) 251±9 (8) 234±10 (10) 269±15 (10) 282±7 (9)
- KCl contraction (mN) 12.8±0.9 (8) 12.7±0.4 (10) 13.0±0.7 (10) 12.3±0.7 (9)
L-NAME presence
- Basal diameter (µm) 240±9 (9) 243±10 (10) 257±13 (9) 248±10 (9)
- KCl contraction (mN) 13.1±0.5 (9) 12.5±0.5 (10) 12.1±0.6 (9) 15.1±0.7§ (9)
Values presented as mean ± SE, n = number of animals. § p<0.05 between placebo- and relaxin- treated rats.
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overweight female rats, it was not significant compared with normal weight female rats 
in the absence or presence of L-NAME. In normal weight female rats, chronic infusion 
with relaxin significantly (p<0.01) increased flow sensitivity 2.67 fold (Flow50% from 48±9 
to 18±4 µl/min) but had the opposite effect in diet-induced overweight female rats (35±7 
to 54±16 µl/min) although this was not significant (p=0.22, Figure 1 and Table 2). There 
was no significant effect of relaxin infusion on mesenteric artery Diammax in either weight 
group (Table 1). NO blockade blunted the different flow-mediated responses to relaxin in 
both weight groups but had no effect on Diammax (Table 2). 
Table 2. Flow-mediated vasodilation curve-fit estimates in mesenteric arteries of normal weight and 
diet-induced overweight female rats pre-treated with relaxin (4 µg/h for 5 days) or placebo. Experiments 
performed in the pressure-perfusion myograph in absence and presence of 100 µM L-NAME.
Flow-mediated vasodilation Placebo (n) Relaxin (n)
* Flow50% (µl/min) - normal weight 48±9 (6) 18±4§ (7)
- diet-induced overweight 35±7 (6) 54±16 (7)
- normal weight (L-NAME) 28±6 (5) 30±10 (4)
- diet-induced overweight (L-NAME) 42±5 (6) 38±6 (8)
* Diammax (%) - normal weight 31±5 (6) 26±2 (7)
  - diet-induced overweight 46±6 (6) 40±12 (7)
- normal weight (L-NAME) 27±3 (5) 31±5 (4)
- diet-induced overweight (L-NAME) 35±3 (6) 40±4 (8)
Curve-fit estimates: amount of flow inducing a 50% response (Flow50%), maximum response to flow 
(Diammax) as a percentage of precontraction to U46619. Values presented as mean ± SE, n = number of 
animals. § p<0.05 between placebo- and relaxin- pre-treated rats.
Myogenic reactivity and vascular compliance
Myogenic reactivity was recorded in the presence of calcium (Figure 2). We detected a 
significant (p=0.02) increase in MRoverall in the mesenteric arteries of placebo-treated diet-
induced overweight female rats compared with those in the normal weight group. This 
was probably due to smaller basal diameter, as MR>60 was not significantly affected (from 
-1±2 to 0±2 µm/10 mmHg, p=0.67). Chronic infusion of relaxin in normal weight female 
rats reduced both MRoverall (p=0.01) and MR>60 (from -1±2 to 7±3 µm/10 mmHg, p=0.03), 
whereas it did not significantly affect MRoverall (p=0.1) and MR>60 (from 2±2 to 3±2 µm/10 
mmHg, p=0.43) in diet-induced overweight female rats.
Mesenteric arterial compliance (measured in the absence of calcium) did not differ 
significantly between the diet-induced overweight and normal weight placebo-treated 
female rats (Figure 3). However, vessel wall thickness in diet-induced overweight female 
rats was significantly increased (p=0.05) compared with normal weight female rats 
(Figure 3C). Chronic infusion of relaxin did not significantly alter stress-strain curves, vessel 
wall thickness, VCoverall or VC>60 in either weight group.
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response to phenylephrine
Mesenteric arteries of placebo-treated diet-induced overweight female rats had 
significantly (p=0.04) increased sensitivity to phenylephrine (C50%) by 17 % (from 
1.39±0.08 to 1.19±0.02 µM) compared with normal weight female rats (Table 3). Pre-
treatment with L-NAME also significantly (p<0.01) diminished Rmax to phenylephrine in 
placebo-treated diet-induced overweight female rats. Relaxin treatment significantly 
(p<0.01) decreased the sensitivity to phenylephrine (C50%) by 28% (from 1.39±0.08 
to 1.78±0.10 µM) in normal weight female rats (Table 3). Under NO blockade, this 
effect was reduced but still significant (from 0.89±0.04 to 1.06±0.07 µM, p=0.04). In 
diet-induced overweight female rats, relaxin had no effect on C50%. However, in the 
presence of L-NAME, there was a significant (p<0.01) desensitizing effect of relaxin (from 
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Figure 1. Flow-mediated vasodilator response (left figures) and corresponding Flow50% (right figures) in 
normal weight (nRLX=7 and nPLAC=6) and diet-induced overweight (nRLX=7 and nPLAC=6) female rat mesenteric 
arteries, pre-treated with relaxin (RLX, 4 µg/h for 5 days) or placebo (PLAC).
§ p<0.05 between placebo- and relaxin-treated rats.
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0.84±0.02 to 1.10±0.05 µM). Relaxin did not affect the maximum response (Rmax) in 
either weight group, although pretreatment with L-NAME increased Rmax in diet-induced 
overweight female rats (p=0.05). 
isolated perfused rat Kidney model
The IPRK experiments resulted in RPFF response curves and corresponding curve fit estimates 
of normal weight and diet-induced overweight female rats (Figure 4). Comparison of 
the two placebo-treated weight groups demonstrated a significant (p<0.001) reduced 
RPFFbaseline by 16% (from 6.9±0.2 to 5.8±0.1 ml/min/100g) in the diet-induced overweight 
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Figure 2. Myogenic reactivity (in presence of calcium) in normal weight (nRLX=10 and nPLAC=8) and diet-
induced overweight (nRLX=9 and nPLAC=9) female rat mesenteric arteries, pre-treated with relaxin (RLX, 4 µg/h 
for 5 days) or placebo (PLAC).
§ p<0.05 between placebo- and relaxin-treated rats. 1 and 2 represent differences in the within-subjects 
factor and the between-subjects factor, respectively.
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Figure 3. Vascular compliance (in absence of calcium) in normal weight (nRLX=9 and nPLAC=8) and diet-
induced overweight (nRLX=9 and nPLAC=9) female rat mesenteric arteries, pre-treated with relaxin (RLX, 4 µg/h 
for 5 days) or placebo (PLAC): outer vessel diameter (A), inner vessel diameter (B), vessel wall thickness (C) 
and stress-strain curve (D).
# p <0.05 between normal weight and diet-induced overweight rats. 2 represents difference in the between-
subjects factor.
female rats, but no effect on NO mediated vasodilation (RPFFdelta from 3.9±0.4 to 3.6±0.1 
ml/min/100g). Chronic infusion with relaxin had no effect on RPFFbaseline (from 6.9±0.2 
to 6.7±0.1 ml/min/100g, p=0.38) and RPFFdelta (from 3.9±0.4 to 4.1±0.3 ml/min/100g, 
p=0,78) in normal weight female rats. In the diet-induced overweight female rats, relaxin 
lowered RPFFbaseline by 3% (from 5.8±0.1 to 5.6±0.1 ml/min/100g, p=0.01) but also lowered 
RPFFdelta 14% (from 3.6±0.1 to 3.1±0.1 ml/min/100g, p<0.001).
Rxfp1 gene expression
To confirm that Rxfp1 was expressed in the mesenteric arteries and test the hypothesis that 
diet or relaxin treatment could affect expression, we used quantified Rxfp1 expression. 
Rxfp1 was expressed in the mesenteric arteries, with a high degree of variation (Ct value 
range of 7.79-19.53). We did not find differences in 18S expression among the weight 
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Table 3. Phenylephrine response curve-fit estimates in mesenteric arteries of normal weight and diet-
induced overweight female rats pre-treated with relaxin (4 µg/h for 5 days) or placebo. Experiments 
performed in the wire myograph in absence and presence of 100 µM L-NAME.
Placebo (n) Relaxin (n)
* C50% (µM) - normal weight 1.39±0.08 (8) 1.78±0.10§ (10)
- diet-induced overweight 1.19±0.02# (10) 1.21±0.04 (9)
- normal weight (L-NAME) 0.89 ±0.04 (9) 1.06 ±0.07§ (10)
- diet-induced overweight (L-NAME) 0.84 ±0.02 (9) 1.10 ±0.04§ (9)
* Rmax (%) - normal weight 115 ±4 (8) 113 ±4 (10)
  - diet-induced overweight 112 ±3 (10) 113 ±3 (9)
- normal weight (L-NAME) 127 ±3 (9) 122 ±4 (10)
- diet-induced overweight (L-NAME) 114 ±3# (9) 124 ±3§ (9)
Curve-fit estimates: concentration of phenylephrine inducing a 50% response (C50%), maximum response 
(Rmax) as a percentage of the maximum response to 124 mM KCl. Values presented as mean ± SE, n = 
number of animals. § p<0.05 between placebo- and relaxin- pre-treated rats, # p <0.05 between normal 
weight and diet-induced overweight rats.
and treatment groups. There was no significant difference in expression between the two 
weight groups, and no effect of relaxin treatment (Figure 5).
discussion
Chronic relaxin exposure stimulates mesenteric vasodilation by affecting various independent 
responses involved in local vascular control. These effects are largely NO dependent. The 
ex vivo kidney is insensitive to relaxin. High-fat diet- induced overweight impairs normal 
mesenteric in vitro vasodilation and lowers RPFF in response to high levels of relaxin.
Chronic relaxin-treatment improves the vasodilator state of normal weight female rat 
mesenteric arteries by affecting several independent pathways. We observed that it raises 
flow-mediated vasodilation and lowers sensitivity to phenylephrine, both (partially) by 
enhanced NO mediated vasodilation. This is in line with observations made by others 
on the relaxin effects on NO dependent vasodilation and angiotensin-II sensitivity 5. Our 
data also confirm that relaxin decreases myogenic reactivity 8;9. Although this effect could 
be due to reduced vessel compliance rather than decreased myogenic tone 9, we did 
not observe an effect of relaxin on compliance. The differences in observations between 
studies may depend on normalization protocol, type, duration and dosage of relaxin, and 
the pressure range of interest. Overall, in normal weight female rats, we conclude that 
relaxin enhances vascular dilatation to flow, inhibits sensitivity to vasoconstrictor agents 
and reduces myogenic reactivity. These effects are predominantly caused by increasing NO 
mediated vasodilation, without altering the extracellular vascular matrix.
High-fat diet-induced overweight and obesity increase overall myogenic reactivity 29, 
enhance sensitivity to phenylephrine 30, and reduce endothelium-dependent vasodilation 31, 
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Figure 4. Renal perfusion flow (RPFF) in response to 100 µM L-NAME (at 60 minutes) in ex vivo isolated 
perfused rat kidney experiments in normal weight (nRLX=9 and nPLAC=9) and diet-induced overweight (nRLX=8 
and nPLAC=8) female rats, pre-treated with relaxin (RLX, 4 µg/h for 5 days) or placebo (PLAC).
whereas arterial compliance is not affected 32. Additionally, in diet-induced overweight 
female rats, mesenteric arteries are virtually resistant to relaxin, as we observed that the 
normal relaxin induced endothelium-dependent NO mediated vasodilation is blunted. The 
effects of relaxin on the vascular responses in diet-induced overweight female rats have not 
been studied before. We suggest that diet-induced overweight impairs all the vasodilatory 
effects of relaxin, in addition to the already present vasoconstriction phenotype in these rats.
In vivo experiments in healthy normal weight female rats have shown that relaxin 
raises renal plasma flow (RPF) up to 40% by increasing NO availability 5. In our ex vivo 
experiments, relaxin had no effect on the RPFF in normal weight female rats. Whole organ 
perfusion is affected by perfusate viscosity and solutions oxygen delivery capacity. As we 
added oxygen-carrier Pluronic to the perfusate and since we were able to detect small 
changes in renal function between the weight groups, we think that the absence of a 
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response to relaxin is unlikely due to the IPRK model. Our data therefore suggest that, in 
healthy female rats, in the absence of humoral and/or autonomic control, relaxin does not 
intrinsically adjust kidney function.
Being mildly overweight in young subjects induces renal hyperfiltration through 
hyperinsulinemia 33. In the isolated setting, we observed that diet-induced overweight 
reduced RPFF without affecting NO synthase activity 34. The reduced basal RPFF may 
be explained by enhanced renal myogenic tone, as observed in overweight-related 
dyslipidemia 35. Above the diet-induced overweight related renal impairment, relaxin pre-
treatment decreased basal RPFF and lowered NO mediated renal vasodilation. 
Our study has several potential limitations. First, our high-fat diet induced only mild 
overweight. On the analogy of human diet-related overweight, this high-fat diet model 
has been used in literature to investigate overweight-related vascular changes in rats 14. 
As reported by others 23;31, the moderate increase in body weight was sufficient to cause 
significant differences in vascular responses. Second, the human relaxin plasma levels we 
detected were a little higher than 30 ng/ml, as reported by others 5. This may be explained 
by volume distribution-, relaxin metabolism- or clearance differences among different rat 
strains. As the acute effects of relaxin predominate 9 and since we exposed both the ex 
vivo kidney and mesenteric artery experiments to the same amount of trial medication as 
used by others, it is unlikely that this may have confounded our results. Third, rats were 
enrolled into the experiments independently of their estrous cycle. We think that our 
randomization-procedure has distributed the estrous stages equally among groups, and 
therefore the cycle stage does not explain the observed effects of relaxin.
PLAC RLX PLAC RLX
3.9×10-03
7.8×10-03
0.015625
0.03125
0.0625
0.125
0.25
0.5
1
2
4
Normal
weight
Diet-induced
overweight
R
x
fp
1:
18
S 
(2∆∆ ∆∆
CT
x
 
10
3 )
Figure 5. Rxfp1 gene expression in mesenteric arteries of normal weight (nRLX=8 and nPLAC=7) and diet-
induced overweight (nRLX=10 and nPLAC=9) female rats, pre-treated with relaxin (RLX, 4 µg/h for 5 days) 
or placebo (PLAC).
Data are presented as mean ± SE 2-ΔCT.
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Relaxin is thought to act through the G protein-coupled Rxfp1 receptor, activating a 
vasoconstrictive mitogen-activated protein kinase (MAPK) pathway 36 and the normally 
predominant NO mediated vasodilator phosphatidylinositol 3-kinase (PI3K) pathway 
37, 
possible by interference of endothelin (ET) and its receptors (ETA and ETB) 
4. High-fat diet, 
similar to that used in the present study, induces overweight related insulin-resistance 38, 
which leads to inhibition of the PI3K pathway and overexpression of the MAPK pathway 
39. 
Although insulin and relaxin induce vasodilation through activation of different receptors 
(tyrosine kinase- and the Rxfp1 receptor, respectively), they both use similar down-stream 
signaling pathways. Our study showed comparable Rxfp1 receptor expression between 
normal diet and high-fat diet female rats. In analogy to insulin-resistance, a downregulated 
PI3K pathway and an upregulated MAPK pathway could explain our findings on relaxin-
resistance in high-fat diet-induced overweight female rats, which results in a relaxin-
induced vasoconstrictive state by a relatively impaired NO pathway.
In summary, diet-induced overweight impairs normal mesenteric endothelium-dependent 
and -independent in vitro vasodilation and reduces RPFF in response to relaxin exposure. This 
suggests the presence of relaxin-resistance in high-fat diet-induced overweight female rats.
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Chapter 6 
aBstract
Relaxin, an insulin-like growth factor peptide, increases endothelium dependent 
vasodilation and vascular compliance, and decreases myogenic reactivity. These vascular 
effects significantly contribute to the physiological circulatory adaptations in pregnancy, 
particularly in the mesentery and kidney. Aging predisposes to vascular maladaptation and 
gestational hypertensive disease. We hypothesized that mild aging reduces the vascular 
responses to relaxin. In 20 young (10-12 weeks) and 20 middle aged (40-46 weeks) female 
Wistar Hannover rats, vascular responses to chronic exposure of relaxin versus placebo (5 
days) were quantified in isolated mesenteric arteries and kidney. Vascular responses were 
evaluated using pressure-perfusion myograph, wire myograph and isolated perfused rat 
kidney model (IPRK). Rxfp1 (relaxin family peptide) gene expression was determined by qPCR. 
In young rats, relaxin stimulated nitric oxide (NO) dependent flow-mediated vasodilation 
(2.67 fold, from 48±9 to 18±4 µl/min), reduced myogenic reactivity (from -1±2 to 7±3 
µm/10 mmHg), decreased mesenteric sensitivity (28%, from 1.39±0.08 to 1.78±0.10 µM), 
but did not change compliance and renal perfusion flow (RPFF). In aged rats, relaxin did not 
affect any of the analyzed mesenteric or renal parameters. In aged compared with young 
placebo-treated rats, all mesenteric characteristics were comparable, while RPFF was lower 
(17%, from 6.9±0.2 to 5.7±0.1 ml/min/100g) even though NO availability was comparable. 
Rxfp1 expression was not different among young and aged rats. Our findings suggest 
that moderate aging involves normal endothelium function, but blunts the physiological 
endothelium-dependent and -independent vasodilator response to relaxin.
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introduction
Relaxin, a member of the insulin-like growth factor superfamily, is an important factor in 
achieving vasodilation in pregnancy 1. In vivo studies suggest that relaxin-induced renal vascular 
relaxation is the consequence of an activated endothelium NO release and an attenuated 
response to angiotensin-II in rats 2. Additionally, in vitro experiments in renal and mesenteric 
rat arteries have shown that relaxin decreases myogenic reactivity 3, and increases compliance 
4. Relaxin infusion induces vasodilation comparable to that observed in pregnancy 5-7, whereas 
relaxin neutralizing antibodies completely diminish pregnancy-induced vascular vasodilation 8. 
These findings suggest that relaxin is involved in gestational vascular adaptation.
Moderate aging is an independent risk factor for gestational hypertensive disease, 
doubling the risk above a maternal age of 40 years 9. It relates to reduced flow-mediated 
vasodilation 10 and increased sensitivity to phenylephrine in female rat mesenteric arteries 11. 
It also reduces myogenic reactivity without affecting vascular compliance in mice 12. Other 
studies report beneficial vascular effects of relaxin treatment in aged subjects 13;14. 
Attenuation of the pregnancy-induced increase in flow-mediated vasodilation, and reduction 
in phenylephrine sensitivity and myogenic reactivity, possibly induced by impaired response 
to relaxin, may be coupled to the development of gestational hypertensive disease 15;16.
We hypothesized that moderate aging (at the end of the reproductive lifespan) blunts 
the vascular responses to relaxin and subsequently induces relaxin-resistance, defined as 
the inability to produce comparable vascular responses to relaxin exposure as observed in 
young subjects. For this reason, we studied the effect of chronic exposure to relaxin in young 
versus moderately aged rats. The mesenteric and renal vascular beds are both important 
determinants of pregnancy-induced changes in peripheral resistance, increasing their 
perfusion by 65% and 40% respectively 17;18. Therefore, we addressed our hypothesis by 
investigating the vascular responses to relaxin in isolated mesenteric arteries and the IPRK.
Materials and MetHods
animals
The experimental protocol was approved by the Animal Experiments Committee of the 
Radboud University Nijmegen Medical Centre, the Netherlands, and was performed in 
accordance to the European guidelines on animal experiments. Forty female virgin Wistar 
Hannover rats (Harlan Netherlands, Horst, the Netherlands) were used in the experiments. 
Young rats (n=20, 10-12 weeks old) and aged rats (n=20, 40-46 weeks old) received 
standard rodent chow (ssniff R/M-H) and water ad libitum. We housed all rats in pairs in 
filter-top cages on a 12/12 h light/dark cycle. Rats were randomly assigned (independent 
from estrous stage) to treatment for 5 days with either placebo or recombinant human 
relaxin (both containing 5mM sodium acetate, pH 5.0; Corthera, San Mateo, California, 
USA). Human recombinant relaxin induces vascular responses comparable to those exerted 
by rat relaxin 2;8. On day 0, an osmotic minipump (Alzet, model 2001, DURECT, Cupertino, 
California, USA) was placed subcutaneously under isoflurane anesthesia. The osmotic 
minipump delivered the study medication at a dose of 4 µg/h during 5 days to achieve 
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plasma relaxin concentrations normally present on day 11 of gestation in rats 2. On day 5, 
the rats were anaesthetized with an intraperitoneal injection of pentobarbital (6 mg/100 
g body weight (BW), Apharmo, Arnhem, the Netherlands). Furosemide (1 mg/100g BW, 
Sigma-Aldrich Chemie, Zwijndrecht, the Netherlands) was also injected intraperitoneally to 
achieve maximal urethral distention for optimal catheter placement. Blood was withdrawn 
from the vena cava to measure human recombinant relaxin plasma levels (Human Relaxin-2 
Quantikine ELISA kit DRL200, R&D Systems Inc, Minneapolis, USA). In all experiments, we 
used perfusate and bath solutions containing 30 ng/ml of the trial-medication supplied.
pressure-perfusion myograph
The flow-mediated vasodilation, the myogenic reactivity to pressure and the compliance 
were analyzed in a pressure-perfusion myograph (Pressure Myograph System-Model 
P100, J. P. Trading, Aarhus, Denmark). The responses were determined in basic phosphate 
buffered saline (PBS: 119 mM NaCl, 4.69 mM KCl, 25 mM NaHCO3, 1.17 mM MgSO4, 
1.18 mM KH2PO4, 5.5 mM glucose and 10 mM HEPES), with additional 2 mM EGTA 
and 0.01 mM Na-Nitroprusside (for calcium-free-PBS) to measure compliance and 2.5 
mM CaCl2, 0.027 mM Na2EDTA (for calcium-PBS) to assess flow-mediated vasodilation 
and myogenic reactivity. The buffers were oxygenated with 95% O2 and 5% CO2 at a 
temperature of 37 ºC. Second-order mesenteric arteries (150-400 µm) were mounted on 
two opposing glass canules (125 µm). Vascular inner diameter was measured through 
video recording (Vessel View, J. P. Trading, Aarhus, Denmark). Arteries were equilibrated at 
an intraluminal pressure of 60 mmHg during 20 minutes. Subsequently, thromboxane A2 
agonist, U46619 (9,11-Dideoxy-11α, 9α-epoxymethanoprostaglandin F2α, Sigma-Aldrich 
Chemie, Zwijndrecht, the Netherlands) was added (bath concentration of 10-7to10-6 M) to 
preconstrict vessels to 30-40% of their basal diameter.
I. Flow-mediated vasodilation
Flow-mediated vasodilation is defined as the vasodilator response to a certain flow 
increase. After reaching a stable contraction, the flow in the vessel was increased every to 
2 minutes in 16.7 µl/min steps from 0 up to 100 µl/min (comparable to shear-stress range 
of 0-10 dyne/cm2), in absence and presence of 100 µM of the NO antagonist L-NAME 
(L-Nitro-Arginine Methyl Ester, Sigma-Aldrich Chemie, Zwijndrecht, the Netherlands), 
while maintaining a mean intraluminal pressure of 60 mmHg. Vessels attaining less than 
20% preconstriction, less than 10% vasodilation over the completed flow-range or with 
instable pressure due to fluid leakage were excluded from the study. Flow-mediated 
vasodilation was expressed as a percentage of the preconstriction status.
II. Myogenic reactivity and vascular compliance
Myogenic reactivity is defined as the vasoconstrictor response to a certain pressure increase 
in the presence of calcium. Compliance is defined as the vasodilator response to a certain 
pressure increase in the absence of calcium, to avoid smooth muscle cell contraction. A new 
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mesenteric vessel was isolated and prepared as described above. Intraluminal pressure was 
increased every 2 minutes in 10 mmHg steps from 20 mmHg up to 110 mmHg to determine 
successive myogenic reactivity (measuring inner vessel diameter) and compliance (measuring 
outer/inner vessel diameter and vessel wall thickness and the stress-strain relationship 19). 
Wire myograph (response to phenylephrine)
We studied the vasoconstrictor response to phenylephrine (Sigma-Aldrich Chemie, 
Zwijndrecht, the Netherlands) with a Mulvany Halpern myograph (Dual Wire Myograph-
Model 400A, J. P. Trading, Aarhus, Denmark). The bath was filled with physiological salt 
solution (PSS: 119 mM NaCl, 4.69 mM KCl, 2.5 mM CaCl2, 25 mM NaHCO3, 1.17 mM 
MgSO4, 1.18 mM KH2PO4, 5.5 mM glucose and 0.027 mM EDTA) and oxygenated with 
95% O2 and 5% CO2 at a temperature of 37 ºC. Four second-order mesenteric arteries 
(150-400 µm) were mounted in two wire myographs, stabilized as previously described 20, 
and set at a tension equivalent generated at 90% of the inner circumference of 100 
mmHg. The response to 124 mM KCl was measured (used for normalization of the 
phenylephrine response). The response to phenylephrine was determined in eight steps 
over a range from 10-7 M to 10-5 M, in the absence or presence of 100 µM L-NAME. The 
data of the two arteries in each myograph were averaged when available.
isolated perfused rat Kidney model (iprK)
The intrinsic adaptation to relaxin of the kidney was assessed in the IPRK. Within the time 
frame of our protocol, this model is known to present stable renal function 21, although 
one has to be restrictive to comparison of absolute values observed in vivo. Briefly, the 
right renal artery was cannulated via the left renal artery and aorta. The right ureter was 
cannulated for urine collection. Perfusion was started in situ and the kidney was removed 
and placed in a perfused bath at a temperature of 37 ºC. The kidney was perfused at 
constant pressure of 90 mmHg with oxygenated cell-free Krebs-Ringer-Henselheit 
(containing 113 mM NaCl, 4.8 mM KCL, 25 mM NaHCO3, 1.4 mM KH2PO4, 2.2 mM 
CaCl2, 1.4 mM MgCl2, and 5 mM Glucose) and 1.7 mM Pluronic F-108 (oxygen carrier and 
oncotic agent, BASF, Arnhem, the Netherlands). Renal perfusion flow (RPFF) was recorded 
in real time with the use of a computer system (Midac testorganizer, W95 [version 3.0], 
Radboud University Nijmegen Medical Centre, the Netherlands).
Stabilization of the RPFF was accomplished during a 40-minute period. From 40 
to 60 minutes the basal renal plasma flow (RPFFbaseline) was determined. At 60 minutes 
L-NAME was added at a final concentration of 100 µM to the perfusate to investigate 
the contribution of NO to the relaxin (or placebo) evoked vasodilator response up to 160 
minutes (RPFF160). RPFF was normalized for body weight (ml/min/100g body weight).
Rxfp1 gene expression
The Rxfp1 gene expression was analyzed by Quantitative Polymerase Chain Reaction (qPCR), 
according to the procedure described by Vodstrcil et al 22. Total RNA was extracted from frozen 
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mesenteric arteries with Trizol (GIBCO-BRL) according to the manufacturer’s instructions. 
Forward/reverse primers and 6-carboxy fluorescein (FAM)-labeled TaqMan probes specific for 
the full-length rat Rxfp1 were from Biosearch Technologies (Novato, California, USA).
statistical analysis
The data were expressed as means ± standard error of the mean (SE); n indicates the number 
of animals. Flow-mediated vasodilation and the responses to phenylephrine and RPFF were 
analyzed by nonlinear regression curve fitting (GraphPad Prism 4.0, Institute for Scientific 
Information, San Diego, California, USA). Subsequent curve fit estimates were: Diammax 
[maximal vascular diameter after flow change], Flow50% (flow rate inducing 50% dilation, 
flow-sensitivity), Rmax (maximum response to phenylephrine) and C50% (phenylephrine 
concentration inducing a 50% response), RPFFbaseline (basal RPFF), and RPFFdelta (RPFFbaseline 
minus RPFF160). Overall myogenic reactivity (MRoverall; using the inner vessel diameter 
corrected for percentage preconstriction) and overall vascular compliance (VCoverall; using the 
inner vessel diameter) were analyzed by using ANOVA for repeated measures (Greenhouse-
Geisser correction; SPSS 16.0.2, SPSS, Chicago, Illinois, USA). Selective straight line curve 
fitting was performed for both myogenic reactivity (MR>60) and compliance (VC>60) of the 
inner vessel diameter, estimating the hill slope over the range of 60-110 mmHg. Baseline 
characteristics were analyzed by using Student’s t-test. In all analyses, we compared relaxin 
versus placebo in young rats, relaxin versus placebo in aged rats, and young versus aged in 
placebo-treated rats. Rxpf1 gene expression was presented as normalized ΔCT, transformed 
by 2n where n = (-ΔCT) 
22. A p-value <0.05 was considered to be statistically significant.
results
The study population contained 20 young and 20 aged female virgin Wistar Hannover rats 
(mean age respectively 83±1 and 309±3 days). Aged rats weighed 29% more than young 
rats (208±2 g versus 268±5 g, p<0.01). Plasma concentrations of human relaxin after 
infusion were comparable (74±16 ng/ml versus 94±8 ng/ml, p=0.30, in young and aged 
rats, respectively). At baseline, aged rats showed larger vessel diameters than observed in 
young rats (reaching statistical difference in two experimental settings: myogenic reactivity 
and response to phenylephrine) with a comparable percentage preconstriction (Table 1). 
Basal diameter, percentage preconstriction and response to 124 mM KCl of mesenteric 
vessels were comparable for relaxin versus placebo, and for the presence versus absence 
of L-NAME for each experimental setting (Table 1).
Flow-mediated vasodilation
In young rats, relaxin enhanced flow-sensitivity (decreased Flow50%) 2.67 fold (from 48±9 
to 18±4 µl/min, p=0.001) without changing maximal reactivity (Diammax 26±2 and 31±5 
% in relaxin- and placebo-treated rats, respectively; Figure 1 and 2). L-NAME blunted the 
relaxin effect on flow-sensitivity (Flow50% 30±10 and 28±6 µl/min in relaxin- and placebo-
treated rats, respectively). In aged rats, relaxin did not change flow-sensitivity nor maximal 
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reactivity (Flow50% 50±10 and 40±9 µl/min and Diammax 34±6 and 23±4 % in relaxin- and 
placebo-treated rats, respectively), independent of NO blockade (Flow50% 47±8 and 56±3 
µl/min in relaxin- and placebo-treated rats, respectively). Aging itself only decreased flow-
sensitivity 2.00 fold (from 28±6 to 56±3 µl/min, p=0.001) when NO production is blocked.
Myogenic reactivity and vascular compliance
In young rats, chronic relaxin infusion reduced MRoverall and MR>60 (from -1±2 to 7±3 µm/10 
mmHg), but did not change MRoverall and MR>60 (from -1±4 to -1±2 µm/10 mmHg) in aged 
rats (Figure 3). Aging itself did not alter MRoverall and MR>60 (from -1±2 to -1±4 µm/10 
mmHg), compared with young placebo-treated rats.
Table 1. Baseline vascular characteristics of mesenteric arteries in young and aged rats pre-treated with 
relaxin (4 µg/h for 5 days) or placebo.
Young Aged
Placebo (n) Relaxin (n) Placebo (n) Relaxin (n)
Flow-mediated vasodilation
L-NAME absence
- Basal diameter (µm) 296±16 (6) 314±15 (7) 341±15 (6) 316±9 (9)
- Preconstriction (µm) 173±17 (6) 197±7 (7) 207±6 (6) 201±10 (9)
- Preconstriction (%) 42±4 37±2 39±3 36±2
L-NAME presence
- Basal diameter (µm) 311±16 (5) 330±18 (4) 340±16 (5) 325±8 (7)
- Preconstriction (µm) 191±7 (5) 219±15 (4) 227±4 (5) 194±17 (7)
- Preconstriction (%) 38±2 36±5 35±3 41±5
Myogenic reactivity
- Basal diameter (µm) 304±11 (8) 320±11 (10) 341±7# (7) 329±14 (8)
- Preconstriction (µm) 182±12 (8) 176±11 (10) 216±11 (7) 209±9 (8)
- Preconstriction (%) 41±3 45±3 37±3 36±2
Vascular compliance 
- Basal diameter (µm) 309±8 (8) 320±11 (9) 335±11 (7) 322±12 (8)
Response to phenylephrine
L-NAME absence
- Basal diameter (µm) 254±9 (8) 234±10 (10) 282±9# (10) 261±7 (10)
- Contraction to KCl (mN/mm2) 9.1±0.6 (8) 9.8±0.4 (10) 9.4±0.5 (10) 8.6±0.5 (10)
L-NAME presence
- Basal diameter (µm) 237±9 (9) 245±9 (10) 285±9# (10) 281±8 (10)
- Contraction to KCl (mN/mm2) 9.8±0.4 (9) 9.3±0.3 (10) 8.9±0.4 (10) 8.4±0.5 (10)
Values presented as mean ± SE, n = number of animals. # p<0.05 between young and aged rats. 
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Figure 1. Flow-mediated vasodilator response of young (nRLX=7 and nPLAC=6) and aged (nRLX=9 and nPLAC=6) 
rat mesenteric arteries, pre-treated with relaxin (RLX, 4 µg/h for 5 days) or placebo (PLAC).
In young and aged rats (Figure 4), relaxin exposure did not affect stress-strain curves, 
VCoverall and VC>60 (young: from 3±1 to 3±2 µm/10 mmHg; aged: from 4±2 to 3±3 µm/10 
mmHg). Aging itself increased VCoverall (p<0.01) without affecting VC>60 (from 3±1 to 
4±2 µm/10 mmHg), compared with young placebo-treated rats. However, this is rather 
dependent upon enlarged basal diameter than changes in vessel elasticity, since both 
curves run parallel and the stress-strain relationship was comparable.
response to phenylephrine
In young rats, relaxin reduced the sensitivity to phenylephrine (C50%) by 28% (p=0.01; 
Table 2), an effect partially persistent after NO blockade (19%, p=0.03). Relaxin did not 
affect Rmax to phenylephrine. In aged rats, relaxin neither affected C50% nor Rmax, whereas 
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under NO blockade relaxin decreased C50% by 67% (p=0.05). Aging itself did not alter 
either sensitivity or the maximum response to phenylephrine, although aging reduced the 
maximum response under L-NAME (p=0.05).
isolated perfused rat Kidney model (iprK)
In the kidney (Figure 5), in both young and aged rats, relaxin did not affect RPFFbaseline 
(young: 6.7±0.1 and 6.9±0.2 ml/min/100g; aged: 6.0±0.1 and 5.7±0.1 ml/min/100g in 
relaxin- and placebo-treated rats, respectively), nor did it change the contribution of NO to 
the vascular tone, measured in RPFFdelta (young: 4.1±0.3 and 3.9±0.4 ml/min/100g; aged: 
4.3±0.2 and 4.1±0.2 ml/min/100g in relaxin- and placebo-treated rats, respectively). 
Aging reduced RPFFbaseline by 17% (from 6.9±0.2 to 5.7±0.1 ml/min/100g, p=0.001) 
without affecting NO mediated vasodilation (RPFFdelta: 6.7±0.1 and 6.0±0.1 ml/min/100g), 
when comparing young versus aged placebo-treated rats.
Rxfp1 gene expression
Rxfp1 was expressed in the mesenteric arteries. However, there was no significant difference 
in expression between the young and aged rats treated with relaxin or placebo (Figure 6).
discussion
The present study reveals three important observations. Relaxin promotes mesenteric 
flow-mediated vasodilatation by stimulating the NO pathway, and reduces myogenic tone 
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Figure 2. Flow50% of young (nRLX=7 and nPLAC=6) and aged (nRLX=9 and nPLAC=6) rat mesenteric arteries, pre-
treated with relaxin (RLX, 4 µg/h for 5 days) or placebo (PLAC). Data are presented as mean ± SE. § within 
age group difference p<0.05.
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Figure 3. Myogenic reactivity of young (nRLX=10 and nPLAC=8) and aged (nRLX=8 and nPLAC=7) rat mesenteric 
arteries, pre-treated with relaxin (RLX, 4 µg/h for 5 days) or placebo (PLAC). § p<0.05 between placebo- and 
relaxin-treated rats. 1 represents difference in the within-subjects factor.
and responsiveness to phenylephrine. Interestingly, moderate aging appears to attenuate 
all of these relaxin-mediated effects. Finally, relaxin does not affect ex vivo RPFF in either 
young or aged rats.
Our data on functional responses in mesenteric arteries of young rats are mostly in 
line with observations made by others. Relaxin enhances flow-mediated vasodilation by 
increasing NO production at lower flow rates and decreases myogenic reactivity 3;4. The 
increased NO production seems to be a direct effect of relaxin, since relaxin exposure to 
isolated cells directly stimulates NO synthesis 23. Relaxin NO dependently reduces sensitivity 
to angiotensin-II 2, which is in line with our phenylephrine data. We did not detect any 
influence of relaxin on vascular compliance, although one study suggests that relaxin 
decreases compliance 4. This discordance may be the result of a variety of differences in 
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Figure 4. Vascular compliance of young (nRLX=9 and nPLAC=8) and aged (nRLX=9 and nPLAC=8) rat mesenteric 
arteries, pre-treated with relaxin (RLX, 4 µg/h for 5 days) or placebo (PLAC): outer vessel diameter (A), inner 
vessel diameter (B), vessel wall thickness (C) and stress-strain curve (D). # p<0.05 between young and aged 
rats. 2 represents difference in the between-subjects factor.
protocol, as Li et al. used Long Evans rats, supplies porcine relaxin at a rate of 4 µg/h for 
three days, and sets the pressure range of interest at 20-60 mmHg. Considering the extent 
of all changes, relaxin enhances the vasodilator state by affecting different local vascular 
responses, mainly by upregulation of NO mediated vasodilation.
Vascular effects of aging in female rodents is still a topic of debate, since some observed 
reduced NO dependent flow-mediated vasodilation 24 and myogenic reactivity 25, and 
increased phenylephrine reactivity 26, while others did not detect any age-dependent effects 
on these parameters 27. We were also unable to observe an age-induced effect on NO 
dependent vasodilation, myogenic reactivity or sensitivity to phenylephrine. Additionally, 
aging enhances vascular compliance 25. In line with morphological data 28, this is mainly due 
to increased basal vessel diameter rather than changes in vessel elasticity, considering the 
shape of the curve (Figure 4). As far as we know, this is the first study addressing effects of 
relaxin on mesenteric vascular function in relation to aging. We observed that, at the onset 
of reproductive senescence, basal responses of mesenteric arteries are comparable to those 
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Table 2. Phenylephrine response curve-fit estimates of young and aged rat mesenteric arteries pre-treated 
with relaxin (4 µg/h for 5 days) or placebo. Experiments performed in the wire myograph in absence and 
presence of 100 µM L-NAME.
Placebo (n) Relaxin (n)
* C50% (µM) - young 1.39±0.08 (8) 1.78±0.10§ (10)
- aged 1.07±0.10 (10) 1.31±0.24 (10)
- young (L-NAME) 0.89±0.04 (9) 1.06±0.07§ (10)
- aged (L-NAME) 0.72±0.07 (10) 1.20±0.29§ (10)
* Rmax (%) - young 115±4 (8) 113±4 (10)
- aged 111±6 (10) 118±11 (10)
- young (L-NAME) 127±3 (9) 125±4 (10)
- aged (L-NAME) 115±5# (10) 122±14 (10)
Curve-fit estimates: concentration of phenylephrine inducing a 50% response (C50%), maximum response (Rmax) 
as a percentage of the maximum response to 124 mM KCl. Values presented as mean ± SE, n = number of 
animals. § p<0.05 between placebo- and relaxin- pre-treated rats, # p <0.05 between young and aged rats.
observed in young rats, implying normal endothelium function in the moderately aged rat. 
However, all relaxin-induced mesenteric vasodilator responses, mostly NO dependent, are 
blunted. These findings suggest that, despite normal endothelium function, the endothelium 
in aged subjects suffers from endothelium-dependent resistance to relaxin.
Relaxin is known to increase in vivo renal plasma flow up to 40% by stimulating the 
NO pathway 2 and to reduce myogenic reactivity in isolated renal arteries 3. In aged rats, 
the increase in renal plasma flow is even more pronounced 13. We observed that in isolated 
kidney, relaxin did not affect RPFF in either young or aged rats. One may allege that renal 
plasma flow and RPFF are not the same parameters, although likely to be strongly related, 
and that perfusate viscosity and solutions oxygen delivery capacity are important factors 
jeopardizing whole organ perfusion function. In our model the oxygen-carrier Pluronic 
was added to the perfusate to optimize both factors. In the presence of this supplement 
we were able to detect a subtle aging-induced reduction in RPFF without concomitant 
changes in NO availability, as observed in vivo studies 13, possibly as a consequence of 
age-related loss in the number of functional glomeruli 29. We therefore think that merits 
of the model are unlikely to explain the absence of response to relaxin. Our findings 
indicate that, in the presence of both myogenic and junxtaglomerular control, the isolated 
kidney is insensitive to relaxin in both young and aged subjects and that extra-renal factors 
mediate relaxin-dependent renal vasodilation.
There are some limitations to our study design. First, our human relaxin plasma levels were 
a little higher than 30 ng/ml, as reported by others 2. This may be explained by differences in 
volume distribution or relaxin metabolism and clearance among different rat strains. Second, 
literature reports different physiological levels of relaxin among humans and rats (1 ng/ml and 
30 ng/ml, respectively) 30. It is difficult to interpret these differences and make comparison to 
our study, since there is no international standardization in the various relaxin assays used. 
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Figure 5. Renal perfusion flow (RPFF) in response to 100 µM L-NAME (at 60 minutes) in young (nRLX=9 and 
nPLAC=9) and aged (nRLX=8 and nPLAC=8) rats, pre-treated with relaxin (RLX, 4 µg/h for 5 days) or placebo (PLAC).
Third, the female rats were not selected for a particular stage of their estrous cycle. This may 
have affected our results, since high levels of estrogen could affect vascular tone. However, 
our randomization procedure was designed to distribute the estrous stages equally among 
groups, and this is unlikely to account for the observed effects of relaxin.
It is thought that the vascular effects of relaxin are mediated through activation of 
the G protein-coupled relaxin family peptide receptor (Rxfp1), initiating both an inferior 
vasoconstrictor and a predominant vasodilator pathway. Activation of the mitogen-
activated protein kinase (MAPK) pathway induces vasoconstriction 31, where stimulation 
of the NO synthase-mediated phosphatidylinositol 3-kinase (PI3K) pathway enhances 
vasodilation 32. Moreover, matrix metalloprotease-2 is also involved 33. The influence of relaxin 
on the vascular tone is likely a combined result of these pathways. It is unlikely that aging 
attenuates vascular Rxfp1 expression because we did not detect any differences between 
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Figure 6. Rxfp1 gene expression in mesenteric arteries in young (nRLX=8 and nPLAC=7) and aged (nRLX=5 and nPLAC=5) 
rats, pre-treated with relaxin (RLX, 4 µg/h for 5 days) or placebo (PLAC). Data are presented as mean ± SE 2-ΔCT.
young and aged rats. Because aging is associated with down regulation of the vasodilatory 
PI3K pathway at the Akt/protein kinase B level 
34;35, this implies that aging affects the down-
stream pathway. This may explain the aging-induced relaxin-resistance, as relaxin equally 
activates both the vasodilator and vasoconstrictor pathway. Whether higher concentrations 
of relaxin may be capable of overcoming the attenuated response, seen at a lower dose, 
remains to be elucidated. Nevertheless, one may speculate that resistance to relaxin relates 
aging-associated circulatory maladaptation with gestational hypertensive disease.
In summary, aging abolishes the physiological vasodilator response to relaxin, without 
affecting baseline vascular function. The disability to develop a pronounced relaxin-
induced vasodilator state supports our concept of relaxin-resistance in aged subjects.
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impaired effect of relaxin on vasoconstrictor 
reactivity in spontaneous hypertensive rats
Chapter 7 
aBstract
Relaxin is thought to be involved in vasodilation to pregnancy by increasing endothelium-
dependent vasodilation and compliance, and decreasing myogenic reactivity. Primary 
(essential) hypertension predisposes to circulatory maladaptation and subsequent 
gestational hypertensive disease. This study aimed to determine that vascular responses to 
chronic exposure to relaxin are impaired in young female rats with primary hypertension. 
In 10-12 weeks old Wistar-Hannover rats (WHR) and spontaneous hypertensive rats (SHR), 
we determined vascular responses in isolated kidney and mesenteric arteries after 5 days 
of chronic exposure to relaxin (4 µg/h) or placebo. SHR show decreased sensitivity to 
phenylephrine (by 67%, p<0.01) and renal perfusion flow (RPFF, by 19%, p<0.01), but 
no changes in flow-mediated vasodilation, myogenic reactivity or vascular compliance. In 
WHR, relaxin stimulated flow-mediated vasodilation (2.67 fold, from 48±9 to 18±4 µl/
min, p=0.001), inhibited myogenic reactivity (from -1±2 to 7±3 µm/10 mmHg, p=0.01), 
and decreased sensitivity to phenylephrine (28%, from 1.39±0.08 to 1.78±0.10 µM, 
p<0.01), but left compliance and RPFF unchanged. NO blockade by L-NAME diminished 
most relaxin-mediated responses. In SHR, the vasodilator effects of relaxin were blunted 
for myogenic reactivity and sensitivity to phenylephrine, with similar effects on flow-
mediated vasodilation, compliance, RPFF and equal Rxfp1 (relaxin family peptide receptor) 
gene expression, as compared with WHR. Primary hypertension blunts both the relaxin-
induced inhibition of myogenic reactivity and α-adrenergic vasoconstrictor response, 
independent from Rxfp1 gene expression, while the relaxin-dependent enhanced flow-
mediated vasodilation remains intact. This implies selective resistance to relaxin in young 
subjects suffering from primary hypertension.
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introduction
Relaxin, a member of the insulin-like growth factor superfamily, is thought to play an 
important role in pregnancy-associated vasodilation 1. In vivo, relaxin induces renal 
vasodilation by activation of endothelium nitric oxide (NO) release and attenuation of 
the response to angiotensin-II in rats 2. Additionally, in vitro, relaxin decreases myogenic 
reactivity 3, and increases compliance 4 in renal and mesenteric rat arteries. Overall, 
relaxin infusion in nonpregnant female rats accomplishes vasodilation comparable to 
that observed in pregnancy 5-7, whereas relaxin neutralizing antibodies completely blunt 
pregnancy-induced vasodilation 8.
In humans, preeclampsia predisposes to the development of chronic hypertension later 
in life 9, which poses individuals at risk for cardiovascular disease  10. Primary (essential) 
hypertension, in turn, increases the risk of subsequent preeclampsia by 25% 11;12. In male 
hypertensive rats, relaxin exposure reduces the systemic arterial load, but also shows a relative 
insensitivity on the cellular level 13-16. As preeclampsia is generally preceded by circulatory 
maladaptation in early pregnancy, these findings raise the question whether primary 
hypertension affects the normal pregnancy-associated relaxin-mediated vascular adaptation.
In this study, we tested the hypothesis that primary hypertension in spontaneous 
hypertensive rats (SHR) induces resistance to chronic exposure to relaxin, defined as 
the inability to produce comparable vascular responses to chronic relaxin exposure as 
observed in non-susceptible Wistar Hannover rats (WHR). Wistar Kyote rats (WKY), often 
seen as the usual SHR control, do not respond to relaxin as seen in other strains 17, show 
genetic dissimilarity to SHR of 50% 18 and were therefore not used as control. Both the 
mesenteric and renal vascular beds largely determine peripheral resistance in nonpregnant 
and pregnant condition 19-22. To this end, we performed an experimental study on vascular 
responses in isolated mesenteric arteries and isolated kidney in nonpregnant female WHR 
and SHR, chronically exposed to relaxin or placebo.
Materials and MetHods
animals
The experimental protocol was approved by the Animal Experiments Committee of the 
Radboud University Nijmegen Medical Centre, the Netherlands, and was performed in 
accordance with the European guidelines on animal experiments. Twenty female virgin 
WHR and 20 virgin SHR (Harlan Netherlands, Horst, the Netherlands) were used for 
approximately parallel experiments. The WHR that were used also served as controls for 
other studies, their results have been previously reported 23;24. SHR are known to have 
primary hypertension from 6 weeks of age 25. Both groups received regular diet (ssniff 
R/M-H) and water ad libitum. We housed all rats in filter-top cages on a 12/12 hour light/
dark cycle. At an age of 73-85 days, rats were randomly assigned (independent from estrous 
stage) to chronic infusion for 5 days with either placebo or recombinant human H2 relaxin 
(both containing 5mM sodium acetate, pH 5.0; Corthera, San Mateo, California, USA). 
Nonpregnant rats, exposed to 4 µg/h human relaxin for 5 days, present serum relaxin levels 
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of ±30 ng/ml and vascular responses comparable to those induced by chronic exposure to 
endogenous relaxin in mid-term pregnant rats 2;8. The experimental protocol was similar to 
the one described before 24. In short, on day 0, an osmotic minipump (Alzet, model 2001, 
DURECT Corporation, Cupertino, California, USA) was implanted subcutaneously, and 
infused human relaxin at a dose of 4 µg/h for 5 days. On day 5, the rats were anesthetized 
with an intraperitoneal injection pentobarbital (Apharmo, Arnhem, the Netherlands). 
Blood was sampled from the caval vein for plasma human H2 relaxin measurement (Human 
Relaxin-2 Quantikine ELISA kit DRL200, R&D Systems, Minneapolis, USA). We continued 
chronic exposure of the vessels to human relaxin or placebo during all experiments, by 
adding 30 ng/ml of the trial-medication supplied to the perfusate and bath solutions.
pressure-perFusion MyograpH
Flow-mediated vasodilation, myogenic reactivity and compliance were analyzed in a 
pressure-perfusion myograph (Pressure Myograph System-Model P100, Danish Myo 
Technology, Aarhus, Denmark). The responses were determined in basic phosphate 
buffered saline (PBS: 119 mM NaCl, 4.69 mM KCl, 25 mM NaHCO3, 1.17 mM MgSO4, 1.18 
mM KH2PO4, 5.5 mM glucose and 10 mM HEPES), with additional 2 mM EGTA and 0.01 
mM Na-Nitroprusside (for calcium-free-PBS) to measure compliance and 2.5 mM CaCl2, 
0.027 mM Na2EDTA (for calcium-PBS) to assess flow-mediated vasodilation and myogenic 
reactivity. The buffers were oxygenated with 95% O2 and 5% CO2 at a temperature of 
37 ºC. Second-order mesenteric arteries (150-400 µm) were mounted on two opposing 
glass cannulae (125 µm). Vascular inner and outer diameter was measured through 
video recording (Vessel View, Danish Myo Technology, Aarhus, Denmark). Arteries were 
equilibrated at an intraluminal pressure of 60 mmHg and basal diameter was measured. 
Thereafter, vessels were preconstricted to 30-40% of their basal diameter by use of the 
thromboxane A2 agonist, U46619 (9,11-Dideoxy-11α, 9α-epoxymethanoprostaglandin 
F2α, Sigma-Aldrich Chemie, Zwijndrecht, the Netherlands).
I. Flow-mediated vasodilation
After reaching a stable contraction, the flow in the vessel was increased every 2 minutes 
in 16.7 µl/min steps from 0 up to 100 µl/min (comparable to shear-stress range of 0-10 
dyne/cm2), in the absence and presence of 100 µM of the NO antagonist L-NAME (L-Nitro-
Arginine Methyl Ester, Sigma-Aldrich Chemie, Zwijndrecht, the Netherlands). Intraluminal 
pressure was maintained at 60 mmHg. Vessels attaining less than 20% preconstriction, 
less than 10% vasodilation over the completed flow-range or with instable pressure due 
to fluid leakage were excluded from the study. Flow-mediated vasodilation was expressed 
as a percentage of the preconstriction status.
II. Myogenic reactivity and vascular compliance
A new mesenteric vessel was isolated and prepared as described above. Intraluminal 
pressure was increased every 2 minutes in 10 mmHg steps from 20 mmHg up to 110 mmHg 
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to determine successive myogenic reactivity and compliance. After the 2-minute time 
interval vessels have reached a stable vascular tone. For compliance, outer and inner vessel 
diameters, and wall thickness were measured, and stress-strain relationship was obtained.
Wire myograph (response to phenylephrine)
The vasoconstrictor response to phenylephrine (Sigma-Aldrich Chemie, Zwijndrecht, the 
Netherlands) was analyzed in a Mulvany Halpern myograph (Dual Wire Myograph-Model 
400A, Danish Myo Technology, Aarhus, Denmark). The bath contained a physiological salt 
solution (PSS: 119 mM NaCl, 4.69 mM KCl, 2.5 mM CaCl2, 25 mM NaHCO3, 1.17 mM 
MgSO4, 1.18 mM KH2PO4, 5.5 mM glucose and 0.027 mM EDTA) and was oxygenated with 
95% O2 and 5% CO2 at a temperature of 37 ºC. Four second-order mesenteric arteries 
(150-400 µm) were mounted in two wire myographs. The response to 124 mM KCl was 
measured and used for normalization of the phenylephrine response. The response to 
phenylephrine was determined in eight steps over a range from 10-7 M to 10-5 M, in the 
absence or presence of 100 µM L-NAME. The data of the two arteries in each myograph 
were averaged when available.
isolated perfused rat Kidney model (iprK)
We assessed relaxin-induced vascular adaptation of the isolated kidney in the IPRK. Within 
the time frame of our protocol, this model shows stable RPFF and provides an indication of 
renal function 26, but may not reflect effective renal plasma flow responses in vivo. Briefly, 
the right renal artery and the right ureter were cannulated. Perfusion was started in situ and 
the kidney was removed and placed in a perfused bath. The kidney was perfused at constant 
pressure of 90 mmHg and a temperature of 37 ºC with oxygenated cell-free Krebs-Ringer-
Henselheit (containing 113 mM NaCl, 4.8 mM KCl, 25 mM NaHCO3, 1.4 mM KH2PO4, 2.2 
mM CaCl2, 1.4 mM MgCl2, and 5 mM Glucose) with 1.7 mM Pluronic F-108 (oxygen carrier 
and oncotic agent, BASF, Arnhem, the Netherlands). RPFF was recorded real-time (Midac 
testorganizer, W95 [V3.0], Radboud University Nijmegen Medical Centre, the Netherlands).
Stabilization of the RPFF was accomplished during a 40-minute period. From 40 to 60 
minutes basal renal plasma flow (RPFFbaseline) was determined. At 60 minutes L-NAME was 
added at a final concentration of 100 µM to the perfusate. At 160 minutes a stable RPFF 
was observed (RPFF160). RPFF was normalised for body weight (ml/min/100g body weight).
Rxfp1 gene expression
Rxfp1 gene expression was analyzed by Quantitative Polymerase Chain Reaction (qPCR), 
as described previously 27. Total RNA was extracted from frozen mesenteric arteries with 
Trizol (GIBCO-BRL) according to the manufacturer’s instructions. Forward/reverse primers 
and 6-carboxy fluorescein (FAM)-labeled TaqMan probes were specific for the full-length 
rat Rxfp1 from Biosearch Technologies (Novato, California, USA). Rxfp1 gene expression 
was compared with expression of the ribosomal 18S reference gene and presented as 
normalized ΔCT, transformed by 2
n where n = (-ΔCT) 
27. 
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statistical analysis
The data were expressed as mean ± standard error of the mean (SE). Flow-mediated vasodilation, 
stress-strain relationship, response to phenylephrine and RPFF were analyzed by nonlinear 
regression curve fitting (GraphPad Prism 4.0, Institute for Scientific Information, San Diego, 
USA). Subsequent curve fit estimates were: Diammax [maximal vascular diameter after flow 
change], Flow50% (flow rate inducing 50% dilation, flow-sensitivity), K1 and K2 (exponential 
constants for stress-strain relationship), Rmax (maximum response to phenylephrine) and C50% 
(phenylephrine concentration inducing a 50% response), RPFFbaseline (basal RPFF), and RPFFdelta 
(RPFFbaseline minus RPFF160). Overall myogenic reactivity (MRoverall; corrected for percentage 
preconstriction) and overall vascular compliance (VCoverall) were analyzed by using analysis of 
variance (ANOVA) for repeated measures (Greenhouse-Geisser correction; SPSS 16.0.2, SPSS, 
Chicago, Illinois, USA). Straight line curve fitting was performed for both myogenic reactivity 
(MR>60) and compliance (VC>60), estimating the slope over the range of 60 to 110 mmHg. 
Baseline characteristics were analyzed with Student’s t-test. In all analyses, we compared 
relaxin versus placebo in WHR, relaxin versus placebo in SHR, and placebo-treated WHR versus 
placebo-treated SHR. A p-value <0.05 was considered to be statistically significant.
results
The study population contained 20 WHR and 20 SHR female virgin rats (4-10 per group 
for each measurement) with average ages of 82±1 days in both groups when sacrificed. 
Overall, body weight was significantly lower (13%) in SHR, as compared with WHR (180±2 
g versus 208±2 g, p<0.001). Plasma concentration of human H2 relaxin was comparable in 
both strains exposed to relaxin (74±16 ng/ml in WHR versus 77±9 ng/ml in SHR, p=0.88).
Vascular baseline characteristics were generally comparable between WHR and SHR 
(Table 1). For flow-mediated vasodilation experiments in the absence of L-NAME, the 
amount of preconstriction was slightly less in placebo-treated SHR compared with placebo-
treated WHR (32±1 versus 42±4 %, p=0.01). For myogenic reactivity experiments, the 
diameter after preconstriction was higher in relaxin- versus placebo-treated SHR, although 
the percentage preconstriction was comparable. For the vascular compliance experiments, 
placebo-treated SHR showed a smaller basal diameter as compared with placebo-treated 
WHR. The concentration U46619 used for preconstriction was comparable for all groups 
and experiments. For the response to phenylephrine, the contraction to 124 mM KCl was 
increased in placebo-treated SHR, compared with placebo-treated WHR.
Flow-mediated vasodilation
Flow-mediated vasodilation in mesenteric arteries of placebo-treated rats was comparable 
between SHR and WHR in the absence (p=0.28) or presence (p=0.92) of L-NAME (Table 2). 
In both WHR and SHR (Figure 1 and Table 2), relaxin stimulated flow-sensitivity (decreased 
Flow50%) 2.67 fold (p=0.001) and 3.78 fold (p=0.001), respectively, without affecting 
maximum dilated diameter (Diammax). This effect was completely NO dependent, as 
L-NAME blunted the increase in sensitivity to relaxin in both WHR and SHR. 
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Table 1. Baseline vascular characteristics of mesenteric arteries in female WHR and SHR pre-treated with 
relaxin (4 µg/h for 5 days) or placebo.
WHR SHR
Placebo (n) Relaxin (n) Placebo (n) Relaxin (n)
Flow-mediated vasodilation
L-NAME absence
- Basal diameter (µm) 296±16 (6) 314±15 (7) 274±9 (7) 279±12 (9)
-  U46619  
for preconstriction (µM)
0.20±0.08 0.14±0.03 1.58±0.93 0.66±0.18
- Preconstriction  (µm)| 
(%)
173
42
±17
±4
197
37
±7
±2
187
32
±7
±1#
182
35
±8
±1
L-NAME presence
- Basal diameter (µm) 311±16 (5) 330±18 (4) 276±6 (10) 281±10 (10)
-  U46619  
for preconstriction (µM)
0.38±0.12 0.10±0.01 2.38±0.98 0.72±0.17
- Preconstriction  (µm) 
(%)
191
38
±7
±2
219
36
±15
±5
161
42
±13
±4
175
38
±12
±3
Myogenic reactivity
- Basal diameter (µm) 304±11 (8) 320±11 (10) 266±15 (6) 294±10 (10)
-  U46619  
for preconstriction (µM)
0.18±0.05 0.18±0.07 0.66±0.28 (6) 0.26±0.04
- Preconstriction  (µm) 
(%)
182
41
±12
±3
176
45
±11
±3
168
36
±5
±2
(6) 199
32
±7§
±1
Vascular compliance 
- Basal diameter (µm) 309±8 (8) 320±11 (9) 278±12# (9) 294±10 (10)
Response to phenylephrine
L-NAME absence
- Basal diameter (µm) 254±9 (8) 234±10 (10) 244±7 (10) 237±7 (10)
-  Contraction to KCl  
(mN/mm2)
9.1±0.6 9.8±0.4 12.3±0.8# 10.0±0.6§
L-NAME presence
- Basal diameter (µm) 237±9 (9) 245±9 (10) 232±6 (10) 228±9 (10)
-  Contraction to KCl  
(mN/mm2)
9.8±0.4 9.3 ±0.3 10.3±0.5 11.6 ±0.5
Values presented as mean ± SE, n = number of animals. § p<0.05 between placebo- and relaxin- pre-
treated rats, # p<0.05 between WHR and SHR. 
Myogenic reactivity and vascular compliance
In the presence of calcium, myogenic reactivity was analyzed (Figure 2). In placebo-treated 
SHR and WHR myogenic reactivity was comparable (MRoverall (p=0.11) and MR>60 (respectively 
5±3 and -1±2 µm/10 mmHg, p=0.07)), although SHR do not show a clear vasoconstrictor 
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response at high pressure levels. Chronic infusion of relaxin in WHR reduced myogenic 
reactivity (MRoverall (p=0.01) and MR>60 (from -1±2 to 7±3 µm/10 mmHg, p=0.03)), while 
in SHR it did not (MRoverall (p=0.83) and MR>60 (from 5±3 to 4±2 µm/10 mmHg, p=0.75)).
In the absence of calcium, mesenteric arterial compliance was comparable between 
placebo treated SHR and WHR: VC>60 (respectively 7±3 and 3±1 µm/10 mmHg, p=0.23), 
vessel wall thickness (p=0.07) and stress-strain relationship (K1: p=0.38; K2: p=0.38) 
(Figure 3C and 3D). Outer and inner diameters in SHR were significantly reduced over the 
whole pressure range of interest (VCoverall outer diameter: p=0.01, VCoverall inner diameter: 
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Figure 1. Flow-mediated vasodilator response (left figures) and corresponding Flow50% (right figures) in 
female WHR (nRLX=7 and nPLAC=6) and SHR (nRLX=9 and nPLAC=7) mesenteric arteries, pre-treated with relaxin 
(RLX, 4 µg/h for 5 days) or placebo (PLAC).
§ p<0.05 between placebo- and relaxin-treated rats.
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Table 2. Flow-mediated vasodilation curve-fit estimates of the pressure-perfusion myograph experiments 
in female WHR and SHR in the absence and presence of 100 µM L-NAME.
Flow-mediated vasodilation Placebo (n) Relaxin (n)
* Flow50% (µl/min) - WHR 48±9 (6) 18±4§ (7)
- SHR 34±9 (7) 9±7§ (9)
- WHR (L-NAME) 28±6* (5) 30±10 (4)
- SHR (L-NAME) 26±9 (10) 24±7 (10)
* Diammax (%) - WHR 31±5 (6) 26±2 (7)
 - SHR 23±3 (7) 20±2 (9)
- WHR (L-NAME) 27±3 (5) 31±5 (4)
- SHR (L-NAME) 50±7 (10) 39±4 (10)
Experiments performed in the pressure-perfusion myograph in absence and presence of 100 µM L-NAME. 
Curve-fit estimates: amount of flow inducing a 50% response (Flow50%), maximum response to flow (Diammax) 
as a percentage of preconstriction to U46619. Values presented as mean ± SE, n = number of animals. § 
p<0.05 between placebo- and relaxin- pre-treated rats, * p<0.05 between absence and presence of L-NAME.
p=0.02, Figure 3A and 3B). Chronic infusion of relaxin did not significantly alter stress-
strain curves, vessel wall thickness, VCoverall or VC>60 in both WHR and SHR.
response to phenylephrine
Mesenteric arteries of placebo-treated SHR had a significantly reduced sensitivity to 
phenylephrine (C50%, p<0.01) by 67% and maximum response (Rmax, p=0.02) by 10%, 
compared with WHR (Table 3). NO blockade blunted the Rmax differences, while lower 
sensitivity to phenylephrine persisted in SHR versus WHR placebo-treated rats. Relaxin 
exposure reduced sensitivity to phenylephrine by 28% (p<0.01) in WHR (Table 3). Under 
NO blockade, this effect decreased but was still significant (p=0.04). This suggests that 
NO is responsible for approximately half of the relaxin-induced reduction in sensitivity to 
phenylephrine. In SHR, relaxin did not alter C50% (p=0.21), independent from NO synthase 
inhibition. Relaxin did not affect the maximum response (Rmax) in both strains, independent 
from NO blockade. 
isolated perfused rat Kidney model (iprK)
In placebo-treated rats, SHR showed 19% (5.6±0.1 versus 6.9±0.2 ml/min/100g, p<0.01) 
lower RPFFbaseline and 18% (3.2±0.1 versus 3.9±0.4 ml/min/100g, p=0.03) less reduction in 
flow in response to L-NAME (RPFFdelta), when compared with WHR (Figure 4). The L-NAME 
induced reduction in flow as a percentage of RPFFbaseline was comparable among SHR 
and WHR: both 57%. In both SHR and WHR, chronic infusion of relaxin did not change 
RPFFbaseline (SHR: from 5.6±0.1 to 5.6±0.1 ml/min/100g; WHR: from 6.9±0.2 to 6.7±0.1 ml/
min/100g) or RPFFdelta (SHR: from 3.2±0.1 to 3.2±0.1 ml/min/100g; WHR: from 3.9±0.4 to 
4.1±0.3 ml/min/100g).
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Figure 2. Myogenic reactivity (in presence of calcium) in female WHR (nRLX=10 and nPLAC=8) and SHR (nRLX=10 
and nPLAC=6) mesenteric arteries, pre-treated with relaxin (RLX, 4 µg/h for 5 days) or placebo (PLAC). 
§ p<0.05 between placebo- and relaxin-treated  rats. 1 represent differences in the within-subjects factor.
Rxfp1 gene expression
Mesenteric arteries expressed Rxfp1 with a high degree of variation (Ct value range 8.79-
18.49). 18S expression was comparable among WHR and SHR, independent from relaxin 
exposure. We did not detect any difference in Rxfp1 expression between WHR and SHR, 
and no effect of relaxin exposure (Figure 5).
discussion
Relaxin has been reported to enhance vasodilation. Our study implies that young SHR, 
which have primary hypertension, do not show the relaxin-induced inhibition of the 
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Figure 3. Vascular compliance (in absence of calcium) in female WHR (nRLX=9 and nPLAC=8) and SHR (nRLX=10 
and nPLAC=9) mesenteric arteries, pre-treated with relaxin (RLX, 4 µg/h for 5 days) or placebo (PLAC): outer 
vessel diameter (A), inner vessel diameter (B), vessel wall thickness (C) and stress-strain curve (D). 
# p<0.05 between WHR and SHR rats. 2 represents difference in the between-subjects factor.
myogenic reactivity and α-adrenergic vasoconstrictor response, as observed in healthy 
controls, while the enhanced flow-mediated vasodilation to relaxin remains intact.
Evaluation of mesenteric arteries in healthy female rats shows that relaxin affects 
several independent vascular responses. In agreement with the literature, our data show 
that relaxin reduces sensitivity to α-adrenergic activation by stimulation of the NO pathway 2 
and decreases myogenic reactivity 3;4. Additionally, we observed that relaxin enhances flow-
mediated vasodilation without affecting vascular compliance. Flow-mediated vasodilation 
seems to be NO dependent, although this is based on a small amount of animals. Others 
have reported a relaxin-induced increase in vascular compliance 4.  Dissimilarities with our 
observation might be explained by differences in exposure protocol (using porcine relaxin 
at 4 µg/h for three days instead of human recombinant relaxin for 5 days) and methods to 
quantify vascular compliance (using Long Evans rats instead of WHR and setting the pressure 
range of interest at 20-60 mmHg compared with 60-110 mmHg). As the physiological 
mean arterial pressure in mesenteric arteries is around 90 mmHg, our data suggest that 
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Table 3. Phenylephrine response curve-fit estimates of the wire myograph experiments in female WHR and 
SHR in the absence and presence of 100 µM L-NAME.
Placebo (n) Relaxin (n)
* C50% (log µM) - WHR 1.39±0.08 (8) 1.78±0.10§ (10)
- SHR 2.32±0.13# (9) 2.26±0.17 (10)
- WHR (L-NAME) 0.89±0.04* (9) 1.06±0.07§ (10)
- SHR (L-NAME) 1.80±0.14#* (9) 1.66±0.14 (10)
* Rmax (%) - WHR 115±4 (8) 113±4 (10)
- SHR 103±4# (9) 113±5 (10)
- WHR (L-NAME) 127±3* (9) 125±4 (10)
- SHR (L-NAME) 121±6* (9) 117±6 (10)
Experiments performed in the wire myograph in absence and presence of 100 µM L-NAME. Curve-fit 
estimates: concentration of phenylephrine inducing a 50% response (C50%), maximum response (Rmax) as 
a percentage of the maximum response to 124 mM KCl. Values presented as mean ± SE, n = number of 
animals. § p<0.05 between placebo- and relaxin- pre-treated rats, # p<0.05 between WHR and SHR rats, 
* p<0.05 between absence and presence of L-NAME.
relaxin does not change compliance, but induces vasodilation by affecting flow-mediated 
vasodilation, myogenic reactivity and sensitivity to α-adrenergic vasopressors.
Relaxin is known to have several positive influences on the cardiovascular status in senescent 
SHR: it reduces cardiac fibrosis, cardiac hypertrophy, cardiac after load and blood pressure, and 
increases cardiac output and arterial compliance 13;15;16;28;29. To our knowledge, the effects of 
relaxin on the local vascular responses have not been investigated before. We found that, 
in young female rats, primary hypertension abolishes the relaxin-mediated inhibition of the 
myogenic reactivity and response to phenylephrine, with intact vasodilator effects of relaxin on 
flow-mediated vasodilation. This explains why others showed a relaxin-induced desensitizing 
effect to vasopressors in presence of continuous flow 14;17;30. On systemic level this translates 
to persistence of relaxin-mediated systemic vasodilation in conscious hypertensive rodents 13. 
Apparently, primary hypertension blunts the relaxin-desensitizing effect on myogenic reactivity 
and vasoconstrictor agents, but does not affect flow-mediated normal vascular adjustments.
The strain of rats used in our study may have affected the results. SHR is a widely 
accepted animal model for insulin-resistance and primary hypertension at young age. 
Based on strain similarities, Wistar Kyoto Rats (WKY) generally function as a control for 
SHR. However, WKY do not respond to relaxin as seen in other strains 17. Above that, 
the WKY has genetic dissimilarity of 50%, as compared with SHR, questioning its role as 
a optimal control for SHR 18. Therefore, we unconventionally used WHR as a control for 
SHR. In correspondence to literature comparing WKY and SHR 31-33, we observed that SHR 
do not differ from WHR in response to flow-mediated vasodilation, myogenic reactivity, 
vascular compliance, but show reduced α-adrenergic sensitivity.
The in vivo effects of relaxin on the renal plasma flow (RPF) are different from those 
observed in vitro. In vivo, relaxin NO dependently enhances RPF by 40% in normotensive 
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female rats 2, where female SHR show increased NO availability, as compared with WKY 34. 
In isolated setting, RPFF is unaltered after 5 days exposure to relaxin in both female WHR 
and SHR, while NO activity is reduced in placebo-treated SHR, as compared with placebo-
treated WHR. One might argue that these differences could relate to reduced oxygen 
delivery ex vivo as a consequence of whole organ perfusion. We used the oxygen-carrier 
Pluronic in our experiments and, under these conditions, we were able to detect known 
differences in RPFF between WHR and SHR 35. Since the in vitro kidney is depleted from 
extra-renal factors (like humoral and autonomic influences), our observations imply that 
relaxin does not intrinsically affect the kidney.
We would like to address several limitations to our study. First, the relaxin plasma levels 
in our study were higher than 30 ng/ml, as reported by others 2. It has been described 
that relaxin levels comparable to ours are ineffective 36. Differences in volume distribution, 
relaxin metabolism and clearance among different rat strains may be held responsible for 
Figure 4. Renal perfusion flow (RPFF) in response to 100 µM L-NAME (at 60 minutes) in female WHR (nRLX=9 and 
nPLAC=9) and SHR (nRLX=9 and nPLAC=10) rats, pre-treated with relaxin (RLX, 4 µg/h for 5 days) or placebo (PLAC).
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these dissimilarities. The different non-standardized techniques to measure the level of 
relaxin may have led to differences in relaxin levels between studies and make appropriate 
comparison not possible. As we observed significant effects in the mesenteric arteries at 
comparable “higher” relaxin levels in WHR and SHR, we do not think this explains the 
unresponsiveness of the kidney. Second, we started experiments independent of the estrous 
cycle, which may have affected vascular function. Since we performed randomization, the 
stages should have been equally distributed among groups and therefore we expect this 
does not explain the observed effects of relaxin. Third, the surgical procedure for placement 
of the osmotic minipumps may have influenced our observations. This is unavoidable and 
has affected both relaxin- and placebo-treated WHR and SHR equally.
Our findings on relaxin in WHR and SHR can be explained by the cellular pathway involved 
and may have clinical implications. Relaxin is thought to accomplish vasodilation by activation 
of the endothelium cell (EC) GqEC-protein-coupled relaxin family peptide receptor (Rxfp1). This 
pathway upregulates NO production, by activation of phosphatidylinositol 3-kinase (PI3K) 
37, 
which enhances vasodilation in the smooth muscle cell (SMC). This pathway is intact in both 
WHR and SHR. The direct effects of relaxin on the SMC remain unclear, but may be induced 
by affecting the GqSMC-coupled pathway for vasoconstrictor stimuli, activation of a vasodilator 
pathway or desensitizing calcium-channels. Possibly, one or more of its actions are less 
functional in SHR, which leads to resistance for relaxin-mediated inhibition of the myogenic 
reactivity and response to α-adrenergic stimuli. It is unlikely that the changes depend on 
Rxfp1 receptor expression, as we did not detect differences between female WHR and SHR. 
The presence of insulin-resistance in SHR also does not explain our findings, as one might 
expect that it would affect both EC- and SMC-dependent responses and not SMC-dependent 
responses only. Although relaxin-induced flow-mediated vasodilation remains unchanged in 
Figure 5. Rxfp1 gene expression in mesenteric arteries in female WHR (nRLX=8 and nPLAC=7) and SHR (nRLX=9 
and nPLAC=9), pre-treated with relaxin (RLX, 4 µg/h for 5 days) or placebo (PLAC). 
Data are presented as mean ± SE 2-ΔCT.
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SHR, the impaired effects on myogenic reactivity and response to α-adrenergic stimuli may 
have implications for therapeutic use of relaxin, and may possibly be a contributing factor 
jeopardizing vascular function in pregnancy in hypertensive subjects.
In summary, primary hypertension relates to inhibition of the relaxin-mediated 
decrease in myogenic reactivity and desensitization to phenylephrine as present in young 
female healthy rats, while flow-mediated relaxin-induced vasodilation remains intact. This 
suggests selective relaxin resistance in female SHR.
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This thesis posed three research questions: 1. To what extent are the pregnancy-induced 
changes in the renal and mesenteric vasculature similar among species, strains and 
gestational periods (Chapter 2 and 3)? 2. To what extent is midgestational vasodilation 
mediated by upregulation of endothelium-dependent mechanisms and vascular compliance, 
and downregulation of vasoconstrictor agent sensitivity and myogenic reactivity (Chapter 
4)? and 3. To what extent are local vascular responses to relaxin impaired in overweight, 
aged and hypertensive female rats (Chapter 5, 6 and 7).
The studies have shown that renal and mesenteric vascular changes to pregnancy 
are markedly different among species, strains and gestational periods. Midgestational 
vasodilation is mediated by upregulation of flow-dependent mechanisms, no change in 
vascular compliance, and downregulation of sensitivity to phenylephrine and myogenic 
reactivity. Local vascular responses to relaxin are impaired in overweight, aged and 
hypertensive female rats, which suggests resistance to relaxin.
Studies on vasodilation important to pregnancy have been performed on pregnant and 
nonpregnant animals, ex vivo and in vivo, in healthy subjects and subjects with vascular 
risk factors. We used the resulting four categories in the further discussion. At the end 
of the chapter we describe possible pathways of vasodilation in healthy and complicated 
pregnancies, with special emphasis on the role of relaxin.
i. ex vivo local vascular responses to pregnancy
We used the technique of systematic review and meta-analysis to investigate pathways 
involved in pregnancy-induced vasodilation ex vivo, thus in the absence of the normal humoral 
and autonomic environment. This methodology of systematic review is commonly used in 
human medicine, but is relatively new in the field of experimental animal research. We used a 
novel application in which we quantified alterations in vessel sensitivity and reactivity through 
stratification by species, strain, gestational age and pathways of receptor complex families.
The meta-analyses (Chapter 2 and 3) have shown that renal and mesenteric vascular 
changes to pregnancy are markedly different among species, strains and gestational 
periods. This raises the question which animal model best simulates human pregnancy 
and various health states, if any.
For our meta-analyses we aimed to include all species. Yet, by lack of data for most 
species, only rats, rabbits, guinea pigs, mice and pigs were included in the analyses. 
Between these species responses differed markedly. We could not determine which animal 
model best simulates human pregnancy, because no human studies on ex vivo vessel 
responses in aged-matched pregnant versus nonpregnant subjects are available.
Rats were best represented in the studies and involved various strains. We observed 
remarkable differences in responses between species. In Wistar rats (WR), a strain known 
for its cardiovascular health, pregnancy induces upregulation of endothelium-dependent 
vasodilation only, without affecting the other pathways. In contrast, Sprague Dawley rats 
(SDR), which are prone to develop cardiovascular disease, activate multiple local vascular 
responses in mid- and late pregnancy. These include not only endothelium-dependent 
vasodilation, but also enhanced compliance and deactivation of vasoconstrictor sensitivity 
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and myogenic reactivity. Impaired gestational circulatory adaptations precede preeclampsia, 
which in turn is associated with cardiovascular disease later in life. Based on these human 
observations, we speculate that the WR is a better model for healthy pregnancy and SDR 
for vascular compromised pregnancy.
Five studies in rats have systematically investigated the gestational age effects on 
vascular adaptation 1-5. These studies, all in SDR and in line with other studies on this 
strain, showed that pregnancy affects the pathways involved in vascular tone differently 
across gestational ages. Limited data suggest that NO activation is more important in 
mid-pregnancy than in late pregnancy. Studies on WR, including our own (Chapter 4), 
compared pregnancy responses at a certain gestational age to nonpregnant responses. 
Those studies show that responses in mid-pregnancy do not differ much from those in late 
pregnancy. Apparently, depending on the strain, vascular adaptation is virtually complete 
at midgestation but the underlying mechanisms may differ.
Ex vivo responses of mesenteric and renal arteries have not been compared directly within 
studies. Renal artery responses have mainly been studied in SDR. Our meta-analyses (Chapters 
2 and 3) show that in mesenteric arteries pregnancy enhances the endothelium cell- (EC) 
dependent vasodilator GqEC-pathway and reduces the smooth muscle cell- (SMC) dependent 
vasoconstrictor GqSMC-coupled pathway, while in renal arteries both pathways are unaffected 
by pregnancy. One may speculate that this is due to the fact that small downstream resistance 
vessels have been used to study mesenteric arteries, while the renal artery represents a major 
blood supplying vessel 6. Therefore, studies on pregnancy-induced vasodilation should take 
into account not only the vascular region, but also the type of vessel.  
Experiments on isolated vessels in the absence of hormonal and autonomic influences 
have their intrinsic limitations. First and foremost, responses on isolated vessels cannot 
safely be extrapolated to whole organ responses because of the absence of humoral 
and autonomic influences. Second, methodological differences between studies (e.g. type 
of myograph, perfusate) may affect results. Third, most studies are limited to a small 
number of animals. These methodological limitations can affect the overall outcome and 
conclusions from experiments. Therefore, results from single studies should be interpreted 
with caution, especially when results are extrapolated to more generalized conclusions. 
Meta-analysis can overcome these limitations to some extent, as their conclusions are 
based on multiple studies and they identify outlier results.
ii. in vivo local vascular responses to pregnancy
In vivo studies have the advantage of investigating an integrated system in the presence 
of humoral and autonomic control. Data on in vivo adaptations to pregnancy were too 
limited to allow meta-analysis of mesenteric vascular responses. Our meta-analysis on 
renal adaptations included data on rats, sheep, rabbits and guinea pigs (Chapter 3). It 
showed marked differences for strains of rats and for gestational age. At midgestation, 
renal vascular resistance (RVR) is decreased by 27%, varying from 18% in SDR to 31% 
in Munich Wistar rats (MWR). Renal flow is increased to a variable degree, ranging from 
13% in Wistar Hannover rats (WHR) to 31% in Long Evans rats (LER). GFR is enhanced 
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by 17% in SDR to 29% in LER (Chapter 3). At late gestation, RVR, renal flow and GFR 
remain at mid-pregnancy levels in SDR, whereas in LER these renal variables return to 
nonpregnant values. The reasons for the differences across strains and gestational ages 
have not been systematically investigated. One may speculate that the degree of vascular 
change depends on strain-specific differences in vascular control mechanisms, as observed 
ex vivo. This suggests that the vascular impaired SDR has a reduced hemodynamic reserve 
capacity compared with the healthier LER.
Our meta-analysis on MWR and LER data are in line with human data, showing 
reduced RVR, and increased renal flow and GFR in pregnancy (Chapter 3) 7. The underlying 
pathways have not been studied in detail in humans because this requires blockade of 
pathways and would be unethical. In LER, changes in RVR, flow and GFR depend on 
upregulation of the NO system. In SDR, these changes are induced by both NO activation 
and deactivation of the autonomic nervous system (Chapter 3). These adaptations are 
likely secondary to humoral changes, as blockade of specific humoral antibodies can 
completely overcome the pregnancy-induced systemic vascular changes 8.
iii. Humoral effects on vascular function in healthy subjects
Several hormones are involved in normal pregnancy-induced vasodilation, most notably 
estradiol, progesterone, human chorionic gonadotrophin and relaxin. These hormones 
have been investigated mainly in rats.
Estradiol induces systemic vasodilator responses as observed during pregnancy 9. Its 
effects are region specific as it enhances uterine, renal, coronary and iliac perfusion, while 
the mesenteric region is relatively insensitive 9;10. Estradiol reduces vascular tone through 
the estrogen receptors that are located on both the EC and SMC 11;12. Stimulation of the 
EC receptor induces NO release which mediates the increase in uterine blood flow 13. 
Estradiol also affects the SMC through activation of potassium channels 14. Estrogens 
apparently are only partly responsible for the decrease in systemic vascular resistance 
in pregnancy as the mesenteric region shows profound pregnancy-induced vasodilation 
despite a lack of response to estradiol.
Progesterone has some vasodilator capacity, but its contribution to vasodilation in 
pregnancy is controversial 15. On the one hand, progesterone induces vasodilation by 
increasing EC NO production 16;17, on the other hand it induces vasoconstriction through 
the SMC 18. Some studies suggest that progesterone is the primary dilator in pregnancy, 
but other studies suggest that it is involved in the control of spatial distribution of the 
uterine blood flow rather than in generalized vasodilation 19. Apparently progesterone is 
not the major vasodilator of pregnancy that it was once considered to be.
Human chorionic gonadotrophin (hCG) is a vasodilator 2. It exerts its effect not by 
affecting the EC, but through deactivation of the SMC 2;20. As hCG levels peak during the 
first trimester and are much lower thereafter, it is unlikely to be responsible for maintaining 
the vasodilator state later in pregnancy.
Relaxin induces vascular changes that mimic those of pregnancy 4;21;22. Relaxin affects 
local vascular tone through various pathways. In healthy WR it stimulates flow-mediated 
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vasodilation, and downregulates myogenic reactivity and sensitivity to phenylephrine 
without affecting vascular compliance (Chapter 5, 6, 7, and Table 1). In other strains, 
including Long Evans rats (LER), relaxin also increases vascular compliance 23. Isolated vessels 
from pregnant rats, in the absence of relaxin in the perfusate, only show increased flow-
mediated vasodilation, whereas vessels continuously exposed to relaxin show activation 
of several additional vasodilator pathways (Chapters 4, 5, 6, and 7). This suggests that 
maximal dilatation requires not only intrinsic adaptation of the EC to pregnancy, but 
also the continuous presence of relaxin. In vivo, relaxin-specific antibodies block all the 
pregnancy-induced systemic vascular changes. These findings imply that relaxin is one of 
the most important hormones involved in vasodilation in pregnancy 8.
iV. Humoral effects on vascular function in subjects with vascular risk factors
Overweight or obesity, moderately advanced age (>40 years) and primary hypertension, are 
associated with increased risk for hypertensive disorders in pregnancy 24, which may lead to 
fetal and maternal morbidity and mortality. In addition, they are associated with increased 
risk for cardiovascular complications later in life 25-27. One may speculate that impaired 
vascular adaptations in pregnancy are in part mediated by resistance to pregnancy-related 
hormones. The vascular effects of the pregnancy hormones estradiol, progesterone, hCG 
and relaxin have only been studied to a limited extent in subjects with these cardiovascular 
risk conditions. In our studies on the vascular effects of relaxin in overweight, aged 
and hypertensive rats, we showed that overweight rats, or those with advanced age or 
hypertension have impaired mesenteric in vitro responses to relaxin as compared with 
healthy controls (Table 1). In fact, overweight and aged rats do not show any vessel adaption 
to relaxin, while hypertensive rats lack the normal adaptation in myogenic reactivity 
or α-adrenergic response and respond to relaxin only by activation of flow-mediated 
vasodilation. This suggests the presence of relaxin- resistance in overweight, aged and 
hypertensive rats. One may question if the relaxin levels reached in our experiments reflect 
physiologic concentrations. We intended to simulate human recombinant relaxin levels 
comparable to those observed during human pregnancy (around 30 ng/ml). Despite an 
identical methode of relaxin exposure as used in other studies in rats, we measured higher 
levels of relaxin in our rats (around 70 ng/ml). Considering no shortcomings in continues 
infusion systems, several variables may have affected this finding, such as differences in 
volume distribution among stains of rats (compared to reported studied rats) or differences 
in test methodology, affinity or test tube degradation of human recombinant relaxin. This 
may imply that we detected relaxin-resistance at little higher supra-physiologic levels, but 
could also be the result of the different non-standardized techniques available to measure 
the level of relaxin. Because we performed our experiments similarly across groups, at 
least results can be compared throughout our study. Additionally, one may question the 
importance of relaxin-resistance in vascular impaired rats, as they seem to reproduce 
without having clearly compromised pregnancies as seen in humans. There are at least 
two factors that may contribute to the different response by limiting the metabolic and 
vascular demands for adaptation. First, severe experimental vascular impairment in rats 
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Table 1. Overview of the effects of relaxin- (RLX) and placebo- (PCB) treatment on flow-mediated 
vasodilation, vascular compliance, renal perfusion flow, response to phenylephrine and myogenic reactivity. 
Experiments performed in healthy, diet-induced overweight, advanced aged and hypertensive rats in the 
presence and/or absence of L-NAME.
Healthy
Diet induced 
overweight
Advanced 
aged Hypertensive
PCB RLX PCB RLX PCB RLX PCB RLX
Vasodilation
- Flow-mediated vasodilation:
- in the absence of L-NAME c ↑↑ ↔ ↔ ↔ ↔ ↔ ↑↑
- in the presence of L-NAME c ↔ ↔ ↔ ↓ ↔ ↔ ↔
- Vascular compliance c ↔ ↔ ↔ ↔ ↔ ↔ ↔
- Renal perfusion flow c ↔ ↓ ↓ ↓ ↔ ↓ ↔
Vasoconstriction
- Phenylephrine
- in the absence of L-NAME c ↓↓ ↑ ↔ ↔ ↔ ↓ ↔
- in the presence of L-NAME c ↓ ↔ ↓ ↔ ↓ ↓ ↔
- Myogenic reactivity c ↓ ↔ ↔ ↔ ↔ ↔ ↔
Effects of relaxin depicted as increased (↑),decreased (↓) or no change (↔) compared with placebo of the 
specific subgroup. Effects of the specific subgroup presented as increased (↑),decreased (↓) or no change 
(↔) compared with healthy placebo (c). Gray filling shows the effects favoring vasodilation. Striped filling 
shows the effects favoring vasoconstriction.
usually results in reduced litter size. Second, rats deliver their pups relatively premature. 
The limited litter size and short duration of pregnancy may well protect them from 
developing hypertension in pregnancy. Although the rat may not be the ideal model for 
human hypertensive pregnancy, the presence of relaxin-resistance in overweight, aged and 
hypertensive rats can be seen as a precursor for vascular impairment, which in humans may 
lead to poor placentation and hypertensive disease in pregnancy.
Vasodilator pathways in pregnancy
Gestational vasodilation is most likely regulated by several hormones, through activation and 
deactivation of a limited set of down-stream pathways. In this paragraph we discuss the known 
pathways involved in vascular tone in healthy nonpregnant, pregnant, relaxin-treated, and 
placebo-treated rats with vascular risk factors (overweight, advanced age and hypertension) 
(Figure 1). Vascular tone in nonpregnant healthy subjects is regulated by the EC (by flow-
mediated vasodilation), SMC (through myogenic reactivity and the response to vasodilator 
and vasoconstrictor agents) and the extra-cellular matrix (ECM, by compliance) (Figure 1A). At 
midgestation, pregnancy upregulates only flow-mediated vasodilation (Figure 1B). 
Relaxin stimulates the flow-mediated vasodilation through activation of the GqEC-
pathway, and by deactivation of α-adrenergic constriction and myogenic reactivity 
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through downregulation of the GqSMC-pathway and calcium-influx in the SMC (Figure 1C). 
The vasodilator GqEC-pathway can be upregulated through four possible mechanisms: 1) 
enhanced sensitivity of the EC flow-receptors and GqEC-receptors which leads to increased 
NO production, 2) stimulation of specific down-stream GqEC-receptor reactions (stimulation 
of Akt/PKB and NO availability) which optimizes the response to flow and GqEC-specific 
substances, 3) direct stimulation of the relaxin specific GqEC-receptors and additional 
formation of NO, and 4) a combination of 1, 2 and 3. All these mechanisms result in 
upregulation of NO production, which can be regarded as an increase in sensitivity to flow 
and GqEC-receptor specific stimuli. Relaxin also changes the vasoconstrictor GqSMC-receptor 
pathway and myogenic reactivity, which are both partially dependent on NO production 
by the EC. As both pathways depend on an increase in intracellular calcium, it is possible 
that adaptation of these pathways to relaxin occurs through a common mechanism that 
has not yet been elucidated. It would be important to differentiate between the various 
mechanisms in order to better understand what happens in the overweight, aged and 
hypertensive rats. This would require relaxin specific GqEC- and GqSMC-receptor blocking 
agents, which have not yet been developed.
Subjects with vascular risk conditions show impaired relaxin-induced vascular 
responses. The various pathways involved are shown in Table 1. Overweight and aged 
rats show impaired upregulation of the flow-mediated vasodilator/GqEC-coupled response 
and reduced downregulation of the α-adrenergic and myogenic reactivity constrictor 
responses (Figure 1D and E). Hypertensive subjects have intact activation of the flow-
mediated vasodilator/GqEC-coupled response, but reduced deactivation of the α-adrenergic 
and myogenic reactivity constrictor responses (Figure 1F). This does not seem to depend 
on relaxin receptor expression, as we did not detect any differences in Rxfp1 (relaxin 
family peptide) gene expression. The mechanisms, as outlined above, indicate how 
cardiovascular risk conditions may negatively affect relaxin-mediated vasodilation through 
resistance to relaxin. As overweight, aging and hypertension carry an increased risk of 
hypertensive disease in pregnancy, one may speculate that relaxin-resistance may also be 
causally involved in the development of hypertensive disorders in human pregnancy.
conclusions
This thesis provides two main insights. First, the extent of vascular changes in pregnancy 
depends on the species, strain, gestational age period and vascular region investigated. 
This implies that most of our current knowledge is based on animal models that hardly 
resemble other species and strains. Therefore, from a scientific point of view, extrapolation 
towards human pregnancy has severe limitations. Second, vascular risk conditions, such as 
overweight, advanced age and hypertension, impair the vascular adjustments to relaxin in 
pregnancy. This suggests that relaxin-resistance may well play role in the development of 
hypertensive disease in human pregnancy.
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Figure 1. Simplified schematic overviews of the effects of pregnancy and relaxin exposure on the endothelium 
cell (EC) and smooth muscle cell (SMC) pathways involved in local vascular tone under different conditions. 
In the absence of additional humoral and autonomic environment, the different conditions are: nonpregnant/
placebo-treated healthy subjects (A), mid-pregnant  healthy subjects (B), relaxin-exposed state in healthy 
subjects (C),  relaxin-exposed state in overweight subjects (D),  relaxin-exposed state in aged subjects (E), 
relaxin-exposed state in hypertensive subjects (F).
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Future researcH
Scientific research is a continuous process. The conclusions from one study induce new 
ideas for future research. Poignant questions that remain after completion of this thesis 
include the following:
1. Is it possible to identify women at risk for hypertensive disease in their first pregnancy, 
through a simple first-line vascular test before conception?
2. To what extent is relaxin-resistance really important in the development of hypertensive 
disease in human pregnancy?
3. Can we indentify an ideal animal model to simulate vascular adaptation in human 
pregnancy?
Identifying women at risk for hypertensive disease in their first pregnancy is most important 
but also most challenging. This type of research needs large numbers of seemingly healthy 
women before their first pregnancy. In addition one may raise the ethical question how 
legitimate it is to expose a large group of healthy women to testing for a disorder that 
will occur in only 1:20 tested individuals. If coupled to an effective treatment, such a test 
could potentially reduce the incidence of some of the biggest problems in obstetrics today, 
including preeclampsia, fetal growth restriction and iatrogenic prematurity.
A first step towards an effective treatment would be to resolve the underlying 
mechanism(s) of disease, which should include the role of relaxin-resistance in the 
development of hypertensive disease in human pregnancy. There are tools available to 
study this question, such as the forearm model, which may be used to test women with 
vascular risk factors (e.g. formerly preeclamptic, obese, over 40 years of age, hypertensive, 
diabetic, renal impaired) for possible impaired responses to relaxin-exposure as compared 
with healthy controls. Such a study should start by testing for relaxin-resistance prior to 
pregnancy and should continue until after the outcome of the next pregnancy is known. 
This would require a large cohort study and sufficient financial support. Yet, it seems a 
necessary first step before embarking on further studies on the importance of such a test 
in nulliparous women or on the efficacy of any interventions in relaxin-resistant women in 
reducing the chance of hypertensive disease in their next pregnancy. 
It would be most useful if we could study the mechanisms of hypertensive disease 
in pregnancy in an animal model instead of in humans, as it would reduce the duration 
and costs of experimentation. Unfortunately, however, all animal models have limitations 
in mimicking human pregnancy, either in the healthy or the vascular impaired state. 
Preeclampsia is almost unique to primates, which are not readily available for experimental 
research. Rats and mice deliver their pups much more immaturely than humans. Nonetheless, 
vascular adaptations to pregnancy in selected species and strains are quite similar to those 
in humans. However, if we want to use an animal model to investigate mechanisms similar 
to vascular (mal)adaptation in human pregnancy, one has to be really careful in the choice 
of species, strain, gestation age and vascular bed. Meta-analysis on animal data is most 
helpful in differentiating between models that are appropriate to study mechanisms of 
vascular adaptation comparable to human pregnancy in health and disease. The uterine 
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artery, aorta and carotid artery are examples of vessels supplying vascular beds that may 
be relevant in this respect. Careful meta-analysis of such responses will result in overall 
reduction, replacement and/or refinement of animal use in pregnancy-specific research.
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suMMary
Pregnancy is known to induce a significant systemic vasodilator response in both humans 
and rodents, most frequently investigated in the mesenteric and renal vascular beds. 
The change reaches a maximum at midgestation and is likely affected by vascular risk 
factor (such as overweight, advanced age and hypertension). The substance responsible 
for this change is still unidentified, although it has been suggested that the hormone 
relaxin is involved. Both pregnancy and exposure to relaxin induce adaptation of several 
endothelium cell (EC) and smooth muscle cell (SMC) dependent local vascular responses in 
mesenteric and renal arteries: 1. Upregulation of the endothelium-dependent nitric oxide 
(NO) pathway, 2. Reduction of the responsiveness to vasoconstrictor stimuli, 3. Decrease 
in myogenic reactivity, and 4. Increase in arterial compliance. From published work, three 
observations can be made. First, it is unclear if one may generalize effects across species, 
strains and the gestational age periods, as results from various studies show substantial 
differences and inconsistencies. Second, data mainly focus on term pregnancy, and for 
some strains data on midgestational effects are not available. Third, relaxin may be an 
important factor in pregnancy-induced vasodilation. As certain risk conditions predispose 
to vascular maladaptation and subsequent hypertensive disease, one may propose the 
idea that vascular risk factors relate to poor vessel reactivity to relaxin and subsequent 
vascular maladaptation during pregnancy.
Based on the three observations, this thesis aimed to provide additional information 
on pregnancy-induced vasodilation by investigating three hypotheses:
1. The extent of renal and mesenteric vascular adaptation to pregnancy is similar across 
species, strains and the course of pregnancy.
2. Midgestational vasodilation in rats is mediated by upregulation of endothelium-
dependent vasodilation, and alteration of vasoconstrictor agent sensitivity, myogenic 
reactivity and vascular compliance as observed at term.
3. Local vascular responses to relaxin are impaired in common risk associates with 
gestational maladaptation (overweight, increased age and hypertension).
The first hypothesis was tested in two separate meta-analyses. The first meta-analysis 
focused on the pregnancy-induced changes of local vascular control in mesenteric arteries 
(Chapter 2). Through a systematic literature search and selection process, we identified 55 
(out of 398) studies with 188 vascular mesenteric responses to stimuli, mostly investigated 
in rodents at term. We observed that pregnancy facilitates flow-mediated vasodilation at 
term, among all investigated species. The contribution of additional local vascular responses 
is species- and strain specific. Late pregnancy mediates vasodilation through changes at 
the receptor level, for the substances tested. As the initial steps of vasodilation in early 
pregnancy have been investigated sparseley, this period deserves attention in the future.
The second meta-analysis investigated the pregnancy-induced vascular changes of the 
kidney (Chapter 3). We identified 37 (out of 1008) studies with 116 responses by performing 
a systematic literature search and selection process. We showed that pregnancy changes 
renal vascular resistance (RVR), renal flow and glomerular filtration rate (GFR) dependent 
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on NO activation and sympathetic deactivation, but adjustments are different among 
species, strains and gestational ages. These changes do not depend on adaptation of 
renal artery responsiveness. It remains unknown at which cellular level pregnancy affects 
the pathways. Our meta-analysis suggests that renal changes during pregnancy in animals 
are qualitatively similar, even in comparison to humans, but quantitatively different.
The second hypothesis was investigated in one experimental study on the pregnancy-
induced vascular changes in mesenteric arteries and the isolated perfused rat kidney at 
midgestation (Chapter 4). For this, we used 20 mid-pregnant and 20 nonpregnant Wistar 
Hannover rats (WHR). We demonstrated that, at midgestation, alterations in rat mesenteric 
vascular tone primarily depend on flow-mediated endothelium-dependent changes and not on 
changes in α-adrenergic vasoconstrictor sensitivity, myogenic reactivity or vascular compliance.
The third hypothesis was analyzed in three separate experimental studies investigating 
the relaxin-induced vascular changes in mesenteric arteries and the isolated perfused rat 
kidney in healthy, overweight, aged and hypertensive rats. The first study focused on the 
effects in normal weight versus overweight WHR (Chapter 5). Rats were fed a regular 
diet or a high-fat cafeteria-style diet. We found that, in overweight rats, the vasodilator 
effects of relaxin were markedly reduced for flow-mediated vasodilation, sensitivity to 
phenylephrine and myogenic response, as compared with the normal diet rats, mostly 
persistent under L-NAME. Our data demonstrate that some of the vasodilator responses to 
in vivo relaxin administration are impaired in isolated mesenteric arteries and the perfused 
kidney in overweight female rats, suggestive for relaxin-resistance. This does not result from 
a decrease in Rxfp1 (relaxin family peptide receptor) expression but is likely to result from 
downstream disruption to endothelium-dependent mechanisms in overweight animals. 
The second study looked at the effects of relaxin in young versus moderately aged WHR 
(Chapter 6). The young (n=20) and moderately aged (n=20) rats were 10-12 and 40-46 
weeks old, respectively. We observed that moderate aging involves normal endothelium 
function, but blunts the physiological endothelium-dependent and -independent 
vasodilator response to relaxin.
The third study investigated the effects of relaxin in normotensive WHR (n=20) and 
spontaneous hypertensive rats (SHR, n=20) (Chapter 7). We illustrated that primary 
hypertension blunts both the relaxin-induced inhibition of myogenic reactivity and 
α-adrenergic vasoconstrictor response, independent from Rxfp1 gene expression, while 
the relaxin-dependent enhanced flow-mediated vasodilation remains intact.
In Chapter 8 we discussed our findings and the implications, propose possible 
pathways through which vascular adjustments appear in vascular uncomplicated and 
complicated pregnancies and suggest opportunities for future research. We conclude that 
the involved pathways in vascular adaptation to pregnancy depend on the species, strain, 
gestational age period and vascular bed investigated. This raises the question which animal 
model, if any, best simulates vascular uncomplicated and complicated human pregnancy. 
Although it remains a topic of debate which substance or substances induce pregnancy-
induced vasodilation, the humoral environment seems to play an essential role. Possibly 
it is not one hormone but the mixture of hormones that share comparable vasodilator 
mechanisms, but have diverged sensitivity to different vascular beds. Vascular risk factors 
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(like overweight, advanced age, and hypertension) relate to impaired vascular adaptation 
to the hormone relaxin. This insinuates relaxin-resistance among these risk factors and a 
possible mechanism through which vascular maladaptation leads to the development of 
hypertensive disorders in pregnancy. The above generates new insights and creates several 
hypotheses that need to be explored in future research.
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Zwangerschap gaat gepaard met belangrijke systemische aanpassingen van de bloedvaten 
bij zowel de mens als het knaagdier. Deze aanpassingen zijn het meest onderzocht in 
het vaatsysteem van de darm en de nieren. De veranderingen bereiken halverwege de 
zwangerschap een maximum en de mate van verandering is waarschijnlijk afhankelijk 
van vasculaire risicofactoren, zoals overgewicht, veroudering en hypertensie. De oorzaak 
van deze vaataanpassingen is nog niet geheel bekend, maar het lijkt dat het hormoon 
relaxine hierbij betrokken is. Zowel zwangerschap als relaxine induceren aanpassingen van 
meerdere endotheelcel- (EC) en gladde spiercel- (SMC) afhankelijke lokale responsen van de 
arteriën van de darm en de nieren: 1. Activatie van de endotheelafhankelijke productie van 
stikstofmonoxide (NO), 2. Onderdrukking van de respons op vaatvernauwende stimuli, 3. 
Verlaging van de myogene reactiviteit, en 4. Toename van de elasticiteit van de bloedvaten. 
Vanuit de literatuur vallen drie observaties op. Ten eerste is het onduidelijk of men mag 
generaliseren tussen diersoorten, dierstammen en verschillende zwangerschapstermijnen. 
Ten tweede is het meest bekend over de late zwangerschapsperiode, terwijl voor meerdere 
dierstammen gegevens ontbreken over het midden van de zwangerschap. Ten derde lijkt 
relaxine een belangrijke factor voor zwangerschapsgeïnduceerde vaatverwijding. Omdat 
bepaalde risicofactoren predisponeren voor vasculaire maladaptatie en hypertensieve 
aandoeningen, zou men zich kunnen voorstellen dat deze risicofactoren leiden tot 
verminderde relaxine-geïnduceerde vaataanpassingen. Dit zou dan weer kunnen leiden 
tot vasculaire maladaptatie in de zwangerschap.
Gebaseerd op deze drie observaties tracht dit proefschrift aanvullende informatie 
te verstrekken omtrent zwangerschapsgeïnduceerde vaatverwijding. Hiervoor zijn drie 
hypotheses onderzocht:
1. De mate van vaataanpassingen in de darm en de nieren ten gevolge van zwangerschap 
zijn vergelijkbaar tussen diersoorten, dierstammen en zwangerschapstermijnen.
2. Vaatverwijding bij ratten in het midden van de zwangerschap wordt veroorzaakt door 
toename van endotheelafhankelijke vaatverwijding en verandering van de respons op 
vaatvernauwende stoffen, myogene reactiviteit en elasticiteit van de arteriën, zoals 
geobserveerd in de a terme periode.
3. Lokale vasculaire responsen ten gevolge van relaxineblootstelling zijn verminderd bij 
risicofactoren voor maladaptatie in de zwangerschap (overgewicht, oudere leeftijd en 
hypertensie).
De eerste hypothese werd getest door middel van twee meta-analyses. De eerste meta-
analyse richtte zich op de zwangerschapsgeïnduceerde veranderingen van de lokale 
vasculaire controle in arteriën van de darm (Hoofdstuk 2). Een systematische zoekstrategie 
van de literatuur en een gestructureerd selectieproces identificeerden 55 (van de 398) studies 
met 188 arteriële responsen van de darm op stimuli, voornamelijk uitgevoerd bij de a terme 
zwangerschap van de rat. Wij zagen dat zwangerschap, in alle onderzochte diersoorten, 
de flow-gemediëerde vaatverwijding versterkt. Beïnvloeding van andere locale vasculaire 
responsen is afhankelijk van de onderzochte diersoort en dierstam. De aanpassingen in 
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de late zwangerschap zijn voor de onderzochte stimuli afhankelijk van veranderingen op 
receptorniveau. Omdat de initiële stappen van vaatverwijding in de vroege zwangerschap 
slechts zeer beperkt onderzocht zijn, verdient deze periode nader onderzoek.
De tweede meta-analyse onderzocht de zwangerschapsgeïnduceerde aanpassingen 
van arteriën van de nier (Hoofdstuk 3). Wij identificeerden 37 (van de 1008) studies 
met 116 responsen, eveneens door middel van een systematische zoekstrategie en een 
gestructureerd selectieproces van de literatuur. Deze studie liet zien dat zwangerschap 
de renale vaatweerstand, renale doorbloeding en glomerulaire filtratiesnelheid van 
de nier beïnvloedt door toename in NO productie en deactivatie van het sympathisch 
systeem, maar dat de aanpassingen verschillen tussen diersoorten, dierstammen en 
zwangerschapstermijnen. De veranderingen zijn niet afhankelijk van aanpassing in de 
reactiviteit van de nierarterie. Het blijft nog onduidelijk op welk celniveau zwangerschap 
de adaptatie bewerkstelligt. Onze meta-analyse suggereert dat de renale aanpassingen 
tijdens zwangerschap in dieren kwalitatief vergelijkbaar zijn, zelfs in vergelijking met de 
mens, maar kwantitatief verschillen.
De tweede hypothese werd onderzocht in een experimentele studie, waarin de arteriële 
vaataanpassingen van de darm en het geïsoleerde niermodel werden bestudeerd in het 
midden van de zwangerschap (Hoofdstuk 4). Hiervoor werden 20 zwangere en 20 niet-
zwangere Wistar Hannover ratten (WHR) gebruikt. Wij zagen dat de verandering in tonus 
van de arteriën van de darm in het midden van de zwangerschap voornamelijk afhankelijk 
is van aanpassing van de flow-gemedieerde vaatverwijding, en niet van aanpassingen in 
de gevoeligheid voor α-adrenerge stimuli, myogene reactiviteit of vasculaire elasticiteit.
De derde hypothese werd onderzocht door middel van drie experimentele studies. 
Hierin analyseerden we de relaxine-geïnduceerde arteriële vaataanpassingen van de darm 
en het geïsoleerde niermodel in ratten met overgewicht, verouderde ratten en ratten met 
hypertensie. De eerste studie richtte zich op de effecten van relaxine in WHR met een 
normaal gewicht versus overgewicht (Hoofdstuk 5). Hiervoor kregen de ratten een normaal 
of een hoog vethoudend dieet. Wij zagen een afname van de vaatverwijdende effecten van 
relaxine op flow-gemedieerde vaatverwijding, gevoeligheid voor phenylephrine en myogene 
reactiviteit van ratten met overgewicht ten opzichte van ratten met een normaal gewicht. 
Deze observatie was grotendeels onafhankelijk van NO blokkade. Deze studie laat zien 
dat meerdere vaatverwijdende responsen ten gevolge van in vivo blootstelling aan relaxine 
zijn aangetast in de geïsoleerde darmarteriën en de nier van ratten met overgewicht. Dit 
suggereert dat overgewicht gepaard gaat met relaxine-resistentie. Dit lijkt niet te berusten 
op een afname van de relaxine-receptor genexpressie, maar mogelijk op een afname van 
‘down-stream’ endotheelafhankelijke processen in ratten met overgewicht.
De tweede studie bekeek de effecten van relaxine in jonge versus oudere (eind 
reproductieve leeftijd) WHR (Hoofdstuk 6). De jonge (n=20) en oudere (n=20) ratten 
waren respectievelijk 10-12 en 40-46 weken oud. Wij zagen dat veroudering gepaard gaat 
met normale endotheelfunctie, maar dat de endotheel-afhankelijke en -onafhankelijke 
vaatverwijdende responsen ten gevolge van relaxine blootstelling zijn aangetast.
De derde studie onderzocht de effecten van relaxine in normotensieve WHR (n=20) 
en spontaan hypertensieve ratten (SHR, n=20) (Hoofdstuk 7). Wij lieten zien dat 
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primaire hypertensie de relaxine-geïnduceerde verlaging van de myogene reactiviteit 
en α-adrenerge vasoconstrictieve respons aantast. Dit is onafhankelijk van de relaxine-
receptor genexpressie, terwijl relaxine-afhankelijke activatie van de flow-gemedieerde 
vaatverwijding intact blijft.
In Hoofdstuk 8 bediscussieerden wij onze resultaten en de implicaties hiervan. 
Daarnaast bespraken wij de mogelijke verklaringen ten aanzien van de vaataanpassingen in 
ongecompliceerde zwangerschappen en zwangerschappen gecompliceerd door vasculaire 
aandoeningen. Tevens suggereerden wij mogelijke onderwerpen voor onderzoek in de 
toekomst. Wij concluderen dat de betrokken mechanismen bij vaataanpassingen ten 
gevolge van zwangerschap afhankelijk zijn van de onderzochte diersoort, dierstam 
en zwangerschapsperiode. Dit roept de vraag op welk diermodel het beste de 
vasculair ongecompliceerde en gecompliceerde zwangerschap bij de mens simuleert. 
Hoewel het nog niet duidelijk is welke stof of stoffen verantwoordelijk zijn voor de 
zwangerschapsgeïnduceerde vaatverwijding, lijkt de humorale omgeving een belangrijke 
rol te hebben. Waarschijnlijk is het niet één hormoon, maar een mix van hormonen 
met vergelijkbare vaatverwijdende effecten met verschillende gevoeligheid voor de 
verschillende vaatgebieden. Vasculaire risicofactoren (zoals overgewicht, oudere leeftijd 
en hypertensie) relateren aan gestoorde vasculaire aanpassingen op relaxine blootstelling. 
Dit insinueert de aanwezigheid van relaxine-resistentie bij deze risicofactoren en een 
mogelijk mechanisme van vasculaire maladaptatie en het ontstaan van hypertensieve 
aandoeningen in de zwangerschap. Het bovenstaande genereert nieuwe inzichten en 
creëert meerdere hypotheses die nader onderzoek verdienen.
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9leGends to abbreviations
legends to aBBreViations
AC adenyl cyclase 
Akt/PKB Akt/phospokinase B
C50% concentration inducing a 50% response 
Ca2+ calcium
CGRP calcitonin gene-related protein
CI confidence interval
DAG  diaglycerol
Diammax maximal vascular diameter after flow change 
EC endothelium cell
EC50 effective concentration, needed to obtain 50% of maximum effect
ECM extra-cellular matrix
EDHF endothelium-dependent hyperpolarizing factor
EFS electric field stimulation 
Emax maximum response
eNOS endothelial nitric oxide synthase
ET endothelin
Flow50% flow rate inducing 50% dilation; flow-sensitivity 
GC  guanyl cyclase
GFR glomerular filtration rate
GP guinea pigs
hCG human chorionic gonadotrophin
I2 heterogeneity
IP3 inositol 1,4,5-triphospate
K+ potassium
LER Long Evans rats
L-NAME L-Nitro-Arginine Methyl Ester, NO blockade
MAPK  mitogen-activated protein kinase
MD mean difference
MgSO4 magnesiumsulphate
MMPs  matrix-metallo proteases
MR myogenic reactivity
MWR Munich Wistar rats
NO nitric oxide, stikstofmonoxide
NP nonpregnant
P mid-pregnant
PBS phosphate buffered saline
PGI2 prostacyclin
PI3K phosphatidylinositol 3-kinase
PKA protein kinase A
PKG  protein kinase G 
PM pressure myograph
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PPM pressure-perfusion myograph
PSS physiological salt solution
RAAS renin-angiotensin-aldosterone system
RBF renal blood flow
RCT randomized controlled trial
Rmax maximum response
RPF renal plasma flow
RPFF renal perfusion flow
RVR renal vascular resistance
Rxfp1 relaxin family peptide receptor
SDR Sprague Dawley rats
SHR spontaneous hypertensive rats
SMC smooth muscle cell
SMD standerdized mean difference
SVR systematic vascular resistance
VC vasculair compliance
WHR Wistar Hannover rats
WKY Wistar Kyoto rats
WM wire myograph
WOP whole organ perfusion
WR Wistar rats
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Na vele jaren is het dan echt zover: mijn proefschrift is af. Terugkijkend was het een mooi 
avontuur met ups en downs, waarin ik op vele fronten wijzer ben geworden. Dit proefschrift 
had uiteraard niet tot stand kunnen komen zonder de inzet en medewerking van vele 
anderen. Een woord van expliciete dank voor enkelen is dan ook zeker op zijn plaats.
Prof. dr. P. Smits, beste Paul, hartelijk dank voor het vertrouwen in mij en het faciliteren 
van dit onderzoek. Jij gaf mij de mogelijkheid om de kennis en kunde op jouw afdeling 
te gebruiken voor de uitvoer van de wetenschappelijke experimenten. Jouw visie zorgde 
voor het concept “relaxine resistentie”. Daarnaast legde jij het contact met Prof. dr. J. 
Ritskes-Hoitinga voor de samenwerking met het team van SYRCLE bij de uitvoering van de 
systematic reviews en meta-analyses. Het was prettig dat de deur altijd open stond voor 
kort, of soms langer, overleg.
Prof. dr. F.L. Lotgering, beste Fred, graag wil ik je bedanken voor je altijd kritische 
houding. Dankzij jou hebben de hoofdstukken de inhoud gekregen die zij verdienen. Jouw 
onvermoeibare inzet voor de wetenschap is bewonderenswaardig. Dagen hebben we 
samen achter de computer gezeten om de stukken tot in detail uit te werken. Je bent een 
uitstekend voorbeeld dat het kan om gedurende je hele carriere zowel wetenschappelijk als 
klinisch enthousiast en gepassioneerd te blijven. Veel dank voor je fantastische begeleiding.
Prof. dr. M.E.A. Spaanderman, beste Marc, het was geweldig dat je mij onder je hoede 
nam. Ik heb genoten van je ideeën over de mechanismen rondom vaataanpassingen in de 
normale- en vasculair gecompliceerde zwangerschap. Jij kunt als geen ander uitkomsten 
van wetenschappelijk onderzoek vertalen naar pathways en toepassen in een klinische 
setting. Je “one-liners” zijn legendarisch (“succes is een keuze”, etc.). En ja, een mens 
kan beter nadenken op zijn “interne schoenen”. Jouw laagdrempelige toegankelijkheid 
(ondanks de drukke klinische taken), relativering en opbeurende woorden wisten van 
tegenslagen nieuwe gezichtpunten te creëren. Jij hebt dit proefschrift gebracht tot dit 
niveau, waarvoor veel dank.
Prof. dr. D.D.M. Braat, beste Didi, hartelijk dank voor het mogelijk maken dit onderzoek. 
Dankzij jouw inzet lukte het om mij in een soort AGIKO-constructie aan te nemen.
Beste Ineke en Ralph, fijn dat jullie mijn paranimfen willen zijn. Jullie zijn fantastische reis- 
en kamergenoten. Veel dank voor jullie hulp en steun in soms moeilijke tijden.
Beste Jeanne, Fons, Arianne en Ivo, hartelijk dank voor jullie hulp bij het uitvoeren van de 
experimenten met de radio op tien. Jullie hebben veel werk verzet in een soms erg vol schema.
Prof. dr. L.J. Parry and dr. J.H. Gooi, dear Laura and Jonathan, thank you very much for 
the efforts you put into this manuscript. You made it possible to do the analyses of the 
relaxin-receptors in the mesenteric arteries of our rats.
Prof. dr. C.G.J. Sweep en R. Hermsen, beste Fred en Rob, hartelijk dank voor de 
ondersteuning en het bepalen van de serum relaxinewaarden van onze ratten.
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Prof. dr. J Ritskes-Hoitinga, dr. C.R. Hooijmans en dr. R.B.M. de Vries, beste Merel, 
Carlijn en Rob, veel dank voor jullie hulp en inzet bij het opzetten en uitvoeren van de 
systematic reviews en meta-analyses. Fantastisch dat we zo aan de vooravond staan van 
een veelbelovende techniek binnen het dierexperimenteel onderzoek.
Ing. W. Abma, beste Wim. Jouw inzet als technicus heeft het mogelijk gemaakt om het 
geïsoleerde niermodel automatisch te perfunderen, zodat wij meerdere experimenten 
simultaan konden uitvoeren. Dank daarvoor.
Medewerkers van de afdeling Verloskunde en Gynaecologie, Farmacologie en Toxicologie, 
en het Centraal Dierenlaboratorium (Geert, Debby en Ilona) van het Radboudumc, en de 
afdeling Verloskunde en Gynaecologie van het Jeroen Bosch Ziekenhuis, hartelijk dank 
voor de prettige werksfeer, jullie gezelligheid en ondersteuning.
Bandleden van DubDlead (oud LosSpul), beste Christoph, Ilja, Sophie, Tom en Wes, bij 
jullie kon ik mij iedere zondag weer uitleven op alle potten en pannen. Zo kon ik mijn 
frustraties over het onderzoek ombuigen naar nieuwe ideeën. Veel dank hiervoor.
Mannen van het Haantje, beste Dennis, Gabe, Gerben, Ivar, Mark, Remco en Ronny. Dank 
voor jullie luisterend oor, grappen en serieuze gesprekken. 
Beste Iris, Ingrid en Jan David, ondanks dat we elkaar soms weinig zien heb ik dankzij 
jullie trouwe vriendschap een fantastische basis waar ik op kan bouwen. Graag wil ik jullie 
hiervoor bedanken.
Beste Piet, Mik, Anne en Jette, veel dank voor jullie gezelligheid en het inspringen op de 
momenten dat ons gezin dat nodig heeft. Een goede buur…
Beste Oma Huurman, Oma Cocky, familie Huurman en aanhang, graag wil ik jullie 
bedanken voor de gastvrijheid in jullie gezin, jullie interesse in mij en jullie begrip voor 
mijn afwezigheid op sommige familiefeestjes.
Lieve opa en oma van Drongelen en van der Wolk, hartelijk dank voor jullie liefde, 
vertrouwen en aanmoedigingen om het maximale uit mijzelf te kunnen halen. Ik koester 
de mooie herinneringen aan jullie.
Lieve papa en mama, jullie hebben het mogelijk gemaakt dat ik mijn ambities na kon 
streven. Niets was te gek. Veel dank voor de mooie en liefdevolle start die jullie mij gaven 
in dit leven.
Lieve Merel, Stijn, Anouk, Roos, Evi, Joep en Tijmen, hartelijk dank voor jullie steun en 
gezelligheid. Familie is alles!
Lieve Merijn, Kas en Siebe, jullie levensvreugde is fantastisch. Het is altijd een feest om 
thuis te komen. Jullie zijn te gekke mannetjes! Dank hiervoor.
Lieve Marike, hartelijk dank voor je begrip en eindeloze geduld met mij. Wat heb jij de 
afgelopen jaren veel moeten accepteren. Zonder jouw steun had dit proefschrift nog veel 
langer op zich laten wachten. Ik ben een gelukkig man met jou aan mijn zijde!
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Tot slot een laatste dank. Het dankwoord wordt wel eens gekscherend het best gelezen 
deel van het proefschrift genoemd. Vervolgens verdwijnt het boekje meestal snel bij het 
oud papier. Ondanks dit gegeven wil ik graag iedereen bedanken die de moeite heeft 
genomen om ook de andere hoofdstukken (deels) door te nemen.
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studeerde af binnen de afstudeerrichting Epidemiologie, met stages aan de John Hopkins 
University te Baltimore en het UMC St Radboud te Nijmegen. Vervolgens startte hij met 
de studie Geneeskunde eveneens aan de Katholieke Universiteit Nijmegen en behaalde 
zijn artsexamen in 2000. Daarna was hij als poortarts werkzaam in het Bernhoven 
Ziekenhhuis te Veghel en als assistent gynaecologie niet in opleiding in het Jeroen Bosch 
Ziekenhuis te ‘s-Hertogenbosch. In 2002 werd hij aangenomen voor de opleiding  tot 
gynaecoloog, waarvan hij zijn perifere delen in het Jeroen Bosch Ziekenhuis (opleider 
dr. H.P. Oosterbaan) en het academische deel in het UMC St Radboud (opleider prof. 
dr. D.D.M. Braat) volbracht. In deze periode startte hij met promotie-onderzoek op het 
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